Antibody-drug conjugates targeting folate receptor alpha and methods of use
By developing antibody-drug conjugates targeting human FRα, utilizing specific antibody constructs and camptothecin analog payloads, the problem of internalization efficiency and selective binding of existing targeting agents in cancer treatment is solved, It achieves efficient killing of cancer cells.
Patent Information
- Application Number
- CN202380029577.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-07
- Filing Date
- 2023-03-24
- Publication Date
- 2024-11-08
AI Technical Summary
Existing targeted human folate receptor alpha (hFRα) targeting agents have limited effectiveness in cancer treatment, especially in improving antibody internalization efficiency and selective binding.
An antibody-drug conjugate (ADC) targeting human FRα is developed, which contains specific antibody constructs and camptothecin analogs as payloads, linked to the antibody through specific linkers, improving the use of cancer cells. Targeting capability and internalization efficiency.
It significantly improves the internalization ability and selectivity of antibodies to cancer cells, enhances the killing efficacy of FRα-expressing cells, and provides a potentially efficient cancer treatment plan.
Smart Images

Figure CN118922447A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of immunotherapeutics, and in particular to antibody-drug conjugates targeting human folate receptor alpha (hFRα). Background Art
[0002] Folate receptor α (FRα) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein encoded by FOLR1 and is a member of the high-affinity FR family, which also includes FRβ (FOLR2), FRg (FOLR3), and FRd (FOLR4). FRα has been identified as a highly relevant cancer therapeutic target because it is overexpressed in multiple cancers (including ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer, mesothelioma, and lung cancer) and has minimal expression in non-malignant tissues.
[0003] Several clinical studies involving FRα-targeted agents in cancer treatment are currently underway, including the anti-FRα antibody, farletuzumab, and the FRα-targeted antibody-drug conjugates (ADCs), mirvetuximab soravtansine (ImmunoGen, Inc.), MORAb-202 (Eisai Inc.), and STRO-002 (Sutro Biopharma, Inc.).
[0004] Camptothecin analogs have been developed as payloads for antibody-drug conjugates (ADCs). Two such ADCs have been approved for the treatment of cancer. TM ), in which the camptothecin analog derugatecan (Dxd) is conjugated to the anti-HER2 antibody trastuzumab via a cleavable tetrapeptide-based linker; and sacituzumab govitecan (Trodelvy TM ), in which the camptothecin analog SN-38 is conjugated to the anti-Trop-2 antibody satuzumab via a hydrolyzable pH-sensitive linker.
[0005] Other camptothecin analogs and derivatives, and ADCs comprising them, have been described. See, for example, International (PCT) Publication Nos. WO 2019 / 195665, WO 2019 / 236954, WO 2020 / 200880, and WO 2020 / 219287.
[0006] The purpose of providing this background information is to make known information believed by the applicant to be of possible relevance to the present disclosure. It is not necessarily intended to, nor should it be construed as, an admission that any of the previous information constitutes prior art to the claimed invention. Summary of the Invention
[0007] Described herein are antibody-drug conjugates (ADCs) targeting human FRα and methods of use. One aspect of the disclosure relates to an antibody-drug conjugate having formula (X):
[0008] T-[L-(D) m ] n
[0009] (X)
[0010] in:
[0011] m is between 1 and 4;
[0012] n is between 1 and 10;
[0013] T is an anti-FRα antibody construct comprising an antigen binding domain that specifically binds to an epitope within human folate receptor α (hFRα) comprising amino acid residues E120, D121, R123, T124, S125, and Y126 of SEQ ID NO: 15;
[0014] L is a connector, and
[0015] D is a compound of formula I:
[0016]
[0017] in:
[0018] R 1 is selected from the group consisting of: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3, -OCF3, and -NH2, and
[0019] R 2 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3,
[0020] And among them:
[0021] When R 1 When it is -NH2, then R is R 3 or R 4 , and when R 1 If it is not -NH2, then R is R 4 ;
[0022] R 3Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0023] R 4 Selected from:
[0024] R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -aryl and -(C1-C6 alkyl)-aryl;
[0025] R 6 and R 7 Each independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ;
[0026] R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0027] Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0028] Each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0029] R 10’ Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0030] R 11 Selected from: -H and -C1-C6 alkyl;
[0031] R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and
[0032] R 13 Selected from: -H and -C1-C6 alkyl;
[0033] R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0034] R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0035] R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0036] R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ;
[0037] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0038] X a and X b are each independently selected from: NH, O and S, and
[0039] X c Selected from: O, S and S(O)2,
[0040] with the proviso that the compound is not (S)-9-amino-11-butyl-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione.
[0041] Another aspect of the present disclosure relates to an antibody-drug conjugate having a structure selected from the group consisting of:
[0042]
[0043]
[0044] in:
[0045] T is an anti-FRα antibody construct comprising two antigen binding domains operably linked to an IgG Fc region, each of said antigen binding domains comprising:
[0046] (a) the VL amino acid sequence as shown in SEQ ID NO: 39 and the VH amino acid sequence as shown in SEQ ID NO: 19; or
[0047] (b) the VL amino acid sequence shown in SEQ ID NO: 124 and the VH amino acid sequence shown in SEQ ID NO: 91; or
[0048] (c) the VL amino acid sequence shown in SEQ ID NO: 64 and
[0049] (i) the VH amino acid sequence shown in SEQ ID NO: 50, or
[0050] (ii) the VH amino acid sequence shown in SEQ ID NO: 54, or
[0051] (iii) the VH amino acid sequence shown in SEQ ID NO: 57, or
[0052] (iv) the VH amino acid sequence shown in SEQ ID NO: 61, or
[0053] (v) the VH amino acid sequence shown in SEQ ID NO: 76, or
[0054] (vi) the VH amino acid sequence shown in SEQ ID NO: 79, or
[0055] (vii) the VH amino acid sequence shown in SEQ ID NO: 82, or
[0056] (viii) the VH amino acid sequence shown in SEQ ID NO: 85, or
[0057] (ix) the VH amino acid sequence shown in SEQ ID NO: 88, or
[0058] (x) the VH amino acid sequence as shown in SEQ ID NO: 106; or
[0059] (d) the VL amino acid sequence shown in SEQ ID NO: 130 and
[0060] (i) the VH amino acid sequence shown in SEQ ID NO: 99, or
[0061] (ii) the VH amino acid sequence shown in SEQ ID NO: 106, or
[0062] (iii) the VH amino acid sequence shown in SEQ ID NO: 113, or
[0063] (iv) the VH amino acid sequence shown in SEQ ID NO: 116, or
[0064] (v) the VH amino acid sequence shown in SEQ ID NO: 133, or
[0065] (vi) the VH amino acid sequence as shown in SEQ ID NO: 136; or
[0066] (e) the VL amino acid sequence shown in SEQ ID NO: 119 and
[0067] (i) the VH amino acid sequence shown in SEQ ID NO: 106, or
[0068] (ii) the VH amino acid sequence as shown in SEQ ID NO: 116,
[0069] And wherein n is between 4 and 8.
[0070] Another aspect of the present disclosure relates to a pharmaceutical composition comprising an antibody-drug conjugate as described herein and a pharmaceutically acceptable carrier or diluent.
[0071] Another aspect of the present disclosure relates to a method of inhibiting the proliferation of cancer cells comprising contacting the cells with an effective amount of an antibody-drug conjugate as described herein.
[0072] Another aspect of the present disclosure relates to a method of killing cancer cells comprising contacting the cells with an effective amount of an antibody-drug conjugate as described herein.
[0073] Another aspect of the present disclosure relates to a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an antibody-drug conjugate as described herein.
[0074] Another aspect of the present disclosure relates to an antibody-drug conjugate as described herein for use in therapy.
[0075] Another aspect of the present disclosure relates to an antibody-drug conjugate as described herein for use in the treatment of cancer.
[0076] Another aspect of the present disclosure relates to the use of an antibody-drug conjugate as described herein in the manufacture of a medicament for the treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] Figure 1A and Figure 1BThe sequences of the rabbit heavy chain variable domain CDRs of chimeric anti-FRα antibody v23924 grafted onto a human VH framework (IGHV3-23*01) (SEQ ID NO: 155) (1A) and the rabbit light chain variable domain CDRs of chimeric antibody v23924 grafted onto a human VL framework (IGKVI-39*01) (SEQ ID NO: 156) (1B) are shown. The CDRs are designated according to the AbM definition and are marked in bold italic font.
[0078] Figure 2 A- Figure 2 D shows the profiles of purified parental chimeric anti-FRα antibody v23924 and purified representative humanized variant v30384 as analyzed by electrophoresis and UPLC-SEC. Figure 2 A and Figure 2 C shows the electrophoretic profiles of the parent chimeric anti-FRα antibody v23924 (2A) and the purified representative humanized variant v30384 (2C) after preparative SEC purification (post-prep-SEC) or after protein A purification (post-pA) under non-reducing (NR) and reducing (R) conditions, Figure 2 B and Figure 2 D shows UPLC-SEC profiles of parental chimeric anti-FRα antibody v23924 after preparative SEC purification (2B) and a representative humanized variant v30384 purified after Protein A purification (2D).
[0079] Figure 3 A and Figure 3 B depicts biolayer interferometry (BLI) sensorgrams of parental chimeric anti-FRα antibody v23924 (3A) and purified representative humanized variant v30384 (3B).
[0080] Figure 4 A- Figure 4 D depicts the complete LC / MS spectra of representative humanized variants v30384 (4A, expanded view of the main peak in 4B) and v31422 (4C, expanded view of the main peak in 4D).
[0081] Figure 5 A and Figure 5 B shows the receptor-mediated internalization capacity of chimeric anti-FRα antibody v23924, representative humanized variant v30384, and FRα-targeting antibodies somituzumab and fatuzumab at various concentrations in the FRα-expressing cell line IGROV-1 after 6 hours of incubation (5A) and 24 hours of incubation (5B) as determined by flow cytometry. The anti-RSV antibody palivizumab was included as a negative control.
[0082] Figure 6 A and Figure 6 B shows the receptor-mediated internalization capacity of chimeric anti-FRα antibody v23924, representative humanized variant v30384, and FRα-targeting antibodies somituzumab and fatuzumab at various concentrations in the FRα-expressing cell line OVCAR-3 after 6 hours (6A) and 24 hours (6B) of incubation, as determined by flow cytometry. The anti-RSV antibody palivizumab was included as a negative control.
[0083] Figure 7 Shown is coverage of the hFRα sequence (SEQ ID NO: 15) by peptides generated by pepsin digestion of hFRα. Each bar below the sequence represents a peptide.
[0084] Figure 8 A and Figure 8 B shows summary (8A) and difference plots (8B) of hydrogen / deuterium exchange mass spectrometry (HDX-MS) kinetics of peptides generated by pepsin digestion of hFRα: hFOLR1 (hFRα) versus hFOLR1-v23924 complex.
[0085] Figure 9 A- Figure 9 C shows the amide deuteration level of peptide 119-126 (WEDCRTSY) (SEQ ID NO: 152) after 1 hour hydrogen / deuterium exchange mass spectrometry (HDX-MS): hFOLR1 (9A) versus hFOLR1-v23924 complex (9B), and the difference plot (9C).
[0086] Figure 10 A and Figure 10 B shows the receptor-mediated internalization capacity of parental anti-FRα humanized antibody variant v30384 and representative affinity matured variant v35356 in FRα-expressing cell lines IGROV-1 (10A) and JEG-3 (10B) as determined by flow cytometry after 5 and 24 hour incubation periods. Palivizumab was included as a non-targeting control.
[0087] Figure 11 A table showing the CDR sequences of representative anti-FRα antibodies as defined by IMGT, Chothia, Kabat, Contact, and AbM definitions is presented.
[0088] Figure 12 A table showing the VH and VL sequences of representative anti-FRα antibodies is presented.
[0089] Figure 13 Exemplary drug-linker (DL) structures comprising camptothecin analogs of Formula (I) having a C7 bond are shown (Table 8).
[0090] Figure 14 Exemplary drug-linker (DL) structures comprising camptothecin analogs of Formula (I) having a C10 bond are shown (Table 9).
[0091] Figure 15 Exemplary drug-linker (DL) structures comprising camptothecin analogs of Formula (I) having a C7 or C10 bond are shown (Table 10).
[0092] Figure 16 Exemplary conjugate (DC) structures comprising camptothecin analogs of Formula (I) having a C7 bond are shown (Table 11).
[0093] Figure 17 Exemplary conjugate (DC) structures comprising camptothecin analogs of Formula (I) having a C10 bond are shown (Table 12).
[0094] Figure 18 Exemplary conjugate (DC) structures comprising camptothecin analogs of Formula (I) having a C7 or C10 linkage are shown (Table 13).
[0095] Figure 19 A- Figure 19 C shows the in vivo anti-tumor activity of ADCs comprising anti-FRα humanized antibody variant v30384 conjugated to camptothecin analogs Compound 139 or Compound 141 (19A and 19B) in the OV90 xenograft model at DAR 8, and to camptothecin analogs Compound 139, Compound 140, Compound 141, or Compound 148 (19C) in the H2110 xenograft model at DAR 8. An ADC comprising palivizumab (v21995) was included as a control.
[0096] Figure 20 Shown are the pharmacokinetics of the anti-FRα humanized antibody v36675 and four ADCs comprising v36675 conjugated with DAR8 to DXd or the camptothecin analogs Compound 139 or Compound 141 evaluated in hFcRn Tg32 mice (n=4). Mean serum concentrations at some time points were calculated using n<4 animals (as some samples were below the limit of detection).
[0097] Figure 21 Shown are the in vivo stability of four ADCs in Tg32 mouse serum comprising the humanized variant v36675 conjugated with DAR8 to DXd or the camptothecin analogs Compound 139 or Compound 141. The solid line shows the % DAR remaining (left axis) and the dashed line shows the % maleimide ring opening (right axis).
[0098] Figure 22 A- Figure 22 E shows the in vivo anti-tumor activity of ADCs comprising anti-FRα humanized antibody variant v36675 conjugated to camptothecin analog compound 139 or compound 141 at DAR 4 or DAR 8, respectively, in the OV90 CDX xenograft model (22A, 22B); conjugated to camptothecin analog compound 140 or compound 141 at DAR 4 or DAR 8, respectively, in the OVCAR3 CDX xenograft model (22C); conjugated to camptothecin analog compound 139 at DAR 8 in the GTG-2025 PDX xenograft model (22D); and conjugated to camptothecin analog compound 139 at DAR 8 in the GTG-0958 PDX xenograft model (22E).
[0099] Figure 23 A- Figure 23 D shows the total antibody serum concentration of ADCs comprising the anti-FRα humanized antibody v36675 in blood samples collected after the first dose in cynomolgus monkey toxicity studies; the ADC comprising v36675 conjugated to compound 139 or compound 141 with a DAR of 8 was administered at 30 mg / kg (23A), the ADC comprising v36675 conjugated to compound 139 or compound 141 with a DAR of 4 was administered at 60 mg / kg (23B), the ADC comprising v36675 conjugated to compound 139 or compound 141 with a DAR of 8 was administered at 80 mg / kg (23C), and the ADC comprising v36675 conjugated to compound 139 or compound 141 with a DAR of 4 or DAR 8 was administered at 120 mg / kg (23D).
[0100] Figure 24 In vitro bystander activity of ADCs comprising anti-FRα humanized antibody variant v30384 conjugated to various camptothecin analogs is shown against the FRα-negative MDA-MB-468 cell line. ADCs v30384-MC-GGFG-AM-DXd1 and v30384-MCvcPABC-MMAE were included as positive controls, and an ADC comprising palivizumab (v22277) conjugated to MC-GGFG-AM-DXd1 and MCvcPABC-MMAE was included as a negative control.
[0101] Figure 25 A- Figure 25D shows the penetration of anti-FRα humanized antibody variant v36675 into JEG-3 cell spheroids at 4 hours (25A), 24 hours (25B), 48 hours (25C), and 96 hours (25D) compared to sometuximab and the negative control palivizumab.
[0102] Figure 26 A and Figure 26 B shows intracellular (26A) and extracellular (26B) payload release from the following ADCs: ADC comprising the anti-FRα humanized antibody variant v36675 conjugated to compound 139 with a DAR of 8 (v36675-MC-GGFG-AM-compound 139) and an ADC comprising the non-targeting control palivizumab (v21995) conjugated to compound 139 with a DAR of 8 in the high FRα-expressing cell line IGROV-1.
[0103] Figure 27 AI shows the in vivo anti-tumor activity of ADCs comprising the anti-FRα humanized antibody variant v36675 conjugated to Compound 139 with DAR 8 (v36675-MC-GGFG-AM-Compound 139) and a control ADC, Sumetuximab-DM4 DAR4, in patient-derived ovarian cancer xenograft (PDX) models: CTG-0703 PDX model (27A), CTG-1301 PDX model (27B), CTG-2025 PDX model (27C), CTG-3383 PDX model (27D), CTG-0947 PDX model (27E), CTG-0958 PDX model (27F), CTG-3718 PDX model (27G), CTG-1703 PDX model (27H), and CTG-1602 PDX model (27I) when dosed at 6 mg / kg.
[0104] Figure 28 A and Figure 28 B shows images of fixed cell confirmation screening using Retrogenix cell microarray technology to screen for specific off-target binding interactions using 20 mg / mL of anti-FRα humanized antibody variant v36675 (28A) and 1 mg / mL of control antibody (rituximab biosimilar) (28B).
[0105] Figure 29 Shown is competition binding between the chimeric anti-FRα antibody v23294 and the anti-FRα antibodies Sumetuximab and Fatuzumab evaluated in H2110 cells. DETAILED DESCRIPTION
[0106] The present disclosure relates to antibody-drug conjugates (ADCs) comprising an antibody construct (anti-FRα antibody construct) that specifically binds to human folate receptor alpha (FRα) conjugated to a camptothecin analog of formula (I) as described herein. Specifically, the present disclosure relates to an ADC having formula (X):
[0107] T-[L-(D) m ] n
[0108] (X)
[0109] in:
[0110] T is an anti-FRα antibody construct as described herein;
[0111] L is the connector;
[0112] D is a camptothecin analog of formula (I) as described herein;
[0113] m is between 1 and 4, and
[0114] n is between 1 and 10.
[0115] The ADCs of the present disclosure can be used, for example, as therapeutic agents, especially in the treatment of cancer.
[0116] definition
[0117] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0118] As used herein, the term "about" refers to a variation of approximately + / - 10% from a given value. It should be understood that such variations are always included in any given value provided herein, whether or not specifically mentioned.
[0119] When used in conjunction with the term "comprising" in this document, the use of the word "a / kind" can mean "one", but it also means "one or more", "at least one" and "one or more than one".
[0120] As used herein, the terms "comprising," "having," "including," and "containing," and grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and / or method steps. When used herein in conjunction with a composition, use, or method, the term "consisting essentially of indicates that additional elements and / or method steps may be present, but that these additions do not materially affect the manner in which the recited composition, method, or use functions. The term "consisting of" does not include the presence of additional elements and / or method steps when used herein in conjunction with a composition, use, or method. A composition, use, or method described herein as comprising certain elements and / or steps may also consist essentially of those elements and / or steps in certain embodiments and consist of those elements and / or steps in other embodiments, whether or not those embodiments are specifically mentioned.
[0121] "Complementarity determining regions" or "CDRs" are amino acid sequences that contribute to antigen binding specificity and affinity. The "framework" region (FR) can help maintain the correct conformation of the CDRs to promote binding between the antigen-binding region and the antigen. From N-terminus to C-terminus, the light chain variable region (VL) and heavy chain variable region (VH) of an antibody typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The three heavy chain CDRs are referred to herein as HCDR1, HCDR2, and HCDR3, and the three light chain CDRs are referred to as LCDR1, LCDR2, and LCDR3. CDRs provide most of the contact residues for the binding of an antibody to an antigen or epitope. Typically, three heavy chain CDRs and three light chain CDRs are required to bind to an antigen. However, in some cases, even a single variable domain can confer antigen binding specificity. In addition, as is known in the art, in some cases, antigen binding can also occur by a combination of at least one or more CDRs (e.g., HCDR3) selected from the VH and / or VL domains.
[0122] Many different definitions of CDR sequences are commonly used, including those described by Kabat et al. (1983, Sequences of Proteins of Immunological Interest, NIH Publication No. 369-847, Bethesda, MD), Chothia et al. (1987, J Mol Biol, 196: 901-917), and IMGT, AbM (University of Bath), and Contact (MacCallum et al., 1996, J Mol Biol, 262(5): 732-745). For example, the CDR definitions according to Kabat, Chothia, IMGT, AbM, and Contact are provided in Table 1 below. Therefore, it will be apparent to those skilled in the art that the exact numbering and placement of the CDRs may vary based on the numbering system employed. However, it will be understood that disclosure of VH herein includes disclosure of the associated (intrinsic) heavy chain CDRs (HCDRs) as defined by any known numbering system. Similarly, disclosure herein of a VL includes disclosure of the associated (intrinsic) light chain CDRs (LCDRs) as defined by any known numbering system.
[0123] Table 1: Common CDR definitions 1
[0124]
[0125] 1 Either the Kabat or Chothia numbering system may be used for all defined HCDR2, HCDR3 and light chain CDRs except for Contact which uses Chothia numbering.
[0126] 2 Kabat numbering is used. The positions in the Kabat numbering scheme that delineate the ends of the Chothia and IMGT CDR-H1 loops vary depending on the length of the loop, as Kabat places insertions outside of those CDR definitions at positions 35A and 35B. However, the IMGT and Chothia CDR-H1 loops can be unambiguously defined using Chothia numbering. CDR-H1 definitions using Chothia numbering are: Kabat H31-H35, Chothia H26-H32, AbM H26-H35, IMGT H26-H33, Contact H30-H35.
[0127] In the context of two or more polynucleotides or polypeptide sequences, the term "identical" refers to two or more identical sequences or subsequences. When sequences are compared and aligned to obtain the maximum consistency measured by using a conventional sequence comparison algorithm known to those of ordinary skill in the art or by manual comparison and visual inspection on a comparison window or in a specified region, if the sequence has a certain percentage of identical amino acid residues or nucleotides (for example, about 80%, about 85%, about 90%, about 95% or about 98% homogeneity in a specified region), the sequence is "substantially identical". For sequence comparison, a test sequence is usually compared with a specified reference sequence. When using a sequence comparison algorithm, test sequence and reference sequence are input into a computer, and if necessary, subsequence coordinates are specified, and sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.
[0128] A "comparison window" refers to a segment of a sequence comprising contiguous amino acid or nucleotide positions, which can be, for example, about 10 to 600 contiguous amino acid or nucleotide positions, or about 10 to about 200, or about 10 to about 150 contiguous amino acid or nucleotide positions over which a test sequence can be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of sequence alignment for comparison are known to those of ordinary skill in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, 1970, Adv. Appl. Math., 2:482c; the homology alignment algorithm of Needleman & Wunsch, 1970, J. Mol. Biol., 48:443; the search for similarity method of Pearson & Lipman, 1988, Proc. Natl. Acad. Sci. USA, 85:2444; or by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, or TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, (1995 supplement), Cold Spring Harbor Laboratory Press). Examples of available algorithms suitable for determining percent sequence identity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., 1997, Nuc. Acids Res., 25:3389-3402 and Altschul et al., 1990, J. Mol. Biol., 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the website of the National Center for Biotechnology Information (NCBI).
[0129] As used herein, the term "acyl" refers to the group -C(O)R, where R is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
[0130] The term "acyloxy" refers to the group -OC(O)R, where R is alkyl.
[0131] As used herein, the term "alkoxy" refers to the group -OR, where R is alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
[0132] As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon group containing the specified number of carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl, n-hexyl, and the like.
[0133] As used herein, the term "alkylaminoaryl" refers to an alkyl group, as defined herein, substituted with an aminoaryl group, as defined herein.
[0134] As used herein, the term "alkylheterocycloalkyl" refers to an alkyl group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.
[0135] As used herein, the term "alkylthio" refers to the group -SR, where R is an alkyl group.
[0136] As used herein, the term "amido" refers to the group -C(O)NRR', where R and R' are independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
[0137] As used herein, the term "amino" refers to the group -NRR', where R and R' are independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
[0138] As used herein, the term "aminoalkyl" refers to an alkyl group, as defined herein, substituted with one or more amino groups (eg, one, two, or three amino groups).
[0139] As used herein, the term "aminoaryl" refers to an aryl group, as defined herein, substituted with an amino group.
[0140] As used herein, the term "aryl" refers to a 6- to 12-membered monocyclic or bicyclic hydrocarbon ring system in which at least one ring is aromatic. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydro-naphthyl, 5,6,7,8-tetrahydro-naphthyl, indanyl, and the like.
[0141] As used herein, the term "carboxy" refers to the group -C(O)OR, where R is H, alkyl, aryl, heteroaryl, cycloalkyl, or cycloheteroalkyl.
[0142] As used herein, the term "cyano" refers to the group -CN.
[0143] As used herein, the term "cycloalkyl" refers to a monocyclic or bicyclic saturated hydrocarbon containing the specified number of carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, and the like.
[0144] As used herein, the term "haloalkyl" refers to an alkyl group, as defined herein, substituted with one or more halogen atoms.
[0145] As used herein, the terms "halogen" and "halo" refer to fluorine (F), bromine (Br), chlorine (Cl), and iodine (I).
[0146] As used herein, the term "heteroaryl" refers to a 6- to 12-membered monocyclic or bicyclic ring system in which at least one ring atom is a heteroatom and at least one ring is aromatic. Examples of heteroatoms include, but are not limited to, O, S, and N. Examples of heteroaryl groups include, but are not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinolyl, benzoxazolyl, benzothiazolyl, isoquinolyl, quinazolinyl, quinoxalinyl, pyrrolyl, indolyl, and the like.
[0147] As used herein, the term "heterocycloalkyl" refers to a monocyclic or bicyclic non-aromatic ring system containing a specified number of atoms and wherein at least one ring atom is a heteroatom (e.g., O, S, or N). The heterocyclyl substituent may be attached via any available ring atom (e.g., ring carbon or ring nitrogen). Examples of heterocycloalkyl include, but are not limited to, aziridinyl, azetidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, etc.
[0148] As used herein, the terms "hydroxy" and "hydroxyl" refer to the group -OH.
[0149] As used herein, the term "hydroxyalkyl" refers to an alkyl group, as defined herein, substituted with one or more hydroxy groups.
[0150] As used herein, the term "nitro" refers to the group -NO2.
[0151] As used herein, the term "sulfonyl" refers to the group -S(O)2R, where R is H, alkyl, or aryl.
[0152] As used herein, the term "sulfonylamino" refers to the group -NH-S(O)2R, where R is H, alkyl, or aryl.
[0153] As used herein, the terms "sulfanyl" and "thiol" refer to the group -SH.
[0154] Unless explicitly stated as "unsubstituted", any alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups mentioned herein are to be understood as "optionally substituted", i.e., each such reference includes unsubstituted and substituted forms of these groups. For example, reference to "-C1-C6 alkyl" includes unsubstituted-C1-C6 alkyl and -C1-C6 alkyl substituted with one or more substituents. Examples of substituents include, but are not limited to, halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxyl, amino, amido, nitro, cyano, azido, alkylthio, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. In certain embodiments, each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group mentioned herein is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxyl, amino, amido, nitro, cyano, azido, alkylthio, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.
[0155] A chemical group described herein as "substituted" may include one substituent or multiple substituents, up to the full valence of the substitution of the group. For example, a methyl group may include 1, 2, or 3 substituents, and a phenyl group may include 1, 2, 3, 4, or 5 substituents. When a group is substituted with more than one substituent, the substituents may be the same or they may be different.
[0156] As used herein, the term "subject" refers to an animal, in some embodiments, a mammal, that is the subject of treatment, observation, or experiment. The animal can be a human, a non-human primate, a companion animal (e.g., a dog, a cat, etc.), a farm animal (e.g., a cow, a sheep, a pig, a horse, etc.), or a laboratory animal (e.g., a rat, a mouse, a guinea pig, a non-human primate, etc.). In certain embodiments, the subject is a human.
[0157] It is contemplated that any embodiment discussed herein can be implemented by any method, use, or composition disclosed herein, and vice versa.
[0158] Certain features, structures, and / or characteristics described in connection with one embodiment disclosed herein may be combined in any suitable manner with features, structures, and / or characteristics described in connection with another embodiment disclosed herein to provide one or more further embodiments.
[0159] It should also be understood that the affirmative recitation of a feature in one embodiment is a basis for excluding that feature in another embodiment. For example, where a list of options is presented for a given embodiment or claim, it should be understood that one or more options may be deleted from the list and that the shortened list may form an alternative embodiment, regardless of whether such alternative embodiment is specifically mentioned.
[0160] Anti-FRα antibody constructs
[0161] The ADC of the present disclosure comprises an anti-FRα antibody construct. In this context, the term "antibody construct" refers to a polypeptide or a group of polypeptides comprising one or more antigen binding domains, wherein each of the one or more antigen binding domains specifically binds to an epitope or antigen. When the antibody construct comprises two or more antigen binding domains, each antigen binding domain can bind to the same epitope or antigen (i.e., the antibody construct is monospecific) or they can bind to different epitopes or antigens (i.e., the antibody construct is bispecific or multispecific). The antibody construct may also include a scaffold, and the one or more antigen binding domains may be fused or covalently linked to the scaffold, optionally connected via a linker, as described herein.
[0162] According to the present disclosure, anti-FRα antibody constructs comprise at least one antigen binding domain that specifically binds to human FRα (hFRα). "Specifically binds" hFRα means that the antibody construct binds to hFRα but does not exhibit significant binding to any of the human folate receptors β (FOLR2), γ (FOLR3), or δ (FOLR4). In certain embodiments, the anti-FRα antibody constructs of the present disclosure are capable of binding to FRα from one or more non-human species. In certain embodiments, the anti-FRα antibody constructs of the present disclosure are capable of binding to cynomolgus monkey FRα.
[0163] Human FRα is also known as "human folate receptor 1" or "FOLR1." Protein sequences of hFRα from various sources are known in the art and are readily available from publicly accessible databases such as GenBank or UniProtKB. Examples of hFRα sequences include, for example, those provided under NCBI reference numbers P15328, AAX29268.1, AAX37119.1, NP_057937.1, and NP_057936.1. An exemplary hFRα protein sequence is provided in Table 2 as SEQ ID NO: 1 (NCBI Reference Sequence: NP_057936.1). Also provided in Table 2 is an exemplary cynomolgus monkey FRα protein sequence (SEQ ID NO: 2; NCBI Reference Sequence: XP_005579002.2).
[0164] Table 2: Human and cynomolgus monkey FRα protein sequences
[0165]
[0166] Specific binding of the antigen binding domain to the target antigen or epitope can be measured, for example, by enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) technology (using, for example, a BIAcore instrument) (Liljeblad et al., 2000, Glyco J, 17:323-329), flow cytometry, or traditional binding assays (Heeley, 2002, Endocr Res, 28:217-229). In certain embodiments, specific binding can be defined as binding to a non-target protein (such as FOLR2, FOLR3, or FOLR4) that is less than about 10% of the binding to hFRα, for example, as measured by ELISA or flow cytometry. In certain embodiments, specific binding of the antibody construct to FRα can be measured by the dissociation constant (K D )≤1 μM, for example, ≤500 nM, ≤250 nM, ≤100 nM, ≤50 nM or ≤10 nM. In certain embodiments, the specific binding of an antibody construct to a particular antigen or epitope can be determined by the dissociation constant (K D ) is 10 -6 M or smaller, such as 10 -7 M or smaller or 10 -8 In some embodiments, the specific binding of an antibody construct to a particular antigen or epitope can be determined by the dissociation constant (K D ) between 10 -6 M and 10 -9 M, for example, between 10 -7 M and 10 -9 Defined between M.
[0167] In certain embodiments, the anti-FRα antibody constructs of the present disclosure show greater internalization into FRα-expressing cells than the reference antibodies somituximab (huMov19 or huFR107) and fatuzumab (MORAb-003).
[0168] Antibody internalization can be measured using methods known in the art, for example, by direct internalization according to the protocol detailed in Schmidt, M. et al., 2008, Cancer Immunol. Immunother., 57: 1879-1890, or using commercially available fluorescent dyes such as pHAb dye (Promega Corporation, Madison, WI), pHrodo iFL and Deep Red dye (ThermoFisher Scientific Corporation, Waltham, MA) and Fabfluor-pH antibody labeling reagent (Sartorius AG, Germany), and analytical techniques such as microscopy, FACS, high-content imaging or other plate-based assays.
[0169] In certain embodiments, when the amount of anti-FRα antibody construct internalized into FRα-expressing cells under the same test conditions is at least 1.2 times the amount of the reference antibody internalized into the same FRα-expressing cells, the anti-FRα antibody construct is considered to exhibit higher internalization into FRα-expressing cells than the corresponding reference antibody (somituzumab or fatuzumab). In certain embodiments, the amount of internalized antibody is determined using appropriate fluorescent dyes and high-content imaging. In some embodiments, the amount of internalized antibody is determined in cells expressing FRα at high levels. In some embodiments, the amount of internalized antibody is determined in IGROV-1 cells or cells expressing FRα at a level similar to that of IGROV-1 cells. In some embodiments, the amount of internalized antibody is determined after a 6-hour incubation period. In some embodiments, the amount of internalized antibody is determined after a 24-hour incubation period.
[0170] In certain embodiments, when the amount of anti-FRα antibody construct internalized into FRα-expressing cells under the same test conditions is at least 1.3 times, at least 1.4 times, at least 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times or 2.0 times the amount of the reference antibody internalized into the same FRα-expressing cells, the anti-FRα antibody construct is considered to exhibit higher internalization into FRα-expressing cells than the corresponding reference antibody (somituzumab or fatuzumab). In certain embodiments, the amount of internalized antibody is determined using appropriate fluorescent dyes and high-content imaging. In some embodiments, the amount of internalized antibody is determined in cells expressing FRα at high levels. In some embodiments, the amount of internalized antibody is determined in IGROV-1 cells or cells expressing FRα at a level similar to that of IGROV-1 cells. In some embodiments, the amount of internalized antibody is determined after a 6-hour incubation period. In some embodiments, the amount of internalized antibody is determined after a 24-hour incubation period.
[0171] Antigen binding domain
[0172] The anti-FRα antibody constructs of the present disclosure comprise at least one antigen-binding domain capable of binding to hFRα. The at least one antigen-binding domain capable of binding to hFRα is typically an immunoglobulin-based binding domain, such as an antigen-binding antibody fragment. Examples of antigen-binding antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, single-chain Fab (scFab), single-chain Fv (scFv), and single-domain antibodies (sdAb).
[0173] A "Fab fragment" contains the constant domain (CL) of the light chain and the first constant domain (CH1) of the heavy chain, as well as the variable domains of the light and heavy chains (VL and VH, respectively). A Fab' fragment differs from a Fab fragment in that it has several additional amino acid residues at the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. A Fab fragment can also be a single-chain Fab molecule, i.e., a Fab molecule in which the Fab light chain and the Fab heavy chain are connected by a peptide linker to form a single peptide chain. For example, the C-terminus of a Fab light chain can be linked to the N-terminus of a Fab heavy chain in a single-chain Fab molecule.
[0174] " scFv " comprises the heavy chain variable domain (VH) and light chain variable domain (VL) of an antibody in a single polypeptide chain. scFv may optionally further comprise a polypeptide linker between the VH and VL domains, thereby enabling the scFv to form the structure required for antigen binding. For example, scFv may comprise a VL connected to the N-terminus of VH from the C-terminus via a polypeptide linker. Alternatively, scFv may comprise a VH connected to the N-terminus of VL via its C-terminus via a polypeptide linker (see the review in Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)).
[0175] The "sdAb" format refers to a single immunoglobulin domain. sdAbs can be, for example, of camel origin. Camelid antibodies lack light chains, and their antigen-binding sites consist of a single domain called "VHH." sdAbs contain three CDRs / hypervariable loops, CDR1, CDR2, and CDR3, that form the antigen-binding site. sdAbs are quite stable and easy to express, for example, as a fusion with an antibody Fc chain (see, e.g., Harmsen & De Haard, 2007, Appl. Microbiol Biotechnol., 77(1):13-22).
[0176] In those embodiments in which the anti-FRα antibody construct comprises two or more antigen-binding domains, each additional antigen-binding domain can independently be an immunoglobulin-based domain (such as an antigen-binding antibody fragment) or a non-immunoglobulin-based domain (such as a non-immunoglobulin-based antibody mimetic), or other polypeptides or small molecules capable of specifically binding to their targets (e.g., natural or engineered ligands). Non-immunoglobulin-based antibody mimetic formats include, for example, anticalins, fynomers, affimers, alphabodies, DARPins, and avimers.
[0177] The present disclosure describes herein the identification of an antibody that specifically binds hFRα (variant v23924), as well as representative humanized versions of this antibody (variants v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, and v31426), and representative affinity matured versions of this antibody (variants v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, and v36675) (see the Examples and Sequence Listing). Figure 7 Epitope mapping of the hFRα sequence shown (SEQ ID NO: 15) determined that the epitope within the hFRα protein to which variant v23924 binds comprises amino acid residues E120, D121, R123, T124, S125, and Y126 of SEQ ID NO: 15 (see Example 13).
[0178] In certain embodiments, the at least one antigen binding domain that binds hFRα comprised by the anti-FRα antibody constructs of the present disclosure binds to an epitope within the hFRα protein comprising amino acid residues E120, D121, R123, T124, S125, and Y126 of SEQ ID NO: 15. In some embodiments, the hFRα epitope bound by the anti-FRα antibody construct is a non-linear (or discontinuous) epitope comprising amino acid residues E120, D121, R123, T124, S125, and Y126 of SEQ ID NO: 15. In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain that competes for binding to hFRα with an antibody that binds to an epitope within the hFRα protein comprising amino acid residues E120, D121, R123, T124, S125, and Y126. In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain that competes for binding to hFRα with antibody v23924 described herein.
[0179] Competition assays known in the art can be used to determine whether an antibody construct competes for binding to hFRα with an antibody that binds to an epitope comprising amino acid residues E120, D121, R123, T124, S125, and Y126 within the hFRα protein, or with antibody v23924. For example, an antibody that binds to an epitope comprising amino acid residues E120, D121, R123, T124, S125, and Y126 within the hFRα protein, or antibody v23924 (reference antibody), is first allowed to bind to hFRα under saturating conditions, and then the ability of the test antibody construct to bind to hFRα is measured. If the test antibody construct is able to bind to hFRα simultaneously with the reference antibody, then the test antibody construct is considered to bind to a different epitope than the reference antibody. Conversely, if the test antibody construct is unable to bind to hFRα simultaneously with the reference antibody, then the test antibody construct is considered to bind to the same epitope as the epitope bound by the reference antibody, an overlapping epitope, or an epitope that is closely adjacent to the epitope bound by the reference antibody. Competition assays can also be run in which the order of binding of the reference and test antibodies is reversed, ie, the test antibody is first allowed to bind hFRα under saturating conditions, and the ability of the reference antibody construct to bind hFRα is then measured.
[0180] Such competition assays can be performed using techniques such as ELISA, radioimmunoassay, surface plasmon resonance (SPR), biolayer interferometry, flow cytometry, etc. An "antibody that competes with a reference antibody" refers to an antibody that blocks the binding of the reference antibody to its epitope in a competition assay by 50% or more.
[0181] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise at least one antigen binding domain that specifically binds to hFRα, wherein the antigen binding domain comprises a set of CDRs based on the CDRs of antibody variant v23924 described herein. The CDR sequences of antibody v23924 and representative humanized or affinity matured versions of this antibody are shown in Figure 11 Analysis of the CDR sequences from the parental and affinity-matured anti-FRα antibodies identified the minimum amino acid sequence present in each CDR as defined by any of the IMGT, Chothia, Kabat, Contact, or AbM numbering systems. These amino acid sequences are represented by the minimum consensus CDR sequences provided in Table 3. An expanded version of these CDR consensus sequences, based on the CDR sequences defined by the AbM numbering system, is shown in Table 4.
[0182] Table 3: Minimal CDR consensus sequences of anti-FRo antibodies
[0183]
[0184]
[0185] Table 4: CDR consensus sequences of anti-FRα antibodies based on the AbM numbering system
[0186]
[0187] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having heavy chain CDR amino acid sequences (HCDR1, HCDR2, and HCDR3) comprising the sequences set forth in SEQ ID NOs: 3, 4, and 5, and light chain CDR amino acid sequences (LCDR1, LCDR2, and LCDR3) comprising the sequences set forth in SEQ ID NOs: 6, 7, and 8.
[0188] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0189] (i) the HCDR1 amino acid sequence as shown in SEQ ID NO: 3; the HCDR2 amino acid sequence as shown in SEQ ID NO: 4; and the HCDR3 amino acid sequence as shown in SEQ ID NO: 5, wherein X 2 is L and X 3 A, or X 2 is H and X 3 is P, and
[0190] (ii) the LCDR1 amino acid sequence as shown in SEQ ID NO: 6, wherein X 4 is G and X 5 D, or X 4 is W and X 5 is Y; the LCDR2 amino acid sequence as shown in SEQ ID NO: 7; and the LCDR3 amino acid sequence as shown in SEQ ID NO: 8, wherein X 6 S, X 7 N, X 8 is V and X 9 D, or X 6 W, X 7 H, X 8 is I and X 9 For L.
[0191] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having a heavy chain CDR amino acid sequence (HCDR1, HCDR2, and HCDR3) comprising the sequences set forth in SEQ ID NOs: 9, 10, and 11, and a light chain CDR amino acid sequence (LCDR1, LCDR2, and LCDR3) comprising the sequences set forth in SEQ ID NOs: 12, 13, and 14.
[0192] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0193] (i) the HCDR1 amino acid sequence as shown in SEQ ID NO: 9; the HCDR2 amino acid sequence as shown in SEQ ID NO: 10, wherein X 11 is S or A and X 12 V, or X 11 is S and X 12 L; and the HCDR3 amino acid sequence as shown in SEQ ID NO: 11, wherein X 13 is L and X 14 A, or X 13 is H and X 14 is P, and
[0194] (ii) the LCDR1 amino acid sequence as shown in SEQ ID NO: 12, wherein X 15 R or Q, X 16 is G and X 17 D, or X 15 R, X 16 is W and X 17 Y; the LCDR2 amino acid sequence as shown in SEQ ID NO: 13; and the LCDR3 amino acid sequence as shown in SEQ ID NO: 14, wherein X 18 S, X 19 N, X 20 is V and X 21 D, or X 18 W, X 19 H, X 20 is I and X 21 For L.
[0195] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0196] (i) a HCDR1 amino acid sequence selected from the group consisting of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v3 a HCDR1 amino acid sequence selected from variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, or v31427; , v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675; and a HCDR3 amino acid sequence selected from variants v23924, v30618, v30384, v30389, v3 the HCDR3 amino acid sequence of any one of v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675, and
[0197] (ii) a LCDR1 amino acid sequence selected from variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35355 a LCDR1 amino acid sequence selected from variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v31427, v31428, v31429, v31430, v31431, v31432, v31433, v31434, v31435, v31436, v31437, v31438, v31439, v31431, v31437, v31438, v31439, v31431, v31432, v31433, v31434, v31435, v31436, v31437, v31438, v31439 ...9, v31431 6, a LCDR2 amino acid sequence of any one of v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675; and a LCDR3 amino acid sequence selected from variants v23924, v30618, v30384, v30389, v35391, v35407, v35408, v35409, v35410, v35411, v35412, v35413, v35414, v35415, v35416 the LCDR3 amino acid sequence of any one of v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675,
[0198] wherein the CDR amino acid sequences are as defined in any of the IMGT, Chothia, Kabat, Contact, or AbM numbering systems (see Figure 11 ).
[0199] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having a heavy chain CDR amino acid sequence (HCDR1, HCDR2, and HCDR3) selected from variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35357, v35358, v35359, v35360, v35361, v35362, v35363, v35364, v35365, v35366, v35367, v35368, v35369, v35370, v35371, v35372, v35373, v35374, v35375 The heavy chain CDR amino acid sequence (HCDR1, HCDR2 and HCDR3) of any one of v6167, v36168 or v36675, and the light chain CDR amino acid sequence is selected from variants v23924, v30618, v30384, v30389, v30394, v30619, v30710, v30711, v30713, v30714, v30715, v30716, v30717, v30718, v30719 ...1, v30713, v30714, v30715
[0145] The light chain CDR amino acid sequences (LCDR1, LCDR2, and LCDR3) of any one of v399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675.
[0200] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, as defined by any of the IMGT, Chothia, Kabat, Contact, or AbM numbering systems. The heavy chain CDR amino acid sequence (HCDR1, HCDR2, and HCDR3) and light chain CDR amino acid sequence (LCDR1, LCDR2, and LCDR3) of any one of v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675.
[0201] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising the CDR sequences of the VH domain of any of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675. In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising the CDR sequences of the VL domain of any of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675. Figure 12 The VH and VL sequences of v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, and v36675 are provided.
[0202] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising a VH amino acid sequence selected from the VH amino acid sequence of any one of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675. In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising a VL amino acid sequence selected from the VL amino acid sequence of any one of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675.
[0203] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising a VH amino acid sequence and a VL amino acid sequence selected from the VH and VL amino acid sequences of any one of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675.
[0204] Those skilled in the art will appreciate that a limited number of amino acid substitutions can be introduced into the CDR sequences or VH or VL sequences of a known antibody without the antibody losing its ability to bind to its target. Candidate amino acid substitutions can be identified by computer modeling or by techniques known in the art, such as alanine scanning, and the binding activity of the resulting variants tested by standard techniques. Thus, in certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising a variant v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35355 A set of CDRs of any one of v56, v35358, v36167, v36168 or v36675 has a set of CDRs (i.e., heavy chain HCDR1, HCDR2 and HCDR3 and light chain LCDR1, LCDR2 and LCDR3) that have 90% or greater, 95% or greater, 98% or greater, 99% or greater or 100% sequence identity, wherein the % sequence identity is calculated across all six CDRs, and wherein the antigen binding domain retains the ability to bind to hFRα.
[0205] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising a variant of a set of CDR sequences of any one of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675, wherein the variant comprises 1 to 10 amino acid substitutions across the set of CDRs (i.e., the CDRs can be modified by up to 10 amino acid substitutions, with any combination of the 6 CDRs being modified), and wherein the antigen binding domain retains the ability to bind to hFRα. In some embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v353 The invention further provides a variant of a set of CDR sequences of any one of v35354, v35356, v35358, v36167, v36168, or v36675, wherein the variant comprises 1 to 7 amino acid substitutions, 1 to 5 amino acid substitutions, 1 to 4 amino acid substitutions, 1 to 3 amino acid substitutions, 1 to 2 amino acid substitutions, or 1 amino acid substitution in the set of CDRs, and wherein the antigen binding domain retains the ability to bind to hFRα.
[0206] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising a polypeptide that is identical to variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, The VH sequence of any one of v35354, v35356, v35358, v36167, v36168, or v36675 has a VH sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, wherein the antigen binding domain retains the ability to bind to hFRα. In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising a polypeptide that is identical to variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, The VL sequence of any one of v35354, v35356, v35358, v36167, v36168, or v36675 has a VL sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, wherein the antigen binding domain retains the ability to bind to hFRα.
[0207] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0208] (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, 31, 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 27, 29, 32, 51, 58, 100, 101, 102, 103, 109, 137, 138, or 139; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, 30, 107, 108, or 110, and
[0209] (ii) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 43, 45, 65, 125, 126, or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42, 47, 120, or 121.
[0210] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising the CDR sequences of a VH domain having a sequence as set forth in any one of SEQ ID NOs: 19, 50, 54, 57, 61, 76, 79, 82, 85, 88, 91, 99, 106, 113, 116, 133, or 136. In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising the CDR sequences of a VL domain having a sequence as set forth in any one of SEQ ID NOs: 39, 64, 119, 124, or 130.
[0211] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0212] (a) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 43, or 45; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; and a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 27, 29, or 32; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30;
[0213] (b) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126, or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; and a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 51; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30;
[0214] (c) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45, or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; and
[0215] (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 51; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0216] (ii) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 58; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0217] (iii) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 24, 100, 101, 102, or 103; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0218] (d) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126, or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; and
[0219] (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 24, 100, 101, 102, or 103; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0220] (ii) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108, or 110; or
[0221] (iii) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0222] (iv) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108, or 110; or
[0223] (v) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0224] (vi) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 137, 138, or 139; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; or
[0225] (e) a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45, or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; and
[0226] (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95, or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108, or 110; or
[0227] (ii) a HCDR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 24, 29, 32, or 109; and a HCDR3 amino acid sequence selected from the group consisting of SEQ ID NOs: 107, 108, or 110.
[0228] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain having:
[0229] (a) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 27, 29 or 32; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 43 or 45; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; or
[0230] (b) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 51; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45 or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; or
[0231] (c) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 58; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45 or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; or
[0232] (d) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 51; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; or
[0233] (e) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 24, 100, 101, 102 or 103; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0234] (f) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108 or 110; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45 or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 42 or 47; or
[0235] (g) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108 or 110; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45 or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0236] (h) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108 or 110; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0237] (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0238] (j) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108 or 110; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 40, 45 or 65; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0239] (k) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28 or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32 or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 107, 108 or 110; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0240] (1) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, or 31; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 29, 32, or 109; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126, or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44, or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121; or
[0241] (m) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 137, 138 or 139; a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25 or 30; a LCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 120 or 121.
[0242] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising a VH amino acid sequence selected from the group consisting of the VH amino acid sequence set forth in any one of SEQ ID NOs: 19, 50, 54, 57, 61, 76, 79, 82, 85, 88, 91, 99, 106, 113, 116, 133, or 136. In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise an antigen binding domain comprising a VL amino acid sequence selected from the group consisting of the VL amino acid sequence set forth in any one of SEQ ID NOs: 39, 64, 119, 124, or 130.
[0243] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising a VH amino acid sequence selected from the group consisting of the VH amino acid sequence set forth in any one of SEQ ID NOs: 19, 50, 54, 57, 61, 76, 79, 82, 85, 88, 91, 99, 106, 113, 116, 133, or 136 and a VL amino acid sequence selected from the group consisting of the VL amino acid sequence set forth in any one of SEQ ID NOs: 39, 64, 119, 124, or 130.
[0244] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising:
[0245] (a) the VL amino acid sequence as shown in SEQ ID NO: 39 and the VH amino acid sequence as shown in SEQ ID NO: 19; or
[0246] (b) the VL amino acid sequence shown in SEQ ID NO: 124 and the VH amino acid sequence shown in SEQ ID NO: 91; or
[0247] (c) the VL amino acid sequence shown in SEQ ID NO: 64 and
[0248] (i) the VH amino acid sequence shown in SEQ ID NO: 50, or
[0249] (ii) the VH amino acid sequence shown in SEQ ID NO: 54, or
[0250] (iii) the VH amino acid sequence shown in SEQ ID NO: 57, or
[0251] (iv) the VH amino acid sequence shown in SEQ ID NO: 61, or
[0252] (v) the VH amino acid sequence shown in SEQ ID NO: 76, or
[0253] (vi) the VH amino acid sequence shown in SEQ ID NO: 79, or
[0254] (vii) the VH amino acid sequence shown in SEQ ID NO: 82, or
[0255] (viii) the VH amino acid sequence shown in SEQ ID NO: 85, or
[0256] (ix) the VH amino acid sequence shown in SEQ ID NO: 88, or
[0257] (x) the VH amino acid sequence as shown in SEQ ID NO: 106; or
[0258] (d) the VL amino acid sequence shown in SEQ ID NO: 130 and
[0259] (i) the VH amino acid sequence shown in SEQ ID NO: 99, or
[0260] (ii) the VH amino acid sequence shown in SEQ ID NO: 106, or
[0261] (iii) the VH amino acid sequence shown in SEQ ID NO: 113, or
[0262] (iv) the VH amino acid sequence shown in SEQ ID NO: 116, or
[0263] (v) the VH amino acid sequence shown in SEQ ID NO: 133, or
[0264] (vi) the VH amino acid sequence as shown in SEQ ID NO: 136; or
[0265] (e) the VL amino acid sequence shown in SEQ ID NO: 119 and
[0266] (i) the VH amino acid sequence shown in SEQ ID NO: 106, or
[0267] (ii) the VH amino acid sequence shown in SEQ ID NO: 116.
[0268] In certain embodiments, an anti-FRα antibody construct of the present disclosure comprises an antigen binding domain comprising:
[0269] (i) the VH amino acid sequence shown in SEQ ID NO: 19 and the VL amino acid sequence shown in SEQ ID NO: 39, or
[0270] (ii) the VH amino acid sequence shown in SEQ ID NO: 50 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0271] (iii) the VH amino acid sequence shown in SEQ ID NO: 54 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0272] (iv) the VH amino acid sequence shown in SEQ ID NO: 57 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0273] (v) the VH amino acid sequence shown in SEQ ID NO: 61 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0274] (vi) the VH amino acid sequence shown in SEQ ID NO: 76 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0275] (vii) the VH amino acid sequence shown in SEQ ID NO: 79 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0276] (viii) the VH amino acid sequence shown in SEQ ID NO: 82 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0277] (ix) the VH amino acid sequence shown in SEQ ID NO: 85 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0278] (x) the VH amino acid sequence shown in SEQ ID NO: 88 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0279] (xi) the VH amino acid sequence shown in SEQ ID NO: 91 and the VL amino acid sequence shown in SEQ ID NO: 124, or
[0280] (xii) the VH amino acid sequence shown in SEQ ID NO: 99 and the VL amino acid sequence shown in SEQ ID NO: 130, or
[0281] (xiii) the VH amino acid sequence shown in SEQ ID NO: 106 and the VL amino acid sequence shown in SEQ ID NO: 64, or
[0282] (xiv) the VH amino acid sequence shown in SEQ ID NO: 106 and the VL amino acid sequence shown in SEQ ID NO: 119, or
[0283] (xv) the VH amino acid sequence shown in SEQ ID NO: 106 and the VL amino acid sequence shown in SEQ ID NO: 130, or
[0284] (xvi) the VH amino acid sequence shown in SEQ ID NO: 113 and the VL amino acid sequence shown in SEQ ID NO: 130, or
[0285] (xvii) the VH amino acid sequence shown in SEQ ID NO: 116 and the VL amino acid sequence shown in SEQ ID NO: 119, or
[0286] (xviii) the VH amino acid sequence shown in SEQ ID NO: 116 and the VL amino acid sequence shown in SEQ ID NO: 130, or
[0287] (xix) the VH amino acid sequence shown in SEQ ID NO: 133 and the VL amino acid sequence shown in SEQ ID NO: 130, or
[0288] (xx) the VH amino acid sequence shown in SEQ ID NO: 136 and the VL amino acid sequence shown in SEQ ID NO: 130.
[0289] Format
[0290] Anti-FRα antibody constructs can have various formats. The minimum component of an anti-FRα antibody construct is an antigen binding domain that binds to hFRα. The anti-FRα antibody construct may also optionally include one or more additional antigen binding domains and / or scaffolds. In those embodiments in which the anti-FRα antibody construct comprises two or more antigen binding domains, each additional antigen binding domain may bind to the same epitope within hFRα, may bind to a different epitope within hFRα, or may bind to a different antigen. Thus, the anti-FRα antibody construct may be, for example, monospecific, biparatopic, bispecific, or multispecific.
[0291] In certain embodiments, an anti-FRα antibody construct comprises at least one antigen-binding domain that binds hFRα and a scaffold, wherein the antigen-binding domain is operably linked to the scaffold. As used herein, the term "operably linked" means that the described components are in a relationship that allows them to function in their intended manner. Examples of suitable scaffolds are described below.
[0292] In certain embodiments, the anti-FRα antibody construct comprises two antigen binding domains that are optionally operably linked to a scaffold. In some embodiments, the anti-FRα antibody construct may comprise three or four antigen binding domains and optionally a scaffold. In these formats, when a scaffold is included, at least the first antigen binding domain is operably linked to the scaffold, and the remaining antigen binding domains can each be independently operably linked to the scaffold or the first antigen binding domain, or when more than two antigen binding domains are present, operably linked to another antigen binding domain.
[0293] Anti-FRα antibody constructs lacking a scaffold may comprise a single antigen binding domain of an appropriate format, such as an sdAb, or they may comprise two or more antigen binding domains optionally operably connected via one or more linkers. In such anti-FRα antibody constructs, the antigen binding domain may be in the format of scFv, Fab, sdAb, or a combination thereof. For example, using scFv as an antigen binding domain, formats such as tandem scFv ((scFv)2 or taFv) may be constructed, in which the scFvs are linked together via flexible linkers. scFv can also be used to construct a double antibody format, which comprises two scFvs connected via a short linker (typically about 5 amino acids in length). The restricted linker length causes scFv to dimerize in a head-to-tail manner. In any of the aforementioned forms, scFv can be further stabilized by comprising an interdomain disulfide bond. For example, a disulfide bond can be introduced between VL and VH by introducing an additional cysteine residue in each chain (e.g., at position 44 of VH and position 100 of VL) (see, e.g., Fitzgerald et al., 1997, Protein Engineering, 10: 1221-1225), or a disulfide bond can be introduced between the two VHs to provide a construct with a DART format (see, e.g., Johnson et al., 2010, J Mol. Biol., 399: 436-449).
[0294] Similarly, in some embodiments, a format comprising two sdAbs (such as VH or VHH) linked together by a suitable linker can be employed. Other examples of anti-FRα antibody construct formats that lack a scaffold include those based on Fab fragments, such as Fab2 and F(ab')2 formats, in which the Fab fragments are connected by a linker or IgG hinge region.
[0295] Combinations of antigen binding domains of varying sizes can also be employed to generate alternative scaffold-free formats. For example, scFv or sdAb can be fused to the C-terminus of one or both of the light and heavy chains of a Fab fragment, thereby generating a bivalent (Fab-scFv / sdAb) construct.
[0296] In certain embodiments, the anti-FRα antibody construct can be an antibody format based on an immunoglobulin (Ig). In certain embodiments, the anti-FRα antibody construct can be based on an IgG class immunoglobulin, such as an IgG1, IgG2, IgG3, or IgG4 immunoglobulin. In some embodiments, the anti-FRα antibody construct can be based on an IgG1 immunoglobulin. In the context of the present disclosure, when the anti-FRα antibody construct is based on a specified immunoglobulin isotype, it means that the anti-FRα antibody construct comprises all or part of the constant region of the specified immunoglobulin isotype. For example, an anti-FRα antibody construct based on a given Ig isotype may comprise at least one antigen binding domain operably linked to an Ig scaffold, wherein the scaffold comprises an Fc region from a given isotype and optionally an Ig hinge region from the same or different isotypes. It should be understood that in some embodiments, the anti-FRα antibody construct may also comprise a hybrid of an isotype and / or subclass. It should also be understood that the Fc region and / or hinge region may be optionally modified to impart one or more desired functional properties known in the art.
[0297] In some embodiments, the anti-FRα antibody construct can be derived from two or more immunoglobulins from different species, for example, the anti-FRα antibody construct can be a chimeric antibody or a humanized antibody. The terms "chimeric antibody" and "humanized antibody" generally refer to antibodies that combine immunoglobulin regions or domains from more than one species.
[0298] "Chimeric antibodies" typically comprise at least one variable domain from a non-human antibody, such as a rabbit or rodent (e.g., murine) antibody, and at least one constant domain from a human antibody. The human constant domain of a chimeric antibody need not have the same isotype as the non-human constant domain it replaces. Chimeric antibodies are discussed, for example, in Morrison et al., 1984, Proc. Natl. Acad. Sci. USA, 81: 6851-55 and U.S. Patent No. 4,816,567.
[0299] "Humanized antibodies" are a class of chimeric antibodies that contain minimal sequence derived from non-human antibodies. Typically, humanized antibodies are human immunoglobulins (recipient antibodies) in which residues from the recipient's hypervariable regions (CDRs) are replaced with residues from hypervariable regions (CDRs) of a non-human species (donor antibody) with the desired specificity and affinity for the target antigen, such as mouse, rat, rabbit, or non-human primate. This technique for creating humanized antibodies is often referred to as "CDR grafting."
[0300] In some cases, additional modifications can be made to humanized antibodies to further improve antibody performance. For example, the framework region (FR) residues of human immunoglobulins are replaced by corresponding non-human residues, or humanized antibodies may include residues not found in the recipient antibody or donor antibody. In general, the variable domains in humanized antibodies will include all or nearly all of the hypervariable regions from non-human immunoglobulins and all or nearly all of the FRs from human immunoglobulin sequences. Humanized antibodies are described in more detail in, for example, Jones et al., 1986, Nature, 321: 522-525; Riechmann et al., 1988, Nature, 332: 323-329, and Presta, 1992, Curr. Op. Struct. Biol., 2: 593-596.
[0301] Many methods are known in the art for selecting the most appropriate people framework for transplanting non-human CDR therein. Early methods use a limited subset of fully characterized human antibodies, unrelated to the sequence identity of the non-human antibodies providing CDR ("fixed framework" method). Recent methods have adopted a variable region with high amino acid sequence identity ("homologous matching" or "best fit" method) with the variable region of the non-human antibodies providing CDR. Alternative methods are to select the fragment of framework sequence from each light chain or heavy chain variable region from several different human antibodies. In some cases, CDR transplantation may cause the molecule of transplantation to partially or completely lose the affinity of its target antigen. In such cases, affinity can be restored by backmutating some human-derived residues to corresponding non-human residues. Methods for preparing humanized antibodies by these methods are well known in the art (see, e.g., Tsurushita & Vasquez, 2004, Humanization of Monoclonal Antibodies, Molecular Biology of B Cells, 533-545, Elsevier Science (USA); Jones et al., 1986, Nature, 321: 522-525; Riechmann et al., 1988, Nature, 332: 323-329; Presta et al., 1997, Cancer Res, 57(20): 4593-4599).
[0302] Alternatively, or in addition to these traditional methods, newer technology can be adopted to further reduce the immunogenicity of the humanized antibody of CDR transplantation.For example, a framework based on human germline sequence or consensus sequence can be adopted as acceptor human framework rather than the human framework with somatic mutation.Another kind of technology that is intended to reduce the potential immunogenicity of non-human CDR is to only transplant specificity determining residues (SDR).In this method, only the minimum CDR residues (" SDR ") required for antigen binding activity are transplanted into the human germline framework.This method improves the " humanity " (i.e., with the similarity of human germline sequence) of humanized antibody, therefore can contribute to reducing the immunogenicity risk of variable region. These techniques have been described in various publications (see, e.g., Almagro & Fransson, 2008, Front Biosci, 13: 1619-1633; Tan, et al., 2002, J Immunol, 169: 1119-1125; Hwang, et al., 2005, Methods, 36: 35-42; Pelat, et al., 2008, J Mol Biol, 384: 1400-1407; Tamura, et al., 2000, J Immunol, 164: 1432-1441; Gonzales, et al., 2004, Mol Immunol, 1: 863-872, and Kashmiri, et al., 2005, Methods, 36: 25-34).
[0303] In certain embodiments, the anti-FRα antibody constructs of the present disclosure comprise humanized antibody sequences, such as one or more humanized variable domains. In some embodiments, the anti-FRα antibody constructs can be humanized antibodies. Non-limiting examples of humanized antibodies based on the anti-FRα antibody v23924 are described herein (v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, and v31426; see Examples and Sequence Listing).
[0304] bracket
[0305] In certain embodiments, the anti-FRα antibody construct comprises one or more antigen binding domains operably linked to a scaffold. The antigen binding domain can be one or a combination of the above forms (e.g., scFv, Fab, and / or sdAb). Examples of suitable scaffolds are described in more detail below and include, but are not limited to, immunoglobulin Fc regions, albumin, albumin analogs and derivatives, heterodimerization peptides (such as leucine zippers, "zipper" peptides forming heterodimers derived from Jun and Fos, IgG CH1 and CL domains, or barnase-barstar toxins), cytokines, chemokines, or growth factors. Other examples include DOCK-AND-LOCK based on the scaffolds developed by IBC Pharmaceuticals, Inc. and Immunomedics, Inc. TM (DNL TM ) technology (see, e.g., Chang et al., 2007, Clin. Cancer Res., 13:5586s-5591s).
[0306] The scaffold can be a peptide, polypeptide, polymer, nanoparticle or other chemical entity. When the scaffold is a polypeptide, each antigen-binding domain of the anti-FRα antibody construct can be linked to the N-terminus or C-terminus of the polypeptide scaffold. In certain embodiments, anti-FRα antibody constructs comprising a polypeptide scaffold are also contemplated, wherein one or more antigen-binding domains are linked to regions other than the N-terminus or C-terminus, for example, via amino acid side chains with or without a linker.
[0307] In embodiments where the anti-FRα antibody construct comprises a scaffold that is a peptide or polypeptide, the antigen binding domain can be linked to the scaffold by genetic fusion or chemical conjugation. Typically, when the scaffold is a peptide or polypeptide, the antigen binding domain is linked to the scaffold by genetic fusion. In some embodiments, where the scaffold is a polymer or nanoparticle, the antigen binding domain can be linked to the scaffold by chemical conjugation.
[0308] Many protein domains are known in the art that comprise selective pairing of two different polypeptides and can be used to form scaffolds. Examples include leucine zipper domains that selectively pair together, such as Fos and Jun (Kostelny et al., J Immunol, 148: 1547-53 (1992); Wranik et al., J. Biol. Chem., 287: 43331-43339 (2012)). Other selectively paired molecular pairs include, for example, barnase-barstar pairs (Deyev et al., Nat Biotechnol, 21: 1486-1492 (2003)), DNA strand pairs (Chaudri et al., FEBS Letters, 450 (1–2): 23-26 (1999)) and split fluorescent protein pairs (International Patent Application Publication No. WO 2011 / 135040).
[0309] Other examples of protein scaffolds include immunoglobulin Fc regions, albumin, albumin analogs and derivatives, toxins, cytokines, chemokines, and growth factors. The use of protein scaffolds in combination with antigen binding moieties has been described (see, e.g., Müller et al., 2007, J. Biol. Chem., 282: 12650-12660; McDonaugh et al., 2012, Mol. Cancer Ther., 11: 582-593; Vallera et al., 2005, Clin. Cancer Res., 11: 3879-3888; Song et al., 2006, Biotech. Appl. Biochem., 45: 147-154 and U.S. Patent Application Publication No. 2009 / 0285816).
[0310] For example, it has been shown that fusing an antigen-binding moiety, such as a scFv, a diabody, or a single-chain diabody, to albumin can improve the serum half-life of the antigen-binding moiety (Müller et al., supra). The antigen-binding moiety can be fused to the N-terminus and / or C-terminus of albumin, optionally via a linker.
[0311] Albumin derivatives in the form of heteromultimers have been described, comprising two transporter polypeptides obtained by fragmenting albumin, such that the transporter polypeptides self-assemble to form a natural albumin-like structure (see International Patent Application Publication Nos. WO 2012 / 116453 and WO 2014 / 012082). Due to the fragmentation of albumin, the heteromultimer comprises four termini and can therefore optionally be fused to up to four different antigen-binding moieties via a linker.
[0312] In certain embodiments, the anti-FRα antibody construct may comprise a protein scaffold. In some embodiments, the anti-FRα antibody construct may comprise a protein scaffold based on an immunoglobulin Fc region, albumin, or an albumin analog or derivative. In some embodiments, the anti-FRα antibody construct may comprise a protein scaffold based on an immunoglobulin Fc region (e.g., an IgG Fc region).
[0313] Fc region
[0314] As used herein, the term "Fc region," "Fc," or "Fc domain" refers to the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. Unless otherwise indicated herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991).
[0315] In certain embodiments, the anti-FRα antibody construct may comprise a scaffold based on the Fc region of an immunoglobulin. The Fc region may be dimeric and consist of two Fc polypeptides, or alternatively, the Fc region may consist of a single polypeptide.
[0316] In the context of a dimeric Fc region, "Fc polypeptide" refers to one of the two polypeptides that form the dimeric Fc domain, i.e., a polypeptide comprising one or more C-terminal constant regions of immunoglobulin heavy chains that are capable of stable self-association. When referring to polypeptides that form a dimeric Fc region, the terms "first Fc polypeptide" and "second Fc polypeptide" can be used interchangeably, provided that the Fc region comprises one first Fc polypeptide and one second Fc polypeptide.
[0317] The Fc region may comprise a CH3 domain or it may comprise both a CH3 and a CH2 domain. For example, in certain embodiments, the Fc polypeptide of a dimeric IgG Fc region may comprise an IgG CH2 domain sequence and an IgG CH3 domain sequence. In such embodiments, the CH3 domain comprises two CH3 sequences, one from each of the two Fc polypeptides of the dimeric Fc region, and the CH2 domain comprises two CH2 sequences, one from each of the two Fc polypeptides of the dimeric Fc region.
[0318] In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on an IgG Fc region. In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on a human IgG Fc region. In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on an IgG1 Fc region. In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on a human IgG1 Fc region.
[0319] In certain embodiments, the anti-FRα antibody construct may comprise a scaffold based on an IgG Fc region, which is a homodimeric Fc region comprising a first Fc polypeptide and a second Fc polypeptide, each comprising a CH3 sequence and optionally a CH2 sequence, and wherein the amino acid sequence of the first and second Fc polypeptides is identical.
[0320] In certain embodiments, the anti-FRα antibody construct may comprise a scaffold based on an IgG Fc region, wherein the IgG Fc region is a heterodimeric Fc region, comprising a first Fc polypeptide and a second Fc polypeptide, each comprising a CH3 sequence and optionally a CH2 sequence, and wherein the first and second Fc polypeptides have different amino acid sequences. In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on an Fc region, wherein the Fc region comprises two CH3 sequences, wherein at least one CH3 sequence comprises one or more amino acid modifications. In some embodiments, the anti-FRα antibody construct may comprise a scaffold based on an Fc region, wherein the Fc region comprises two CH3 sequences and two CH2 sequences, wherein at least one CH2 sequence comprises one or more amino acid modifications.
[0321] In some embodiments, the anti-FRα antibody construct may comprise a heterodimeric Fc region comprising a modified CH3 domain, wherein the modified CH3 domain is an asymmetrically modified CH3 domain comprising one or more asymmetric amino acid modifications. As used herein, "asymmetric amino acid modification" refers to a modification, such as a substitution or insertion, in which the amino acid at a specific position on a first CH3 or CH2 sequence is different from the amino acid at the same position on a second CH3 or CH2 sequence. These asymmetric amino acid modifications may be modifications of only one of the two amino acids at the same corresponding amino acid position on each sequence, or the result of different modifications of the two amino acids at the same corresponding position on each of the first and second CH3 or CH2 sequences. Each of the first and second CH3 or CH2 sequences of the heterodimeric Fc may comprise one or more asymmetric amino acid modifications.
[0322] In some embodiments, the anti-FRα antibody construct may comprise a heterodimeric Fc comprising a modified CH3 domain, wherein the modified CH3 domain comprises one or more amino acid modifications that promote heterodimeric Fc formation over homodimeric Fc formation. In some embodiments, one or more of the amino acid modifications are asymmetric amino acid modifications.
[0323] Amino acid modifications that can be made to the CH3 domain of an Fc to promote the formation of heterodimeric Fc are known in the art and include, for example, those described in International Publication No. WO 96 / 027011 ("knob-mold"), Gunasekaran et al., 2010, J Biol Chem, 285, 19637-46 ("electrostatic manipulation"), Davis et al., 2010, Prot Eng Des Sel, 23(4): 195-202 (strand exchange engineered domain (SEED) technology), and Labrijn et al., 2013, Proc Natl Acad Sci USA, 110(13): 5145-50 (Fab arm exchange). Other examples include methods that combine positive and negative design strategies to generate stable asymmetric modified Fc regions, such as those described in International Publication Nos. WO 2012 / 058768 and WO 2013 / 063702. In certain embodiments, an anti-FRα antibody construct may comprise a modified Fc region-based scaffold as described in International Publication Nos. WO 2012 / 058768 or WO 2013 / 063702.
[0324] Table 5 provides the amino acid sequence of the human IgG1 Fc sequence (SEQ ID NO: 16), which corresponds to amino acids 231 to 447 of the full-length human IgG1 heavy chain. The CH3 sequence comprises amino acids 341-447 of the full-length human IgG1 heavy chain. Also shown in Table 5 are CH3 domain amino acid modifications that promote heterodimeric Fc formation, as described in International Patent Application Publication Nos. WO 2012 / 058768 and WO 2013 / 063702.
[0325] In certain embodiments, the anti-FRα antibody construct may comprise a heterodimeric Fc scaffold with a modified CH3 domain comprising modifications of any of Variant 1, Variant 2, Variant 3, Variant 4, or Variant 5, as shown in Table 5.
[0326] Table 5: Human IgG1 Fc sequence and CH3 domain amino acid modifications that promote heterodimer formation
[0327]
[0328]
[0329] 1 Sequence of positions 231-447 (EU numbering)
[0330] In some embodiments, an anti-FRα antibody construct may comprise an Fc region-based scaffold comprising two CH3 sequences and two CH2 sequences, wherein at least one CH2 sequence comprises one or more amino acid modifications. Modifications in the CH2 domain may affect binding of Fc receptors (FcRs) to Fc, such as receptors of the FcγRI, FcγRII, and FcγRIII subclasses.
[0331] In some embodiments, the anti-FRα antibody construct comprises an IgG Fc-based scaffold with a modified CH2 domain, wherein the modification of the CH2 domain results in altered binding to one or more of the FcγRI, FcγRII, and FcγRIII receptors.
[0332] A variety of amino acid modifications that selectively change the affinity of Fc for different Fcγ receptors to the CH2 domain are known in the art. Amino acid modifications that result in increased binding and amino acid modifications that result in reduced binding can each be used for certain indications. For example, increasing the binding affinity of Fc to FcγRIIIa (an activating receptor) can cause an increase in antibody-dependent cell-mediated cytotoxicity (ADCC), which in turn causes an increase in the lysis of target cells. Reducing binding to FcγRIIb (an inhibitory receptor) may also be beneficial in some cases. In certain indications, it may be necessary to reduce or eliminate ADCC and complement-mediated cytotoxicity (CDC). In such cases, a modified CH2 domain ("knockout" variant) comprising an amino acid modification that results in increased binding to FcγRIIb or that reduces or eliminates the binding of the Fc region to all Fcγ receptors may be useful.
[0333] Examples of amino acid modifications to the CH2 domain that alter Fcγ receptor binding to Fc include, but are not limited to, the following: S298A / E333A / K334A and S298A / E333A / K334A / K326A (increased affinity for FcγRIIIa) (Lu, et al., 2011, J Immunol Methods, 365(1-2):132-41); F243L / R292P / Y300L / V305I / P396L (increased affinity for FcγRIIIa) (Stavenhagen, et al., 2007, Cancer Res, 67(18):8882-90); F243L / R292P / Y300L / L235V / P396L (increased affinity for FcγRIIIa) (Nordstrom JL, et al., 2011, Breast Cancer Res, 13(6):R123); F243L (increased affinity for FcγRIIIa) (Stewart, et al., 2011, Protein Eng Des Sel., 24(9):671-8); S298A / E333A / K334A (increased affinity for FcγRIIIa) (Shields, et al., 2001, J Biol Chem, 276(9):6591-604); S239D / I332E / A330L and S239D / I332E (increased affinity for FcγRIIIa) (Lazar, et al., 2006, Proc Natl Acad Sci USA, 103 (11): 4005-10), and S239D / S267E and S267E / L328F (increased affinity for FcγRIIb) (Chu, et al., 2008, Mol Immunol, 45 (15): 3926-33). Various amino acid modifications to the CH2 domain that alter the binding of FcγRIIb to Fc are described in International Publication No. WO 2021 / 232162. Additional modifications that affect the binding of Fc to Fcγ receptors are described in Therapeutic Antibody Engineering (Strohl & Strohl, Woodhead Publishing series in Biomedicine No 11, ISBN 1 907568 37 9, October 2012, page 283).
[0334] In certain embodiments, the anti-FRα antibody construct comprises an IgG Fc-based scaffold with a modified CH2 domain comprising one or more amino acid modifications that result in reduced or eliminated binding of the Fc region to all Fcγ receptors (i.e., a "knockout" variant).
[0335] Various publications describe strategies that have been used to engineer antibodies to produce "knockout" variants (see, e.g., Strohl, 2009, Curr Opin Biotech 20: 685-691, and Strohl & Strohl, "Antibody Fcengineering for optimal antibody performance" In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing, 2012, pp. 225-249). These strategies include reducing effector function by glycosylation modification, using IgG2 / IgG4 scaffolds, or introducing mutations in the hinge or CH2 domains of Fc (see also U.S. Patent Publication No. 2011 / 0212087, International Publication No. WO 2006 / 105338, U.S. Patent Publication No. 2012 / 0225058, U.S. Patent Publication No. 2012 / 0251531, and Strop et al., 2012, J. Mol. Biol., 420: 204-219).
[0336] Examples of mutations that can be introduced into the hinge or CH2 domain to generate "knockout" variants include amino acid modifications L234A / L235A and L234A / L235A / D265S.
[0337] In certain embodiments, the anti-FRα antibody constructs described herein may comprise an IgG Fc-based scaffold in which the native glycosylation has been modified. As is known in the art, the carbohydrate groups of Fc can be modified to increase or decrease effector function. For example, mutation of the conserved asparagine residue at position 297 to alanine, glutamine, lysine, or histidine (i.e., N297A, Q, K, or H) results in the production of a non-glycosylated Fc lacking all effector functions (Bolt et al., 1993, Eur. J. Immunol., 23:403-411; Tao & Morrison, 1989, J. Immunol., 143:2595-2601).
[0338] In contrast, removal of fucose from heavy chain N297-linked oligosaccharides has been shown to enhance ADCC based on improved binding to FcγRIIIa (see, e.g., Shields et al., 2002, J Biol Chem., 277:26733-26740, and Niwa et al., 2005, J. Immunol. Methods, 306:151-160). Such low-fucose antibodies can be produced, for example, in knockout Chinese hamster ovary (CHO) cells that lack fucosyltransferase (FUT8) (Yamane-Ohnuki et al., 2004, Biotechnol. Bioeng., 87:614-622); in a variant CHO cell line, Lec 13, with reduced ability to attach fucose to N297-linked carbohydrates (International Publication No. WO 03 / 035835), or other cells that produce afucosylated antibodies (see, e.g., Li et al., 2006, Nat Biotechnol, 24:210-215; Shields et al., 2002, ibid., and Shinkawa et al., 2003, J. Biol. Chem., 278:3466-3473). Additionally, International Publication No. WO 2009 / 135181 describes the addition of a fucose analog to the culture medium during antibody production to inhibit the incorporation of fucose into carbohydrates on the antibody.
[0339] Other methods for producing antibodies with little or no fucose at the Fc glycosylation site (N297) are well known in the art. For example, Technology (ProBioGen AG) (see von Horsten et al., 2010, Glycobiology, 20(12): 1607-1618 and US Pat. No. 8,409,572).
[0340] Other glycosylation variants include those with bisected oligosaccharide variants, for example, variants in which the biantennary oligosaccharide attached to the Fc region of the antibody is bisected by N-acetylglucosamine (GlcNAc). Such glycosylation variants can have reduced fucosylation and / or improved ADCC function (see, for example, International Publication No. WO 2003 / 011878, U.S. Patent No. 6,602,684 and U.S. Patent Application Publication No. US 2005 / 0123546). Useful glycosylation variants also include those with at least one galactose residue in the oligosaccharide attached to the Fc region, which can have improved CDC function (see, for example, International Publication No. WO 1997 / 030087, WO 1998 / 58964 and WO 1999 / 22764).
[0341] In certain embodiments, the anti-FRα antibody construct has the format of a full-size antibody (FSA). In some embodiments, the anti-FRα antibody construct has an IgG FSA format, such as an IgG1 FSA. In some embodiments, the anti-FRα antibody construct is an FSA comprising a first heavy chain sequence (H1), a second heavy chain sequence (H2), a first light chain sequence (L1), and a second light chain sequence (L2). In some embodiments, the anti-FRα antibody construct is a monospecific FSA with a homodimeric Fc and comprises H1, H2, L1, and L2 sequences, wherein H1 and H2 have the same amino acid sequence, and L1 and L2 have the same amino acid sequence. In some embodiments, the anti-FRα antibody construct is a monospecific FSA with a heterodimeric Fc and comprises H1, H2, L1, and L2 sequences, wherein H1 and H2 have different amino acid sequences, and L1 and L2 have the same amino acid sequence. In some embodiments, the anti-FRα antibody construct is a bispecific or biparatopic FSA with a heterodimeric Fc and comprises H1, H2, L1, and L2 sequences, wherein H1 and H2 have different amino acid sequences, and L1 and L2 have different amino acid sequences.
[0342] In certain embodiments, the anti-FRα antibody construct is a FSA having a set of H1, H2, L1, and L2 sequences comprising the H1, H2, L1, and L2 amino acid sequences as set forth in Tables A and B for any of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675. As is known in the art, expression of antibody heavy chain sequences in certain cell lines or from certain expression vectors can result in the inclusion of a C-terminal lysine residue on one or both heavy chains. Thus, certain embodiments of the present disclosure relate to anti-FRα antibody constructs that are FSAs having a set of H1, H2, L1, and L2 sequences comprising the H1, H2, L1, and L2 amino acid sequences as set forth in Tables A and B for any of variants v23924, v30618, v30384, v30389, v30394, v30399, v31422, v31423, v31424, v31425, v31426, v35305, v35342, v35347, v35348, v35350, v35354, v35356, v35358, v36167, v36168, or v36675, wherein one or both of the H1 and H2 sequences comprise a C-terminal lysine (see, e.g., SEQ ID NO: 105). NO:157).
[0343] Preparation of anti-FRα antibody constructs
[0344] The anti-FRα antibody constructs described herein can be produced using standard recombinant methods known in the art (see, eg, US Pat. No. 4,816,567 and “Antibodies: A Laboratory Manual,” 2nd ed., Greenfield, ed., Cold Spring Harbor Laboratory Press, New York, 2014).
[0345] Typically, in order to recombinantly produce an antibody construct, a polynucleotide or a set of polynucleotides encoding an anti-FRα antibody construct is generated and inserted into one or more vectors for further cloning and / or expression in a host cell. Polynucleotides encoding anti-FRα antibody constructs can be produced by standard methods known in the art (see, for example, Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1994 and updates, and "Antibodies: A Laboratory Manual," 2nd edition, Greenfield ed., Cold Spring Harbor Laboratory Press, New York, 2014). As will be appreciated by those skilled in the art, the number of polynucleotides required to express an anti-FRα antibody construct will depend on the format of the construct, including whether the antibody construct comprises a scaffold. For example, when the anti-FRα antibody construct is in a mAb format with a homodimeric Fc, two polynucleotides each encoding one polypeptide chain will be required, while when the anti-FRα antibody construct is in a mAb format with a heterodimeric Fc, three polynucleotides each encoding one polypeptide chain will be required. When multiple polynucleotides are desired, they can be incorporated into one vector or more than one vector.
[0346] Typically, for expression, a polynucleotide or a group of polynucleotides is incorporated into one or more expression vectors together with one or more regulatory elements, such as transcription elements, which are required for the effective transcription of the polynucleotides. Examples of such regulatory elements include, but are not limited to, promoters, enhancers, terminators, and polyadenylation signals. It will be understood by those skilled in the art that the selection of regulatory elements depends on the host cell selected for expressing the antibody construct, and such regulatory elements can be derived from a variety of sources, including bacteria, fungi, viruses, mammals, or insect genes. The expression vector may optionally further contain a heterologous nucleic acid sequence that facilitates expression or purification of the expressed protein. Examples include, but are not limited to, signal peptides and affinity tags, such as metal affinity tags, histidine tags, avidin / streptavidin coding sequences, glutathione-S-transferase (GST) coding sequences, and biotin coding sequences. The expression vector may be an extrachromosomal vector or an integrating vector.
[0347] Suitable host cells for cloning or expressing anti-FRα antibody constructs include various prokaryotic or eukaryotic cells known in the art. Eukaryotic host cells include, for example, mammalian cells, plant cells, insect cells, and yeast cells (such as Saccharomyces or Pichia cells). Prokaryotic host cells include, for example, Escherichia coli, Aeromonas salmonicida, or Bacillus subtilis cells.
[0348] In certain embodiments, anti-FRα antibody constructs can be produced in bacteria, particularly when glycosylation and Fc effector functions are not desired, as described, for example, in U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523; and in Charlton, Methods in Molecular Biology, Vol. 248, pp. 245-254, BKC Lo, ed., Humana Press, Totowa, NJ, 2003.
[0349] In certain embodiments, eukaryotic microorganisms such as filamentous fungi or yeast can be suitable expression host cells, particularly fungal and yeast strains whose glycosylation pathways have been "humanized" to result in the production of antibody constructs with partially or fully human glycosylation patterns (see, e.g., Gerngross, 2004, Nat. Biotech. 22: 1409-1414, and Li et al., 2006, Nat. Biotech. 24: 210-215).
[0350] Suitable host cells for expressing glycosylated anti-FRα antibody constructs are generally eukaryotic cells. For example, U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 describe PLANTIBODIES for producing antigen-binding constructs in transgenic plants. TM Mammalian cell lines adapted to growth in suspension are particularly useful for expressing antibody constructs. Examples include, but are not limited to, monkey kidney CV1 line transformed by SV40 (COS-7), human embryonic kidney (HEK) line 293 or 293 cells (see, e.g., Graham et al., 1977, J. Gen Virol., 36:59), baby hamster kidney cells (BHK), mouse Sertoli TM4 cells (see, e.g., Mather, 1980, Biol Reprod, 23:243-251), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma (HeLa) cells, canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), mouse mammary tumor (MMT 060562), TRI cells (see, e.g., Mather et al., 1982, Annals NY Acad Sci, 383:44-68), MRC 5 cells, FS4 cells, Chinese hamster ovary (CHO) cells (including DHFR -CHO cells (see Urlaub et al., 1980, Proc Natl Acad Sci USA, 77:4216) and myeloma cell lines (such as Y0, NS0 and Sp2 / 0). Exemplary mammalian host cell lines suitable for producing antibody constructs are reviewed in Yazaki and Wu, Methods in Molecular Biology, Vol. 248, pp. 255-268 (BKCLo ed., Humana Press, Totowa, NJ, 2003).
[0351] In certain embodiments, the host cell can be a transient or stable higher eukaryotic cell line, such as a mammalian cell line. In some embodiments, the host cell can be a mammalian HEK293T, CHO, HeLa, NS0, or COS cell line, or a cell line derived from any of these cell lines. In some embodiments, the host cell can be a stable cell line that allows mature glycosylation of the antibody construct.
[0352] Host cells containing expression vectors encoding anti-FRα antibody constructs can be cultured using conventional methods to produce anti-FRα antibody constructs. Alternatively, in some embodiments, host cells containing expression vectors encoding anti-FRα antibody constructs can be used therapeutically or prophylactically to deliver anti-FRα antibody constructs to a subject, or the polynucleotide or expression vector can be administered ex vivo to cells from a subject and then the cells returned to the subject's body.
[0353] Typically, anti-FRα antibody constructs are purified after expression. Proteins can be isolated or purified in a variety of ways known to those skilled in the art (see, for example, Protein Purification: Principles and Practice, 3rd Edition, Scopes, Springer-Verlag, NY, 1994). Standard purification methods include chromatographic techniques, including ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, fractionated chromatography or gel filtration and reverse phase chromatography, performed at atmospheric pressure or high pressure using systems such as FPLC and HPLC. Additional purification methods include electrophoresis, immunoassays, precipitation, dialysis, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques combined with protein concentration are also useful. As is well known in the art, a variety of natural proteins bind to Fc and antibodies, and these proteins can be used to purify certain antibody constructs. For example, bacterial proteins A and G bind to the Fc region. Similarly, the bacterial protein L binds to the Fab region of some antibodies. Purification can also be performed by specific fusion partners. For example, if a GST fusion is used, glutathione resin can be used to purify the antibody, and if a His tag is used, Ni can be used. +2Purify the antibody by affinity chromatography, or if a Flag tag is used, an immobilized anti-Flag antibody can be used to purify the antibody. The degree of purification required will vary depending on the anti-FRα antibody construct used. In some cases, no purification may be necessary.
[0354] In certain embodiments, the anti-FRα antibody construct is substantially pure. The term "substantially pure" (or "substantially purified"), when used in reference to the anti-FRα antibody constructs described herein, means that the antibody construct is substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment (such as a natural cell, or in the case of a recombinantly produced construct, a host cell). In certain embodiments, a substantially pure anti-FRα antibody construct is a protein preparation having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5% (by dry weight) of contaminating protein.
[0355] Certain embodiments of the present disclosure relate to methods of preparing an anti-FRα antibody construct, the methods comprising culturing a host cell into which one or more polynucleotides encoding the anti-FRα antibody construct or one or more expression vectors encoding the anti-FRα antibody construct have been introduced under conditions suitable for expression of the anti-FRα antibody construct, and optionally recovering the anti-FRα antibody construct from the host cell (or from host cell culture medium).
[0356] Post-translational modification
[0357] In certain embodiments, the anti-FRα antibody constructs described herein may comprise one or more post-translational modifications. Such post-translational modifications may occur in vivo, or in vitro after the anti-FRα antibody construct is isolated from a host cell.
[0358] Post-translational modifications include various modifications known in the art (see, e.g., Proteins-Structure and Molecular Properties, 2nd ed., E.C. Creighton, W.H. Freeman and Company, New York, 1993; Post-Translational Covalent Modification of Proteins, ed. B.C. Johnson, Academic Press, New York, pp. 1-12, 1983; Seifter et al., 1990, Meth. Enzymol., 182: 626-646, and Rattan et al., 1992, Ann. NY Acad. Sci., 663: 48-62). In those embodiments in which the anti-FRα antibody construct comprises one or more post-translational modifications, the construct may comprise the same type of modification at one or several sites, or it may comprise different modifications at different sites.
[0359] Examples of post-translational modifications include glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, formylation, oxidation, reduction, proteolytic cleavage, or specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, or NaBH4.
[0360] Other examples of post-translational modifications include, for example, the addition or removal of N-linked or O-linked carbohydrate chains, chemical modification of N-linked or O-linked carbohydrate chains, manipulation of the N-terminus or C-terminus, attachment of chemical moieties to the amino acid backbone, and the addition or deletion of an N-terminal methionine residue resulting from expression in prokaryotic host cells. Post-translational modifications may also include modification with a detectable label (such as an enzyme label, a fluorescent label, a luminescent label, an isotope label, or an affinity label) to allow for detection and isolation of the protein. Examples of suitable enzyme labels include, but are not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, and acetylcholinesterase. Examples of suitable prosthetic group complexes include, but are not limited to, streptavidin / biotin and avidin / biotin. Examples of suitable fluorescent materials include, but are not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, and phycoerythrin. Examples of luminescent materials include luminol and bioluminescent materials such as luciferase, luciferin, and aequorin. Examples of suitable radioactive materials include iodine, carbon, sulfur, tritium, indium, technetium, thallium, gallium, palladium, molybdenum, xenon, and fluorine.
[0361] Additional examples of post-translational modifications include acetylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, gamma-carboxylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, pegylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA-mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
[0362] Camptothecin analogs
[0363] The camptothecin analogs encompassed by the ADCs of the present disclosure are compounds having formula (I):
[0364]
[0365] in:
[0366] R 1 is selected from the group consisting of: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3, -OCF3, and -NH2, and
[0367] R 2 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3,
[0368] And among them:
[0369] When R 1 When it is -NH2, then R is R 3 or R 4 , and when R 1 If it is not -NH2, then R is R 4 ;
[0370] R 3 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0371] R 4 Selected from:
[0372] R 5Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -aryl and -(C1-C6 alkyl)-aryl;
[0373] R 6 and R 7 Each independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ;
[0374] R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0375] Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0376] Each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0377] R 10’ Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0378] R 11 Selected from: -H and -C1-C6 alkyl;
[0379] R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and
[0380] R 13 Selected from: -H and -C1-C6 alkyl;
[0381] R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0382] R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0383] R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0384] R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ;
[0385] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0386] X a and X b are each independently selected from: NH, O and S, and
[0387] X c Selected from: O, S and S(O)2,
[0388] with the proviso that the compound is not (S)-9-amino-11-butyl-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione.
[0389] In some embodiments, the camptothecin analog is a compound of formula (I), provided that when R 1 When it is NH2, R 2 Not H.
[0390] In some embodiments, in the compound of formula (I), R 1 Selected from: -CH3, -CF3, -OCH3, -OCF3 and NH2.
[0391] In some embodiments, in the compound of formula (I), R 1 It's NH2.
[0392] In some embodiments, in the compound of formula (I), R 1 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3.
[0393] In some embodiments, in the compound of formula (I), R 1Selected from: -CH3, -CF3, -OCH3 and -OCF3.
[0394] In some embodiments, in the compound of formula (I), R 2 Selected from: -H, -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0395] In some embodiments, in the compound of formula (I), R 2 Selected from: -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0396] In some embodiments, in the compound of formula (I), R 2 Selected from: -H, -F, -Br and -Cl.
[0397] In some embodiments, in the compound of formula (I), R 2 Selected from: -F, -Br and -Cl.
[0398] In some embodiments, in the compound of formula (I), R 3 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0399] In some embodiments, in the compound of formula (I), R 4 Selected from:
[0400] In some embodiments, in the compound of formula (I), R 5 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0401] In some embodiments, in the compound of formula (I), R 6 and R 7 Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17.
[0402] In some embodiments, in the compound of formula (I), R 8 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0403] In some embodiments, in the compound of formula (I), each R 9 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0404] In some embodiments, in the compound of formula (I), each R 9 Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0405] In some embodiments, in the compound of formula (I), each R 9 Independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0406] In some embodiments, in the compound of formula (I), each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl and -(C1-C6 alkyl)-aryl.
[0407] In some embodiments, in the compound of formula (I), each R 10 Independently selected from: -C1-C6 alkyl, -NR 14 R 14’ , -aryl and -(1-C6 alkyl)-aryl.
[0408] In some embodiments, in the compound of formula (I), each R 10 Independently selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0409] In some embodiments, in the compound of formula (I), R 10’Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0410] In some embodiments, in the compound of formula (I), R 11 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0411] In some embodiments, in the compound of formula (I), R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16 .
[0412] In some embodiments, in the compound of formula (I), R 12 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl, -S(O)2R 16 and
[0413] In some embodiments, in the compound of formula (I), R 13 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0414] In some embodiments, in the compound of formula (I), R 14 and R 14’ Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0415] In some embodiments, in the compound of formula (I), R 16 Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0416] In some embodiments, in the compound of formula (I), R 16Selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0417] In some embodiments, in the compound of formula (I), R 17 Selected from: unsubstituted C1-C6 alkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, unsubstituted aryl, -hydroxyaryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0418] In some embodiments, in the compound of formula (I), R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, unsubstituted C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 .
[0419] In some embodiments, in the compound of formula (I), X a and X b are each independently selected from: NH and O.
[0420] Combinations of any of the foregoing embodiments of compounds of formula (I) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0421] In certain embodiments, the compound of Formula (I) has Formula (II):
[0422]
[0423] in:
[0424] R 2 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0425] R 20 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl,
[0426] R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0427] R 6 and R 7 Each independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ;
[0428] R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0429] Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0430] Each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0431] R 10’ Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0432] R 11 Selected from: -H and -C1-C6 alkyl;
[0433] R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and
[0434] R 13 Selected from: -H and -C1-C6 alkyl;
[0435] R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0436] R 16Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0437] R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0438] R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ;
[0439] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0440] X a and X b are each independently selected from: NH, O and S, and
[0441] X c Selected from: O, S and S(O)2,
[0442] with the proviso that the compound is not (S)-9-amino-11-butyl-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione.
[0443] In some embodiments, in the compound of formula (II), R 2 Selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3.
[0444] In some embodiments, in the compound of formula (II), R 2 Selected from: -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0445] In some embodiments, in the compound of formula (II), R 2 Selected from F and Cl.
[0446] In some embodiments, in the compound of formula (II), R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 –(C1-C6 alkyl)-aryl,
[0447] In some embodiments, in the compound of formula (II), R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 –(C1-C6 alkyl)-aryl,
[0448] In some embodiments, in the compound of formula (II), R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、
[0449] In some embodiments, in the compound of formula (II), R 20 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , unsubstituted aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl,
[0450] In some embodiments, in the compound of formula (II), R 2 is selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3, and R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 –(C1-C6 alkyl)-aryl,
[0451] In some embodiments, in the compound of formula (II), R 2 is selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3, and R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 –(C1-C6 alkyl)-aryl,
[0452] In some embodiments, in the compound of formula (II), R 2 is selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3, and R 20 Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、
[0453] In some embodiments, in the compound of formula (II), R 5 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0454] In some embodiments, in the compound of formula (II), R 6 and R 7 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C(O)R 17 .
[0455] In some embodiments, in the compound of formula (II), R 6 is H, and R 7 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 .
[0456] In some embodiments, in the compound of formula (II), R 6 is H, and R 7 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C(O)R 17 .
[0457] In some embodiments, in the compound of formula (II), R 6 and R 7 Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 .
[0458] In some embodiments, in the compound of formula (II), R 8Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0459] In some embodiments, in the compound of formula (II), each R 9 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0460] In some embodiments, in the compound of formula (II), each R 9 Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0461] In some embodiments, in the compound of formula (II), each R 9 Independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0462] In some embodiments, in the compound of formula (II), each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl and -(C1-C6 alkyl)-aryl.
[0463] In some embodiments, in the compound of formula (II), each R 10 Independently selected from: -C1-C6 alkyl, -NR 14 R 14’ , -aryl and -(1-C6 alkyl)-aryl.
[0464] In some embodiments, in the compound of formula (II), each R 10 Independently selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0465] In some embodiments, in the compound of formula (II), R 10’Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0466] In some embodiments, in the compound of formula (II), R 11 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0467] In some embodiments, in the compound of formula (II), R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16 .
[0468] In some embodiments, in the compound of formula (II), R 12 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl, -S(O)2R 16 and
[0469] In some embodiments, in the compound of formula (II), R 13 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0470] In some embodiments, in the compound of formula (II), R 14 and R 14’ Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0471] In some embodiments, in the compound of formula (II), R 16 Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0472] In some embodiments, in the compound of formula (II), R 16Selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0473] In some embodiments, in the compound of formula (II), R 17 It is a -C1-C6 alkyl group.
[0474] In some embodiments, in the compound of formula (II), R 17 Selected from: unsubstituted C1-C6 alkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, unsubstituted aryl, -hydroxyaryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0475] In some embodiments, in the compound of formula (II), R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 .
[0476] In some embodiments, in the compound of formula (II), X a and X b are each independently selected from: NH and O.
[0477] Combinations of any of the foregoing embodiments of compounds of formula (II) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0478] In certain embodiments, the compound of Formula (I) has Formula (III):
[0479]
[0480] in:
[0481] R 2 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0482] R 15 Selected from: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0483] R 4 Selected from:
[0484] R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0485] R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0486] Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0487] Each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl;
[0488] R 10’ Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0489] R 11 Selected from: -H and -C1-C6 alkyl;
[0490] R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and
[0491] R 13 Selected from: -H and -C1-C6 alkyl;
[0492] R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0493] R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0494] R 18 and R19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ;
[0495] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0496] X a and X b are each independently selected from: NH, O and S, and
[0497] X c Selected from: O, S and S(O)2.
[0498] In some embodiments, in the compound of formula (III), R 2 Selected from: -H, -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0499] In some embodiments, in the compound of formula (III), R 2 Selected from: -H, -F and -Cl.
[0500] In some embodiments, in the compound of formula (III), R 15 Selected from: -CH3, -CF3, -OCH3 and -OCF3.
[0501] In some embodiments, in the compound of formula (III), R 15 Selected from: -CH3 and -OCH3.
[0502] In some embodiments, in the compound of formula (III), R 2 is selected from: -H, -F and -Cl, and R 15 Selected from: -CH3, -CF3, -OCH3 and -OCF3.
[0503] In some embodiments, in the compound of formula (III), R 2 is selected from: -H, -F and -Cl, and R 15 Selected from: -CH3 and -OCH3.
[0504] In some embodiments, in the compound of formula (III), R 4 Selected from:
[0505] In some embodiments, in the compound of formula (III), R 5 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0506] In some embodiments, in the compound of formula (III), R 8 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0507] In some embodiments, in the compound of formula (III), each R 9 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0508] In some embodiments, in the compound of formula (III), each R 9 Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0509] In some embodiments, in the compound of formula (III), each R 9 Independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0510] In some embodiments, in the compound of formula (III), each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl and -(C1-C6 alkyl)-aryl.
[0511] In some embodiments, in the compound of formula (III), each R 10 Independently selected from: -C1-C6 alkyl, -NR 14 R 14’ , -aryl and -(1-C6 alkyl)-aryl.
[0512] In some embodiments, in the compound of formula (III), each R 10Independently selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0513] In some embodiments, in the compound of formula (III), R 10 ' is selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0514] In some embodiments, in the compound of formula (III), R 11 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0515] In some embodiments, in the compound of formula (III), R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16 .
[0516] In some embodiments, in the compound of formula (III), R 12 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl, -S(O)2R 16 and
[0517] In some embodiments, in the compound of formula (III), R 13 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0518] In some embodiments, in the compound of formula (III), R 14 and R 14’ Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0519] In some embodiments, in the compound of formula (III), R 16 Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0520] In some embodiments, in the compound of formula (III), R 16 Selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0521] In some embodiments, in the compound of formula (III), R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, unsubstituted C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 .
[0522] In some embodiments, in the compound of formula (III), X a and X b are each independently selected from: NH and O.
[0523] Combinations of any of the foregoing embodiments of compounds of formula (III) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0524] In certain embodiments, each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as defined in any one of formula (I), (II), or (III) is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, sulfanyl, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl. In some embodiments, each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as defined in any one of formula (I), (II), or (III) is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, sulfanyl, sulfonyl, and sulfonamido.
[0525] In certain embodiments, the camptothecin analog comprised by the ADC according to the present disclosure is a compound having Formula (I) and is selected from the compounds shown in Table 6 and Table 7.
[0526] In certain embodiments, the camptothecin analog is a compound having formula (II). In certain embodiments, the camptothecin analog is a compound having formula (II), wherein R 2 is F, and R 20 H, -(C1-C6)-OR 5 or In some embodiments, the camptothecin analog is a compound having formula (II), wherein R 2 F; R 20 H, -(C1-C6)-OR 5 or R 5 is H, and R 18 and R 19 Together with the N atom to which they are bound, they form an unsubstituted 4-, 5-, 6-, or 7-membered ring. In some embodiments, the camptothecin analog is a compound of formula (II), wherein R 2 F; R 20 -(C1-C6)-OR 5 , and R 5 is H. In certain embodiments, the camptothecin analog is a compound having formula (II) and is selected from the compounds shown in Table 6.
[0527] In certain embodiments, the camptothecin analog is a compound having the formula (III). In certain embodiments, the camptothecin analog is a compound having the formula (III), wherein R 2 F; R 15 -CH3; R 4 for R 9 is -C1-C6 hydroxyalkyl, and X a and X b Each is O. In certain embodiments, the camptothecin analog is a compound having formula (III) and is selected from the compounds shown in Table 7.
[0528] In certain embodiments, the camptothecin analog comprised by the ADC according to the present disclosure is Compound 139, Compound 140, Compound 141, or Compound 148. In some embodiments, the camptothecin analog comprised by the ADC according to the present disclosure is Compound 139 or Compound 141.
[0529] Table 6: Exemplary Camptothecin Analogs of Formula (II)
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536] Table 7: Exemplary Camptothecin Analogs of Formula (II)
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543] It should be understood that references throughout this disclosure to compounds of formula (I) include, in various embodiments, compounds of formula (II) and formula (III), as well as the individual compounds shown in Tables 6 and 7, to the same extent as if embodiments of each of these formulas or compounds were individually specifically recited.
[0544] Antibody-drug conjugates
[0545] The present disclosure relates to antibody-drug conjugates (ADCs) comprising an anti-FRα antibody construct conjugated to a camptothecin analog having formula (I). In certain embodiments, the ADC has formula (X):
[0546] T-[L-(D) m ] n
[0547] (X)
[0548] in:
[0549] T is an anti-FRα antibody construct as described herein;
[0550] L is the connector;
[0551] D is a camptothecin analog having formula (I);
[0552] m is between 1 and 4, and
[0553] n is between 1 and 10.
[0554] In certain embodiments, in the conjugate of formula (X), m is between 1 and 2. In some embodiments, m is 1.
[0555] In some embodiments, in the conjugate of formula (X), n is between 1 and 8, for example, between 2 and 8. In some embodiments, n is between 4 and 8.
[0556] In certain embodiments, in the conjugate of formula (X), m is between 1 and 2, and n is between 2 and 8, or between 4 and 8. In some embodiments, in the conjugate of formula (X), m is 1, and n is between 2 and 8, or between 4 and 8.
[0557] As shown above and reflected by the parameters m and n in Formula (X), the anti-FRα antibody construct "T" can be conjugated to more than one compound "D" of Formula (I). One skilled in the art will understand that, while any particular anti-FRα antibody construct T is conjugated to an integer number of compounds D, analysis of a preparation of the conjugate to determine the ratio of compound D to anti-FRα antibody construct T may yield a non-integer result, reflecting a statistical average. This ratio of compound D to targeting moiety T can generally be referred to as the drug-to-antibody ratio, or "DAR." Thus, conjugate preparations having non-integer DARs are intended to be encompassed by Formula (X).
[0558] In certain embodiments, in the conjugate of formula (X), D is a compound of formula (II) or formula (III). In certain embodiments, in the conjugate of formula (X), D is a compound selected from the compounds shown in Table 6 and Table 7. In certain embodiments, in the conjugate of formula (X), D is compound 139, compound 140, compound 141 or compound 148. In some embodiments, in the conjugate of formula (X), D is compound 139 or compound 141.
[0559] Certain embodiments of the present disclosure relate to ADCs having formula (X), wherein D is a compound of formula (IV):
[0560]
[0561] in:
[0562] R 1a Selected from: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3, -OCF3 and -NH2;
[0563] R 2a Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0564] X is -O-, -S- or -NH-, and R 4a Selected from:
[0565] wherein * is the point of attachment to X, and wherein p is 1, 2, 3, or 4; or
[0566] X is O, and R 4a -X- is selected from:
[0567] R 5a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0568] R 8a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0569] Each R 9a independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; or R 9a does not exist, and X b =X;
[0570] Each R 10a are independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and
[0571] Each R 10a’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0572] Each R 10b Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0573] R 11a Not present or -C1-C6 alkyl;
[0574] R 12a Selected from: -C1-C6 alkyl, -CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16a and
[0575] R 13aSelected from: -H and -C1-C6 alkyl;
[0576] R 14a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0577] R 14a’ Selected from: H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0578] R 16a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0579] R 21 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5a ;
[0580] R 22 and R 23 Each is independently selected from: -H, -halogen, -C1-C6 alkyl and -C3-C8 cycloalkyl;
[0581] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0582] X a and X b are each independently selected from: NH, O and S;
[0583] X c is selected from the group consisting of: O, S and S(O)2, and
[0584] Indicates the connection point with the linker L.
[0585] In some embodiments, in the compound of formula (IV), R 1a Selected from: -CH3, -CF3, -OCH3, -OCF3 and -NH2.
[0586] In some embodiments, in the compound of formula (IV), R 1a Selected from: -CH3, -CF3, -OCH3 and -OCF3.
[0587] In some embodiments, in the compound of formula (IV), R 1a Selected from: -CH3, -OCH3 and NH2.
[0588] In some embodiments, in the compound of formula (IV), R 1aSelected from: -CH3 and -OCH3.
[0589] In some embodiments, in the compound of formula (IV), R 2a Selected from: -H, -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0590] In some embodiments, in the compound of formula (IV), R 2a Selected from: -H, -F and -Cl.
[0591] In some embodiments, in the compound of formula (IV), R 2a Yes -F.
[0592] In some embodiments, in the compound of formula (IV), X is -O-, -S-, or -NH-, and R 4a Selected from:
[0593] In some embodiments, in the compound of Formula (IV), X is -O- or -NH-.
[0594] In some embodiments, in the compound of formula (IV), each R 9a Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0595] In some embodiments, in the compound of formula (IV), each R 9a Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0596] In some embodiments, in the compound of formula (IV), each R 10a Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -(C1-C6 alkyl)-aryl and
[0597] In some embodiments, in the compound of formula (IV), each R 10a Independently selected from: -C1-C6 alkyl, -aryl, -(1-C6 alkyl)-aryl and
[0598] In some embodiments, in the compound of formula (IV), R 12a Selected from: -C1-C6 alkyl, -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16 .
[0599] In some embodiments, in the compound of formula (IV), R13a Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0600] In some embodiments, in the compound of formula (IV), R 14a’ Selected from: H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0601] In some embodiments, in the compound of formula (IV), R 16a Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0602] In some embodiments, in the compound of formula (IV), R 22 and R 23 Each is independently selected from: -H, -halogen, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 aminoalkyl, -C1-C6 hydroxyalkyl and -C3-C8 cycloalkyl.
[0603] In some embodiments, in the compound of formula (IV), X a and X b are each independently selected from: NH and O.
[0604] In some embodiments, in the compound of formula (IV), X a and X b Each is O. and X b Each is O, and R 9a It is a -C1-C6 alkyl group.
[0605] In some embodiments, in the compound of formula (IV), X is O; R 4a for X a
[0606] In some embodiments, in the compound of formula (IV), R 1a is -CH3 or -OCH3; X is O; R 4a for X a and X b Each is O; and R 9a It is a -C1-C6 alkyl group.
[0607] In some embodiments, in the compound of formula (IV), R 1a is -CH3 or -OCH3; R 2a is H or F; X is O; R4a for X a and X b Each is O; and R 9a It is a -C1-C6 alkyl group.
[0608] Other combinations of any of the foregoing embodiments of compounds of formula (IV) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0609] Certain embodiments of the present disclosure relate to ADCs having formula (X), wherein D is a compound of formula (V):
[0610]
[0611] in:
[0612] R 2a Selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0613] R 20a Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl,
[0614] R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0615] R 6 and R 7 Each independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ;
[0616] R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0617] Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0618] Each R 10independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and -NR 14 R 14’ ;
[0619] Each R 10’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0620] R 11 Selected from: -H and -C1-C6 alkyl;
[0621] R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and
[0622] R 13 Selected from: -H and -C1-C6 alkyl;
[0623] R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0624] R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0625] R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0626] R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ;
[0627] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0628] X a and X bare each independently selected from: NH, O and S;
[0629] X c is selected from the group consisting of: O, S and S(O)2, and
[0630] Indicates the connection point with the linker L.
[0631] In some embodiments, in the compound of formula (V), R 2a Selected from: -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0632] In some embodiments, in the compound of formula (V), R 2a Selected from: -CF3, -F, -Cl and -OCH3.
[0633] In some embodiments, in the compound of formula (V), R 2a It's F.
[0634] In some embodiments, in the compound of formula (V), R 20a Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl,
[0635] In some embodiments, in the compound of formula (V), R 20a Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 -(C1-C6 alkyl)-aryl,
[0636] In some embodiments, in the compound of formula (V), R 20a Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、 -(C1-C6 alkyl)-aryl,
[0637] In some embodiments, in the compound of formula (V), R 20a Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 、
[0638] In some embodiments, in the compound of formula (V), R 20a Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 、 -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl,
[0639] In some embodiments, in the compound of formula (V), R 6 and R 7 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C(O)R 17 .
[0640] In some embodiments, in the compound of formula (V), R 6 is H, and R 7 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 .
[0641] In some embodiments, in the compound of formula (V), R 6 is H, and R 7 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C(O)R 17 .
[0642] In some embodiments, in the compound of formula (V), R 6 and R 7 Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 .
[0643] In some embodiments, in the compound of formula (V), R 8 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0644] In some embodiments, in the compound of Formula (V), each R 9 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0645] In some embodiments, in the compound of Formula (V), each R 9 Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0646] In some embodiments, in the compound of Formula (V), each R 9 Independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0647] In some embodiments, in the compound of Formula (V), each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl and -(C1-C6 alkyl)-aryl.
[0648] In some embodiments, in the compound of Formula (V), each R 10 Independently selected from: -C1-C6 alkyl, -NR 14 R 14’ , -aryl and -(1-C6 alkyl)-aryl.
[0649] In some embodiments, in the compound of formula (V), R 11 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0650] In some embodiments, in the compound of formula (V), R 12 Selected from: -H, -C1-C6 alkyl, -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16 .
[0651] In some embodiments, in the compound of formula (V), R 12 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -CO2R 8 , unsubstituted -aryl, -aminoaryl, -heteroaryl, -(C1-C6 alkyl)-aminoaryl, -S(O)2R 16and
[0652] In some embodiments, in the compound of formula (V), R 13 Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0653] In some embodiments, in the compound of formula (V), R 14 and R 14’ Each is independently selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0654] In some embodiments, in the compound of formula (V), R 16 Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0655] In some embodiments, in the compound of formula (V), R 16 Selected from: unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl, unsubstituted -aryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0656] In some embodiments, in the compound of formula (V), R 17 Selected from: unsubstituted -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, unsubstituted -aryl, -hydroxyaryl, -aminoaryl, -heteroaryl and -(C1-C6 alkyl)-aminoaryl.
[0657] In some embodiments, in the compound of formula (V), R 18 and R 19 Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 aminoalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 .
[0658] In some embodiments, in the compound of formula (V), R 17 It is a -C1-C6 alkyl group.
[0659] In some embodiments, in the compound of formula (V), Xa and X b are each independently selected from: NH and O.
[0660] In some embodiments, in the compound of formula (V), X a and X b Each is O.
[0661] In some embodiments, in the compound of formula (V), R 20a -(C1-C6 alkyl)-OR 5 .
[0662] In some embodiments, in the compound of formula (V), R 20a -(C1-C6 alkyl)-OR 5 , and R 5 For H.
[0663] In some embodiments, in the compound of formula (V), R 2a F; R 20a -(C1-C6 alkyl)-OR 5 , and R 5 For H.
[0664] Other combinations of any of the foregoing embodiments of compounds of formula (V) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0665] Certain embodiments of the present disclosure relate to ADCs having formula (X), wherein D is a compound of formula (VI):
[0666]
[0667] in:
[0668] R 2a Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3;
[0669] X is -O-, -S- or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a 、-CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl,
[0670] wherein * is the point of attachment to X, and wherein p is 1, 2, 3, or 4; or
[0671] X is O, and R25 -X- is selected from:
[0672] R 5a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0673] R 6a Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0674] R 7a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5a , -C3-C8 heterocycloalkyl and -C(O)R 17a ;
[0675] R 8a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0676] Each R 9a independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; or R 9a does not exist, and X b =X;
[0677] Each R 10a are independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and
[0678] Each R 10a’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0679] Each R 10b Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0680] R 11a Not present or -C1-C6 alkyl;
[0681] R 12a Selected from: -C1-C6 alkyl, -CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16a and
[0682] R 13a Selected from: -H and -C1-C6 alkyl;
[0683] R 14a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0684] R 14a’ Selected from: H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl;
[0685] R 16a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0686] R 17a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl;
[0687] R 21 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5a ;
[0688] R 22 and R 23 Each is independently selected from: -H, -halogen, -C1-C6 alkyl and -C3-C8 cycloalkyl;
[0689] R 24 、R 25 and R 26 Each is a -C1-C6 alkyl group;
[0690] X a and X b are each independently selected from: NH, O and S;
[0691] X c is selected from the group consisting of: O, S and S(O)2, and
[0692] Indicates the connection point with the linker L.
[0693] In some embodiments, in the compound of formula (VI), R 2a Selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3.
[0694] In some embodiments, in the compound of formula (VI), R 2aSelected from: -CH3, -CF3, -F, -Cl, -OCH3 and -OCF3.
[0695] In some embodiments, in the compound of formula (VI), R 2a Selected from: F and Cl.
[0696] In some embodiments, in the compound of formula (VI), R 2a It's F.
[0697] In some embodiments, in the compound of formula (VI), X is -O-, -S-, or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a , -(C1-C6 alkyl)-aryl,
[0698] Or X is O, and R 25 -X- is selected from:
[0699] In some embodiments, in the compound of formula (VI), X is -O-, -S-, or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a , -(C1-C6 alkyl)-aryl,
[0700] In some embodiments, in the compound of formula (VI), X is -O-, -S-, or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a 、
[0701] In some embodiments, in the compound of formula (VI), X is -O-, -S-, or -NH-, and R 25 Selected from:
[0702] In some embodiments, in the compound of Formula (VI), X is -O- or -NH-.
[0703] In some embodiments, in the compound of formula (VI), R 6a It’s H.
[0704] In some embodiments, in the compound of formula (VI), R6a Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0705] In some embodiments, in the compound of formula (VI), R 7a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C(O)R 17a .
[0706] In some embodiments, in the compound of formula (VI), each R 9a Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl and -(C1-C6 alkyl)-aryl.
[0707] In some embodiments, in the compound of formula (VI), each R 9a Independently selected from: -C1-C6 alkyl and -(C1-C6 alkyl)-aryl.
[0708] In some embodiments, in the compound of formula (VI), each R 10a Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -(C1-C6 alkyl)-aryl and
[0709] In some embodiments, in the compound of formula (VI), each R 10a Independently selected from: -C1-C6 alkyl, -aryl, -(1-C6 alkyl)-aryl and
[0710] In some embodiments, in the compound of formula (VI), R 12a Selected from: -C1-C6 alkyl, -aryl, -(C1-C6 alkyl)-aryl and -S(O)2R 16a .
[0711] In some embodiments, in the compound of formula (VI), R 13a Selected from: -H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl and -C1-C6 aminoalkyl.
[0712] In some embodiments, in the compound of formula (VI), R 14a’ Selected from: H, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl.
[0713] In some embodiments, in the compound of formula (VI), R 16a Selected from: -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl.
[0714] In some embodiments, in the compound of formula (VI), R 17a It is a -C1-C6 alkyl group.
[0715] In some embodiments, in the compound of formula (VI), R 22 and R 23 Each is independently selected from: -H, -halogen, unsubstituted -C1-C6 alkyl, -C1-C6 haloalkyl, -C1-C6 hydroxyalkyl, -C1-C6 aminoalkyl and -C3-C8 cycloalkyl.
[0716] In some embodiments, in the compound of formula (VI), X a and X b are each independently selected from: NH and O.
[0717] In some embodiments, in the compound of formula (VI), X a and X b Each is O.
[0718] In some embodiments, in the compound of formula (VI), X is O, and R 25 It is a -C1-C6 alkyl group.
[0719] In some embodiments, in the compound of formula (VI), R 2a is F; X is O, and R 25 It is a -C1-C6 alkyl group.
[0720] Other combinations of any of the foregoing embodiments of compounds of formula (VI) are also contemplated, and each combination forms a separate embodiment for the purposes of this disclosure.
[0721] In certain embodiments, each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as defined in any one of formula (IV), (V), or (VI) is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, sulfanyl, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl. In some embodiments, each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as defined in any one of formula (IV), (V), or (VI) is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, sulfanyl, sulfonyl, and sulfonamido.
[0722] In certain embodiments, in an ADC having formula (X), D is a compound of formula (IV) wherein R 1a is -CH3, and R 2a is F. In some embodiments, in the ADC having formula (X), D is a compound of formula (IV), wherein R 1a -CH3; R 2a is F; X is -O-; R 4a for R 9a is -C1-C6 alkyl, and X a and X b Each is O.
[0723] In certain embodiments, in an ADC having formula (X), D is a compound of formula (V), wherein R 2a is F, and R 20a H, -(C1-C6)-OR 5 or In some embodiments, in an ADC having formula (X), D is a compound of formula (V), wherein R 2a F; R 20a H, -(C1-C6)-OR 5 or R 5 is H, and R 18 and R 19 Together with the N atom to which they are bound, they form an unsubstituted 4-, 5-, 6-, or 7-membered ring. In some embodiments, in the ADC having formula (X), D is a compound of formula (V), wherein R 2a F; R 20a -(C1-C6)-OR 5 , and R 5 For H.
[0724] In certain embodiments, in an ADC having formula (X), D is a compound of formula (VI), wherein R 2a is F; X is -O-, and R 25 It is a -C1-C6 alkyl group.
[0725] Connector L
[0726] The conjugate of formula (X) includes a linker L, which is a bifunctional or multifunctional moiety capable of linking one or more camptothecin analogs D to the anti-FRα antibody construct T. A bifunctional (or monovalent) linker L links a single compound D to a single site on the anti-FRα antibody construct T, while a multifunctional (or multivalent) linker L links more than one compound D to a single site on the anti-FRα antibody construct T. Linkers that link one compound D to more than one site on the anti-FRα antibody construct T can also be considered multifunctional.
[0727] The linker L includes a functional group capable of reacting with one or more target groups on the anti-FRα antibody construct T and at least one functional group capable of reacting with a target group on the camptothecin analog D. Suitable functional groups are known in the art and include, for example, those described in Bioconjugate Techniques (G.T. Hermanson, 2013, Academic Press). Groups on the anti-FRα antibody construct T and the camptothecin analog D that can be used as target groups for linker attachment include, but are not limited to, thiol, hydroxyl, carboxyl, amine, aldehyde, and ketone groups.
[0728] Non-limiting examples of functional groups capable of reacting with thiols include maleimides, haloacetamides, haloacetyl groups, activated esters (such as succinimidyl esters, 4-nitrophenyl esters, pentafluorophenyl esters, and tetrafluorophenyl esters), anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. In this case, "self-stabilizing" maleimides as described in Lyon et al., 2014, Nat. Biotechnol., 32: 1059-1062 can also be used.
[0729] Non-limiting examples of functional groups capable of reacting with amines include activated esters (such as N-hydroxysuccinamide (NHS) esters and sulfo-NHS esters), imidoesters (such as Traut's reagent), isothiocyanates, aldehydes, and anhydrides (such as diethylenetriaminepentaacetic anhydride (DTPA). Other examples include the use of succinimidyl-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU) or benzotriazol-1-yl-oxytripyrrolphosphonium hexafluorophosphate (PyBOP) to convert carboxylic acids into activated esters, which can then react with amines.
[0730] Non-limiting examples of functional groups capable of reacting with an electrophilic group such as an aldehyde or ketone carbonyl group include hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
[0731] In certain embodiments, the linker L may comprise a functional group that allows for bridging of two interchain cysteines on the anti-FRα antibody construct, such as ThioBridge TMlinkers (Badescu et al., 2014, Bioconjug. Chem. 25: 1124–1136), dithiomaleimide (DTM) linkers (Behrens et al., 2015, Mol. Pharm. 12: 3986–3998), dithioaryl (TCEP) pyridazinedione-based linkers (Lee et al., 2016, Chem. Sci., 7: 799–802), or dibromopyridazinedione-based linkers (Maruani et al., 2015, Nat. Commun., 6: 6645).
[0732] Alternatively, the anti-FRα antibody construct T may be modified to include non-natural reactive groups, such as azide, which allows conjugation to the joint by the complementary reactive group on the joint. For example, the conjugation of the joint to the anti-FRα antibody construct can utilize click chemistry (see, for example, Chio & Bane, 2020, Methods Mol.Biol., 2078: 83-97), such as azide-alkyne cycloaddition (AAC) reaction, which has been successfully used to develop antibody-drug conjugates. The AAC reaction can be a copper-catalyzed AAC (CuAAC) reaction, which involves the conjugation of azide to straight-chain alkynes; or a strain-promoted AAC (SPAAC) reaction, which involves the conjugation of azide to cyclooctyne.
[0733] The linker L can be a cleavable or non-cleavable linker. A cleavable linker is a linker that is easily cleaved under specific conditions, for example, under intracellular conditions (such as in endosomes or lysosomes) or in the vicinity of target cells (such as in the tumor microenvironment). Examples include protease-sensitive, acid-sensitive, or reduction-sensitive linkers. In contrast, non-cleavable linkers rely on degradation of the antibody in the cell, which generally results in the release of the amino acid-linker-drug moiety.
[0734] The example of cleavable linker includes for example a linker comprising an amino acid sequence that is a cleavage recognition sequence for a protease. Many such cleavage recognition sequences are known in the art. For conjugates that are not intended to be internalized by cells, for example, an amino acid sequence that is recognized and cleaved by a protease present in the extracellular matrix near target cells such as cancer cells can be used. The example of extracellular tumor-associated protease includes for example plasmin, matrix metalloproteinase (MMP), elastase and kallikrein-related peptidase.
[0735] For conjugates intended to be internalized by cells, the linker L may comprise an amino acid sequence that is recognized and cleaved by an endosomal or lysosomal protease. Examples of such proteases include, for example, cathepsins B, C, D, H, L, and S, and legumin.
[0736] The cleavage recognition sequence can be, for example, a dipeptide, a tripeptide, or a tetrapeptide. Non-limiting examples of dipeptide recognition sequences that can be included in the cleavable linker include, but are not limited to, Ala-(D)Asp, Ala-Lys, Ala-Phe, Asn-Lys, Asn-(D)Lys, Asp-Val, His-Val, Ile-Cit, Ile-Pro, Ile-Val, Leu-Cit, Me3Lys-Pro, Met-Lys, Met-(D)Lys, NorVal-(D)Asp, Phe-Arg, Phe-Cit, Phe-Lys, phenylGly-(D)Lys, Pro-(D)Lys, Trp-Cit, Val-Ala, Val-(D)Asp, Val-Cit, Val-Gly, Val-Gln, and Val-Lys. Examples of tripeptide and tetrapeptide cleavage sequences include, but are not limited to, Ala-Ala-Asn, Ala-Val-Cit, (D)Ala-Phe-Lys, Asp-Val-Ala, Asp-Val-Cit, Gly-Cit-Val, Lys-Val-Ala, Lys-Val-Cit, Met-Cit-Val, (D)Phe-Phe-Lys, Asn-Pro-Val, Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Gly-Gly-Phe-Gly, and Gly-Phe-Gly-Gly.
[0737] Other examples of cleavable linkers include disulfide-containing linkers, such as N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB) and N-succinimidyl-4-(2-pyridyldithio)-2-sulfobutyrate (sulfo-SPDB). Linkers containing disulfide bonds may optionally include additional groups to provide steric hindrance near the disulfide bond to improve the extracellular stability of the linker, for example, including a geminal dimethyl group. Other cleavable linkers include linkers that are hydrolyzable at a specific pH or pH range, such as hydrazone linkers. Linkers comprising a combination of these functionalities may also be useful, for example, linkers comprising both hydrazone and disulfide bonds are known in the art.
[0738] Another example of a cleavable linker is a linker comprising β-glucuronide, which can be cleaved by β-glucuronidase, an enzyme present in lysosomes and tumor stroma (see, e.g., De Graaf et al., 2002, Curr. Pharm. Des. 8: 1391–1403, and International Patent Publication No. WO 2007 / 011968). β-glucuronide can also be used to improve the hydrophilicity of the linker L.
[0739] Another example of a linker that is cleaved internally within the cell and improves hydrophilicity is a linker comprising a pyrophosphate diester moiety (see, eg, Kern et al., 2016, J Am Chem Soc., 138:2430-1445).
[0740] In certain embodiments, the linker L comprised by the conjugate of formula (X) is a cleavable linker. In some embodiments, the linker L comprises a cleavage recognition sequence. In some embodiments, the linker L may comprise an amino acid sequence that is recognized and cleaved by a lysosomal protease.
[0741] The cleavable linker may optionally further comprise one or more additional functional groups, such as self-immolative and self-immolative groups, extending groups, or hydrophilic moieties.
[0742] Self-decomposition and self-elimination group that can be used for joint include for example p-aminobenzyl (PAB) and p-aminobenzyloxycarbonyl (PABC) group, methylated ethylenediamine (MED) and hemiacetal group.Other examples of self-decomposition group include but are not limited to aromatic compounds similar to PAB or PABC group electronics, such as heterocyclic derivatives, for example 2-aminoimidazole-5-methanol derivatives described in U.S. Patent number 7,375,078.Other examples are included in the group that carries out cyclization when amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amide (Rodrigues et al., 1995, Chemistry Biology 2:223-227) and 2-aminophenylpropionic acid amide (Amsberry et al., 1990, J.Org.Chem.55:5867-5877).Self-decomposition / self-elimination group is usually connected to the amino or hydroxyl group on compound D.Self-decomposition / self-elimination group is usually included in the joint based on peptide alone or in combination, but can also be included in other types of joints.
[0743] Extenders that can be used in the linker of the drug conjugate include, for example, alkylene groups and extenders based on aliphatic acids, diacids, amines or diamines, such as diglycolates, malonates, hexanoates and hexanamides. Other extenders include, for example, glycine-based extenders and polyethylene glycol (PEG) or monomethoxypolyethylene glycol (mPEG) extenders.
[0744] PEG and mPEG extenders can also be used as hydrophilic moieties within the joint. For example, PEG or mPEG can be "directly inserted" or included in the joint as a side group to increase the hydrophilicity of the joint (see, for example, U.S. Patent Application Publication No. US2016 / 0310612). Various PEG-containing joints are commercially available from companies such as Quanta BioDesign, Ltd (Plain City, OH). Other hydrophilic groups that may be optionally incorporated into the joint L include, for example, β-glucuronide, sulfonic acid groups, carboxylic acid groups, and pyrophosphate diesters.
[0745] In certain embodiments, the ADC of formula (X) may comprise a cleavable linker. In some embodiments, the ADC of formula (X) may comprise a peptide-containing linker. In some embodiments, the ADC of formula (X) may comprise a protease-cleavable linker.
[0746] In some embodiments, in the ADC of formula (X), m is 1, and the linker L is a cleavable linker having formula (XI):
[0747]
[0748] in:
[0749] Z is a functional group capable of reacting with a target group on the anti-FRα antibody construct T;
[0750] Str is the extension segment;
[0751] AA1 and AA2 are each independently an amino acid, wherein AA1-[AA2] r Formation of protease cleavage sites;
[0752] X is a self-immolative group;
[0753] q is 0 or 1;
[0754] r is 1, 2, or 3;
[0755] s is 0, 1, or 2;
[0756] # is the connection point with the anti-FRα antibody construct T, and
[0757] % is the point of attachment to camptothecin analog D.
[0758] In some embodiments, in the linker of formula (XI), q is 1.
[0759] In some embodiments, in the linker of formula (XI), s is 1. In some embodiments, in the ADC of formula (XI), s is 0.
[0760] In some embodiments, in the linker of formula (XI), r is 1. In some embodiments, in the ADC of formula (XI), r is 3.
[0761] In some embodiments, in the linker of formula (XI):
[0762] Z is Where # is the point of connection to T, and * is the point of connection to the rest of the linker.
[0763] In some embodiments, in the linker of formula (XI), Str is selected from:
[0764]
[0765] in:
[0766] R is H or C1-C6 alkyl;
[0767] t is an integer between 2 and 10, and
[0768] u is an integer between 1 and 10.
[0769] In some embodiments, in the linker of formula (XI), Str is selected from:
[0770]
[0771] in:
[0772] t is an integer between 2 and 10, and
[0773] u is an integer between 1 and 10.
[0774] In some embodiments, in the linker of formula (XI), AA1-[AA2] r is a dipeptide (ie, r=1). In some embodiments, in the linker of formula (XI), AA1-[AA2] r having a sequence selected from the group consisting of: Ala-(D)Asp, Ala-Lys, Ala-Phe, Asn-Lys, Asn-(D)Lys, Asp-Val, His-Val, Ile-Cit, Ile-Pro, Ile-Val, Leu-Cit, Me3Lys-Pro, Met-Lys, Met-(D)Lys, NorVal-(D)Asp, Phe-Arg, Phe-Cit, Phe-Lys, PhenylGly-(D)Lys, Pro-(D)Lys, Trp-Cit, Val-Ala, Val-(D)Asp, Val-Cit, Val-Gly, Val-Gln, and Val-Lys.
[0775] In some embodiments, in the linker of formula (XI), AA1-[AA2] r is a tripeptide (ie, r=2). In some embodiments, in the linker of formula (XI), AA1-[AA2] r Having a sequence selected from the group consisting of Ala-Ala-Asn, Ala-Val-Cit, (D)Ala-Phe-Lys, Asp-Val-Ala, Asp-Val-Cit, Gly-Cit-Val, Lys-Val-Ala, Lys-Val-Cit, Met-Cit-Val, (D)Phe-Phe-Lys, and Asn-Pro-Val.
[0776] In some embodiments, in the linker of formula (XI), AA1-[AA2] r is a tetrapeptide (ie, r=3). In some embodiments, in the linker of formula (XI), AA1-[AA2] r Having a sequence selected from the group consisting of: Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Gly-Gly-Phe-Gly, and Gly-Phe-Gly-Gly.
[0777] In certain embodiments, in the ADC of formula (X), m is 1, and the linker L is a cleavable linker having formula (XII):
[0778]
[0779] in:
[0780] Z is a functional group capable of reacting with a target group on the anti-FRα antibody construct T;
[0781] Str is the extension segment;
[0782] AA1 and AA2 are each independently an amino acid, wherein AA1-[AA2] r Formation of protease cleavage sites;
[0783] Y is -NH-CH2- or -NH-CH2-C(O)-;
[0784] q is 0 or 1;
[0785] r is 1, 2, or 3;
[0786] v is 0 or 1;
[0787] # is the connection point with the anti-FRα antibody construct T, and
[0788] % is the point of attachment to camptothecin analog D.
[0789] In some embodiments, in the linker of formula (XII), q is 1.
[0790] In some embodiments, in the linker of formula (XII), v is 0. In some embodiments, in the ADC of formula (XII), v is 1.
[0791] In some embodiments, in the linker of formula (XII), r is 1. In some embodiments, in the ADC of formula (XII), r is 3.
[0792] In some embodiments, in the linker of formula (XII):
[0793] Z is Where # is the point of connection to T, and * is the point of connection to the rest of the linker.
[0794] In some embodiments, in the linker of formula (XII), Str is selected from:
[0795]
[0796] in:
[0797] R is H or C1-C6 alkyl;
[0798] t is an integer between 2 and 10, and
[0799] u is an integer between 1 and 10.
[0800] In some embodiments, in the linker of formula (XII), Str is selected from:
[0801]
[0802] in:
[0803] t is an integer between 2 and 10, and
[0804] u is an integer between 1 and 10.
[0805] In some embodiments, in the linker of formula (XII), AA1-[AA2] r is a dipeptide (ie, r=1). In some embodiments, in the linker of formula (XII), AA1-[AA2] rhaving a sequence selected from the group consisting of: Ala-(D)Asp, Ala-Lys, Ala-Phe, Asn-Lys, Asn-(D)Lys, Asp-Val, His-Val, Ile-Cit, Ile-Pro, Ile-Val, Leu-Cit, Me3Lys-Pro, Met-Lys, Met-(D)Lys, NorVal-(D)Asp, Phe-Arg, Phe-Cit, Phe-Lys, PhenylGly-(D)Lys, Pro-(D)Lys, Trp-Cit, Val-Ala, Val-(D)Asp, Val-Cit, Val-Gly, Val-Gln, and Val-Lys.
[0806] In some embodiments, in the linker of formula (XII), AA1-[AA2] r is a tripeptide (ie, r=2). In some embodiments, in the linker of formula (XII), AA1-[AA2] r Having a sequence selected from the group consisting of Ala-Ala-Asn, Ala-Val-Cit, (D)Ala-Phe-Lys, Asp-Val-Ala, Asp-Val-Cit, Gly-Cit-Val, Lys-Val-Ala, Lys-Val-Cit, Met-Cit-Val, (D)Phe-Phe-Lys, and Asn-Pro-Val.
[0807] In some embodiments, in the linker of formula (XII), AA1-[AA2] r is a tetrapeptide (ie, r=3). In some embodiments, in the linker of formula (XII), AA1-[AA2] r Having a sequence selected from the group consisting of: Ala-Leu-Ala-Leu, Gly-Phe-Leu-Gly, Gly-Gly-Phe-Gly, and Gly-Phe-Gly-Gly.
[0808] In some embodiments, in the linker of formula (XII), Y is -NH-CH2. In some embodiments, in the linker of formula (XII), v is 1 and Y is -NH-CH2.
[0809] In some embodiments, the ADC of formula (X) may comprise a disulfide bond-containing linker. In some embodiments, in the ADC of formula (X), m is 1, and the linker L is a cleavable linker having formula (XIII):
[0810]
[0811] in:
[0812] Z is a functional group capable of reacting with a target group on the anti-FRα antibody construct T;
[0813] Q is -(CH2) p -or-(CH2CH2O) q -, wherein p and q are each independently an integer between 1 and 10;
[0814] Each R is independently H or C1-C6 alkyl;
[0815] n is 1, 2, or 3;
[0816] # is the connection point with the anti-FRα antibody construct T, and
[0817] % is the point of attachment to camptothecin analog D.
[0818] In some embodiments, the ADC of Formula (X) may comprise a b-glucuronide-containing linker.
[0819] Various non-cleavable linkers are known in the art for connecting drugs to targeting moieties and can be used in the ADC of the present disclosure in certain embodiments. Examples of non-cleavable linkers include N-succinimidyl esters or N-sulfosuccinimidyl esters for reacting with anti-FRα antibody constructs, and linkers based on maleimido or haloacetyl moieties for reacting with camptothecin analogs, or vice versa. Examples of such non-cleavable linkers are based on sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylates (sulfoSMCC). Sulfo-SMCC conjugation typically occurs via a maleimide group, which reacts with sulfhydryls (thiols, -SH) on camptothecin analogs, while sulfo-NHS esters are reactive to primary amines (as found in lysine and at the N-terminus of proteins or peptides) on anti-FRα antibody constructs. Other non-limiting examples of such linkers include those based on N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC), N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-aminohexanoate) ("long chain" SMCC or LC-SMCC), kappa-maleimidoundecanoic acid N-succinimidyl ester (KMUA), gamma-maleimidobutyric acid N-succinimidyl ester (GMBS), epsilon-maleimidobutyric acid N-succinimidyl ester (EMB), and succinimidyl-succinimidyl-succinimidyl ester (SMB), ... Examples of the linker include N-hydroxysuccinimidyl imide hexanoate (EMCS), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-(α-maleimidoacetoxy)-succinimide ester (AMAS), succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH), N-succinimidyl 4-(p-maleimidophenyl)-butyrate (SMPB), and N-(p-maleimidophenyl) isocyanate (PMPI). Other examples include those containing haloacetyl-based functional groups such as N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), N-succinimidyl iodoacetate (SIA), N-succinimidyl bromoacetate (SBA), and N-succinimidyl 3-(bromoacetamido) propionate (SBAP).
[0820] Non-limiting examples of drug-linkers comprising camptothecin analogs of Formula (I) are shown in Table 8 ( Figure 13 )、Table 9( Figure 14 ) and Table 10( Figure 15 ). Non-limiting examples of conjugates containing these drugs-linkers are shown in Table 11 ( Figure 16 )、Table 12( Figure 17 ) and Table 13( Figure 18). In certain embodiments, the ADC of formula (X) comprises a drug-linker selected from the group consisting of the drug-linkers shown in Table 8, Table 9, and Table 10. In certain embodiments, the ADC of formula (X) is selected from the conjugates shown in Table 11, Table 12, and Table 13, wherein T is an anti-FRα antibody construct and n is between 1 and 10. In some embodiments, the ADC of formula (X) is selected from the group consisting of the conjugates shown in Table 11, Table 12, and Table 13, wherein T is an anti-FRα antibody construct and n is between 2 and 8. In some embodiments, the ADC of formula (X) is selected from the group consisting of the conjugates shown in Table 11, Table 12, and Table 13, wherein T is an anti-FRα antibody construct and n is between 4 and 8.
[0821] In certain embodiments, the ADC of formula (X) comprises a drug-linker (L-(D)) selected from the group consisting of m ): MT-GGFG-AM-Compound 139, MC-GGFG-AM-Compound 139, MT-GGFG-Compound 140, MC-GGFG-Compound 140, MT-GGFG-AM-Compound 141, MC-GGFG-AM-Compound 141, MT-GGFG-Compound 141, MC-GGFG-Compound 141, MT-GGFG-Compound 148, and MC-GGFG-Compound 148, and n is 4 or 8. In some embodiments, the ADC of formula (X) comprises a drug-linker (L-(D)) selected from the group consisting of: m ): MT-GGFG-AM-compound 139, MC-GGFG-AM-compound 139, MT-GGFG-compound 140, MC-GGFG-compound 140, MT-GGFG-AM-compound 141, MC-GGFG-AM-compound 141, MT-GGFG-compound 141, MC-GGFG-compound 141, MT-GGFG-compound 148 and MC-GGFG-compound 148, and n is 8.
[0822] Preparation of ADC
[0823] ADCs of formula (X) can be prepared by standard methods known in the art (see, for example, Bioconjugate Techniques (G T Hermanson, 2013, Academic Press)). Various linkers and linker components are commercially available or can be prepared using standard synthetic organic chemistry techniques (see, for example, March's Advanced Organic Chemistry (Smith & March, 2006, Sixth Ed., Wiley); Toki et al., (2002) J. Org. Chem. 67: 1866-1872; Frisch et al., (1997) Bioconj. Chem. 7: 180-186; Bioconjugate Techniques (G T Hermanson, 2013, Academic Press)). In addition, various antibody-drug conjugation services are commercially available from companies such as Lonza Inc. (Allendale, NJ), Abzena PLC (Cambridge, UK), ADC Biotechnology (St. Asaph, UK), Baxter BioPharma Solutions (Baxter Healthcare Corporation, Deerfield, IL), and Piramal Pharma Solutions (Grangemouth, UK).
[0824] Typically, the preparation of ADCs involves first preparing a drug-linker DL comprising one or more camptothecin analogs of Formula (I) and a linker L, and then conjugating the drug-linker DL to an appropriate group on an anti-FRα antibody construct T. However, linking the linker L to the anti-FRα antibody construct T and subsequently linking the anti-FRα antibody construct-linker TL to one or more camptothecin analogs D of Formula (I) remains an alternative approach that can be used in some embodiments.
[0825] In any of the above methods, suitable groups on the compound D of formula (I) for linking the linker L include, but are not limited to, thiol groups, amine groups, carboxylic acid groups, and hydroxyl groups. In some embodiments of the present disclosure, the linker L is linked to the compound D of formula (I) via a hydroxyl or amine group on the compound.
[0826] In any of the above methods, suitable groups on the anti-FRα antibody construct T for attachment to the linker L include sulfhydryl groups (e.g., on the side chain of a cysteine residue), amino groups (e.g., on the side chain of a lysine residue), carboxylic acid groups (e.g., on the side chain of an aspartic acid or glutamic acid residue), and carbohydrate groups.
[0827] For example, the anti-FRα antibody construct T may comprise one or more naturally occurring sulfhydryl groups that allow the anti-FRα antibody construct T to be bonded to the linker L via the sulfur atom of the sulfhydryl group. Alternatively, the anti-FRα antibody construct T may comprise one or more lysine residues that may be chemically modified to introduce one or more sulfhydryl groups. Reagents that can be used to modify lysine residues include, but are not limited to, N-succinimidyl S-acetylthioacetate (SATA), N-succinimidyl-3-(2-pyridyldithio) propionate ("SPDP"), and 2-iminothiolane hydrochloride (Traut's reagent). Alternatively, the anti-FRα antibody construct T may comprise one or more carbohydrate groups that may be chemically modified to include one or more sulfhydryl groups.
[0828] Carbohydrate groups on anti-FRα antibody construct T can also be oxidized to provide aldehyde (-CHO) groups (see, e.g., Laguzza et al., 1989, J. Med. Chem. 32(3):548-55), which can then react with linker L, e.g., via a hydrazine or hydroxylamine group on linker L.
[0829] Anti-FRα antibody construct T can also be modified to include additional cysteine residues (see, e.g., U.S. Patent Nos. 7,521,541; 8,455,622 and 9,000,130) or unnatural amino acids that provide a reactive handle, such as selenomethionine, p-acetylphenylalanine, formylglycine, or p-azidomethyl-L-phenylalanine (see, e.g., Hofer et al., 2009, Biochemistry, 48: 12047-12057; Axup et al., 2012, PNAS, 109: 16101-16106; Wu et al., 2009, PNAS, 106: 3000-3005; Zimmerman et al., 2014, Bioconj. Chem., 25: 351-361), to allow site-specific conjugation. Alternatively, the anti-FRα antibody construct T can be modified to include a non-natural reactive group, such as an azide, which allows conjugation to the linker through a complementary reactive group on the linker, for example, by click chemistry (see, e.g., Chio & Bane, 2020, Methods Mol. Biol., 2078: 83-97). Another option is to use GlycoConnect TM technology (Synaffix BV, Nijmegen, Netherlands), which involves enzymatic remodeling of antibody glycans to allow attachment of linkers via metal-free click chemistry (see, eg, European Patent No. EP 2 911 699).
[0830] Other protocols for modifying proteins to attach or associate a linker L are known in the art and include those described in Coligan et al., Current Protocols in Protein Science, Vol. 2, John Wiley & Sons (2002).
[0831] Alternatively, ADCs can be prepared using transglutaminases, particularly bacterial transglutaminases (BTG) from Streptomyces mobaraensis (see, e.g., Jeger et al., 2010, Angew. Chem. Int. Ed., 49: 9995-9997). BTG forms an amide bond between the side chain carboxamide of glutamine (amine acceptor, typically on antibodies) and an alkyleneamino group (amine donor, typically on drug-linkers), which can be, for example, the ε-amino group of lysine or a 5-amino-n-pentyl group. Antibodies can also be modified to include glutamine-containing peptides or "tags" that allow conjugation of antibodies to drug-linkers using BTG conjugation (see, e.g., U.S. Patent Application Publication No. US2013 / 0230543 and International (PCT) Publication No. WO 2016 / 144608).
[0832] A similar conjugation method utilizes the enzyme transpeptidase A. In this approach, the antibody is typically modified to include a transpeptidase A recognition motif (LPXTG, where X is any natural amino acid), and the drug-linker is designed to include an oligoglycine motif (usually GGG) to allow transpeptidase A-mediated transpeptidation (see, e.g., Beerli et al., 2015, PLos One, 10:e0131177; Chen et al., 2016, Nature: Scientific Reports, 6:31899).
[0833] Once conjugation is complete, the average number of compounds of formula (I) conjugated to anti-FRα antibody constructs T (i.e., the "drug-antibody ratio" or DAR) can be determined by standard techniques such as UV / VIS spectroscopy, ELISA-based techniques, chromatographic techniques such as hydrophobic interaction chromatography (HIC), UV-MALDI mass spectrometry (MS), and MALDI-TOF MS. In addition, the distribution of drug-linked forms (e.g., the fraction of anti-FRα antibody constructs T containing 0, 1, 2, 3, etc., compounds D of formula (I)) can also be optionally analyzed. Various techniques for measuring DAR distribution are known in the art, including MS (with or without an accompanying chromatographic separation step), hydrophobic interaction chromatography, reversed-phase HPLC, or isoelectric focusing gel electrophoresis (IEF) (see, e.g., Wakankar et al., 2011, mAbs, 3: 161-172).
[0834] Pharmaceutical composition
[0835] For therapeutic use, the ADCs of the present disclosure are typically formulated as pharmaceutical compositions. Therefore, certain embodiments of the present disclosure relate to pharmaceutical compositions comprising an ADC as described herein and a pharmaceutically acceptable carrier, diluent, or excipient. Such pharmaceutical compositions can be prepared using well-known and readily available ingredients by known procedures.
[0836] The pharmaceutical composition can be formulated for administration to a subject, for example, by oral (including, for example, buccal or sublingual), topical, parenteral, rectal or vaginal routes, or by inhalation or spraying. "Parenteral" administration can be subcutaneous injection or intradermal, intraarticular, intravenous, intramuscular, intravascular, intrasternal, intrathecal injection or infusion. The pharmaceutical composition will typically be formulated into a form suitable for administration to a subject, such as a syrup, elixir, tablet, lozenge, pastille, hard or soft capsule, pill, suppository, oily or aqueous suspension, dispersible powder or granules, emulsion, injection or solution. The pharmaceutical composition can be provided as a unit dose formulation.
[0837] In certain embodiments, the pharmaceutical composition comprising the ADC is formulated for parenteral administration, for example, in the form of a lyophilized formulation or an aqueous solution. Such pharmaceutical compositions can be provided, for example, in a unit dose injectable form.
[0838] Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed. Examples of such carriers include, but are not limited to, buffers such as phosphate, citrate, and other organic acids; antioxidants such as ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, benzyl alcohol, alkyl parabens (such as methyl paraben or propyl paraben), catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol; low molecular weight (less than about 10 residues) polypeptides; Proteins such as serum albumin or gelatin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates such as glucose, mannose or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium ions; metal complexes such as Zn-protein complexes; and non-ionic surfactants such as polyethylene glycol (PEG).
[0839] In certain embodiments, the composition comprising the ADC may be in the form of a sterile injectable aqueous or oily solution or suspension. Such suspensions may be prepared using suitable dispersants or wetting agents and / or suspending agents known in the art. Sterile injectable solutions or suspensions may comprise the ADC in a non-toxic, parenterally acceptable diluent or carrier. Acceptable diluents and carriers that may be employed include, for example, 1,3-butanediol, water, Ringer's solution, or isotonic sodium chloride solution. In addition, sterile, fixed oils may be used as carriers. To this end, various mild, fixed oils may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used to prepare injections. Adjuvants, such as local anesthetics, preservatives, and / or buffers may also be included in the injectable solution or suspension.
[0840] In certain embodiments, the composition comprising ADC can be formulated for intravenous administration to humans. Typically, the composition for intravenous administration is a solution in a sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizing agent and / or a local anesthetic, such as lidocaine, to alleviate pain at the injection site. Typically, the components are provided separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or anhydrous concentrate in a sealed container (such as an ampoule or a sachet) indicating the amount of the active agent. When the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. When the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the components can be mixed before administration.
[0841] Other pharmaceutical compositions and methods of preparing pharmaceutical compositions are known in the art and are described, for example, in "Remington: The Science and Practice of Pharmacy" (formerly "Remingtons Pharmaceutical Sciences"); Gennaro, A., Lippincott, Williams & Wilkins, Philadelphia, PA (2000).
[0842] How to use
[0843] Certain embodiments of the present disclosure relate to therapeutic uses of the ADCs described herein. Some embodiments relate to the use of ADCs as therapeutic agents.
[0844] Certain embodiments of the present disclosure relate to methods of inhibiting abnormal cancer cell or tumor cell growth; inhibiting cancer cell or tumor cell proliferation in a subject, or treating cancer, comprising administering an ADC described herein. In certain embodiments, the ADC described herein can be used to treat cancer. Thus, some embodiments of the present disclosure relate to the use of an ADC as an anticancer agent.
[0845] Certain embodiments of the present disclosure relate to methods of inhibiting the proliferation of cancer or tumor cells, comprising contacting the cells with an ADC as described herein, e.g., an ADC of formula (X). Some embodiments relate to methods of killing cancer or tumor cells, comprising contacting the cells with an ADC as described herein, e.g., an ADC of formula (X).
[0846] Some embodiments relate to methods of treating a subject having cancer by administering an ADC as described herein, e.g., an ADC of Formula (X), to the subject. In this case, treating the subject can result in one or more of the following: a decrease in tumor size, a slowing or prevention of an increase in tumor size, a prolonged disease-free survival time between disappearance or removal of a tumor and its reappearance, prevention of subsequent occurrence of a tumor (e.g., metastasis), a prolonged time to progression, a reduction in one or more adverse symptoms associated with the tumor, and / or a prolonged overall survival time of the subject having cancer.
[0847] Certain embodiments relate to the use of an ADC as described herein, e.g., an ADC of formula (X), in a method of inhibiting tumor growth in a subject. Some embodiments relate to the use of an ADC as described herein, e.g., an ADC of formula (X), in a method of inhibiting cancer cell proliferation and / or killing cancer cells in vitro. Some embodiments relate to the use of an ADC as described herein, e.g., an ADC of formula (X), in a method of inhibiting cancer cell proliferation and / or killing cancer cells in a subject having cancer.
[0848] Examples of cancers that can be treated in certain embodiments are carcinomas, including adenocarcinomas and squamous cell carcinomas; melanomas and sarcomas. Carcinomas and sarcomas are also commonly referred to as "solid tumors." Examples of common solid tumors that can be treated in certain embodiments include, but are not limited to, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, uterine cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Various forms of lymphoma can also lead to the formation of solid tumors and, therefore, can also be considered solid tumors in certain cases. Typically, the cancer to be treated is a cancer that expresses FRα.
[0849] Certain embodiments relate to methods of inhibiting the growth of FRα-positive tumor cells, comprising contacting the cells with an ADC as described herein, e.g., an ADC of Formula (X). The cells can be in vitro or in vivo. In certain embodiments, the ADC can be used in methods of treating FRα-positive cancers or tumors in a subject.
[0850] Cancers that overexpress FRα are typically solid tumors. Examples include, but are not limited to, ovarian cancer, endometrial cancer, lung cancer (such as non-small cell lung cancer (NSCLC)), mesothelioma, breast cancer (including triple-negative breast cancer (TNBC)), colorectal cancer, biliary tract cancer, pancreatic cancer, and esophageal cancer. Certain embodiments of the present disclosure relate to methods for treating FRα-positive cancers with an ADC as described herein, such as an ADC of formula (X), wherein the cancer is ovarian cancer, endometrial cancer, lung cancer (such as non-small cell lung cancer (NSCLC)), mesothelioma, breast cancer, colorectal cancer, biliary tract cancer, pancreatic cancer, or esophageal cancer. In some embodiments, the ADC of formula (X) can be used to treat triple-negative breast cancer (TNBC).
[0851] Certain embodiments of the present disclosure relate to methods for treating FRα-positive cancers with an ADC as described herein, such as an ADC of formula (X), wherein the cancer is a solid tumor expressing FRα at high levels (high FRα solid tumors). Certain embodiments of the present disclosure relate to methods for treating FRα-positive cancers with an ADC as described herein, such as an ADC of formula (X), wherein the cancer is a solid tumor expressing FRα at moderate levels (medium FRα solid tumors). Certain embodiments of the present disclosure relate to methods for treating FRα-positive cancers with an ADC as described herein, such as an ADC of formula (X), wherein the cancer is a solid tumor expressing FRα at moderate to low levels (medium / low FRα solid tumors). Certain embodiments of the present disclosure relate to methods for treating FRα-positive cancers with an ADC as described herein, such as an ADC of formula (X), wherein the cancer is a solid tumor expressing FRα at low levels (low FRα solid tumors). In certain embodiments, the solid tumor is breast cancer, ovarian cancer, colorectal cancer, lung cancer (such as NSCLC), pancreatic cancer, or endometrial cancer.
[0852] Drug kit
[0853] Certain embodiments relate to pharmaceutical kits comprising an ADC as described herein, eg, an ADC of Formula (X).
[0854] The kit will typically include a container for containing the ADC and a label and / or package insert on or accompanying the container. The label or package insert contains instructions typically included in the commercial packaging of a therapeutic product, providing information about the indications, usage, dosage, administration, contraindications, and / or warnings for using such therapeutic products. The label or package insert may also include a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of a drug or biological product, which reflects the manufacturer's approval of the use or sale for human or animal administration. In some embodiments, the container may have a sterile access port. For example, the container may be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic needle.
[0855] In addition to the container holding the ADC, the kit may optionally contain one or more additional containers containing other components of the kit, for example, a pharmaceutically acceptable buffer (such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, or dextrose solution), other buffers, or diluents.
[0856] Suitable containers include, for example, bottles, vials, syringes, and intravenous solution bags. The containers can be made of various materials such as glass or plastic. Where appropriate, one or more components of the kit can be lyophilized or provided in a dry form (such as a powder or granules), and the kit can additionally contain a suitable solvent for reconstituting the lyophilized or dried component.
[0857] The kit may also include other materials desirable from a commercial and user standpoint, such as filters, needles, and syringes.
[0858] The following examples are offered for illustrative purposes and are not intended to limit the scope of the claimed invention in any way.
[0859] Example
[0860] Overview
[0861] Chemistry: Examples 1 to 3 below illustrate various methods for preparing camptothecin analogs of formula (I). It should be understood that those skilled in the art can prepare these compounds by similar methods or by combining other methods known in the art. It should also be understood that those skilled in the art will be able to use the methods described below or similar methods by using appropriate starting components and modifying synthesis parameters as needed to prepare compounds of other formulas (I) not specifically described below. Typically, starting components can be obtained from commercial sources, such as Sigma Aldrich (Merck KGaA), Alfa Aesar and Maybridge (ThermoFisher Scientific Inc.), Matrix Scientific, Tokyo Chemical Industry Ltd. (TCI) and Fluorochem Ltd., or synthesized according to sources known to those skilled in the art (see, for example, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th edition, John Wiley & Sons, Inc., 2013) or prepared as described herein.
[0862] Bioassays: The expression levels of FRα in the cell lines and CDX models employed in the Examples were assessed in-house using a research-grade IHC assay and assigned relative expression levels (high / medium / low or strong / medium / weak). PDX models were similarly assessed using archival tumor samples.
[0863] abbreviation
[0864] The following abbreviations are used throughout the Examples section: BCA: bicinchoninic acid; Boc: di-tert-butyl dicarbonate; CE-SDS: capillary electrophoresis sodium dodecyl sulfate; DCM: dichloromethane; DTPA: diethylenetriaminepentaacetic acid; DIPEA: N,N-diisopropylethylamine; DMF: dimethylformamide; DMMTM: (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; Fmoc: fluorenylmethoxycarbonyl; HATU: Tetramethyluronium azabenzotriazole hexafluorophosphate; HIC: hydrophobic interaction chromatography; HOAt: 1-hydroxy-7-azabenzotriazole; HPLC: high-performance liquid chromatography; LC / MS: liquid chromatography-mass spectrometry; MC: maleimidocaproyl; MT: maleimidotriglycolate; NMM: N-methylmorpholine; PNP: p-nitrophenol; RP-UPLC-MS: reversed-phase ultra-performance chromatography-mass spectrometry; SEC: size-exclusion chromatography; TCEP: tris(2-carboxyethyl)phosphine; Tfp: tetrafluorophenyl; TLC: thin-layer chromatography; TFA: trifluoroacetic acid.
[0865] General Chemistry Procedures
[0866] General Procedure 1: Conversion of Chlorides to Amines
[0867] To a stirred solution of the chloride compound in dimethylformamide (0.05 M to 0.1 M) is added the appropriate secondary amine (3 equiv.) Upon completion (determined by LC / MS, typically 1 to 3 hours), the reaction mixture is purified by reverse phase HPLC to provide the desired product after lyophilization.
[0868] General Procedure 2: Conversion of amines to amides
[0869] To a stirred solution of the amine compound in dimethylformamide (0.05-0.1 M) was added triethylamine (1.2 eq), the appropriate carboxylic acid (1.1 eq), followed by a solution of DMM™ (2 eq) in water (1 M). Upon completion (determined by LC / MS, typically 16 hours), the reaction mixture was purified by reverse phase HPLC to provide the desired product after lyophilization.
[0870] General Procedure 3: Conversion of Amines to Sulfonamides
[0871] To a stirred solution of the amine compound in dimethylformamide (0.05M to 0.1M) was added DIPEA (3 equiv.) followed by the appropriate sulfonyl chloride. Upon completion (determined by LC / MS, typically 16 hours), the reaction mixture was purified by reverse phase HPLC to provide the desired product after lyophilization.
[0872] General Procedure 4: Two-step conversion of amines to ureas (Synthetic Scheme IV; Figure 1D)
[0873] Step 1: p-nitrophenyl carbonate (1 equivalent) is added to a stirred solution of the amine compound in dichloromethane or dimethylformamide (0.05M to 0.1M), followed by triethylamine (2 equivalents). After completion (determined by LC / MS, typically 1 to 4 hours), the reaction mixture is concentrated to dryness and then purified by reverse phase HPLC to provide the desired PNP-carbamate intermediate after lyophilization. This intermediate can be used to generate a single analog or be divided into multiple batches to generate multiple analogs in the second step. Step 2: Appropriate primary amine (3 equivalents) is added to the PNP-carbamate intermediate (0.1M to 0.2M) in dimethylformamide. After completion (determined by LC / MS, typically 1 hour), the reaction mixture is purified by reverse phase HPLC to provide the desired product after lyophilization.
[0874] General Procedure 5 Conversion of Amines to Carbamates
[0875] To a stirred solution (0.05M to 0.1M) of the amine compound in dichloromethane or dimethylformamide, p-nitrophenyl carbonate (1 equivalent) is added, followed by triethylamine (2 equivalents). After completion (determined by LC / MS, typically 1 to 4 hours), the appropriate alcohol is added to the resulting PNP-carbamate intermediate. After completion (determined by LC / MS, typically 1 to 16 hours), the reaction mixture is purified by reversed-phase HPLC to provide the desired product after lyophilization.
[0876] General Procedure 6: Removal of Boc Protecting Group
[0877] To a stirred solution of the Boc-protected amine compound in dichloromethane (0.1 M) was added TFA (20 vol %). Upon completion (determined by LC / MS, typically 1 hour), the reaction mixture was concentrated in vacuo to afford a crude solid or purified as described in General Procedure 9.
[0878] General Procedure 7: Copper-mediated amide coupling
[0879] To a rapidly stirred solution (0.02 M) of Boc-GGFG-OH (3 equivalents) and HOAt (3 equivalents) in a 10% v / v mixture of dimethylformamide in dichloromethane was added EDC (HCl salt, 3 equivalents). After 5 minutes, a solution (0.02 M) of a 10% v / v mixture of dimethylformamide in dichloromethane containing an amine payload (1 equivalent) was added, followed immediately by the addition of CuCl (4 equivalents). Upon completion (determined by LC / MS, typically 1 to 16 hours), the reaction mixture was concentrated in vacuo to provide a crude solid or purified by preparative HPLC to provide the desired product after lyophilization.
[0880] General Procedure 8: MT Placement
[0881] To a stirred solution of the amine compound (1 eq) in dimethylformamide (about 0.02 M) was added a solution of MT-OTfp (1.2 eq to 1.5 eq) in acetonitrile (about 0.02 M), followed by DIPEA (10 uL, 4 eq). Upon completion (determined by LC / MS, typically 1 to 16 hours), the reaction mixture was concentrated in vacuo to afford a crude solid, which was purified by preparative HPLC to afford the desired product after lyophilization.
[0882] General Procedure 9 Compound Purification
[0883] Flash chromatography : The crude reaction product was Snap Ultra columns (10 g, 25 g, 50 g, or 100 g) (Biotage, Charlotte, NC) were used for purification. Isolera TM Elution was performed on an automated rapid system (Biotage, Charlotte, NC) using a linear gradient of ethyl acetate / hexane or methanol / dichloromethane. Alternatively, the elution was performed using Reverse phase flash purification was performed on a Snap Ultra C18 column (12 g, 30 g, 60 g or 120 g) eluting with a linear gradient of 0.1% TFA in acetonitrile / 0.1% TFA in water. The purified compound was isolated by removing the organic solvent by rotary evaporation or lyophilizing the acetonitrile / water mixture.
[0884] Preparative HPLC: Reverse phase HPLC of crude compound was performed using 5-μm C18 The HPLC-MS / MS results were analyzed using a 150×30 mm column (Phenomenex, Torrance, CA) on an Agilent 1260 Infinity II preparative LC / MSD system (Agilent Technologies, Inc., Santa Clara, CA) and eluted with a linear gradient of 0.1% TFA in acetonitrile / 0.1% TFA in water. The purified compound was isolated by lyophilization of the acetonitrile / water mixture.
[0885] General Procedure 10: Compound Analysis
[0886] LC / MS: Monitor the reaction for completion and use 2.6-μm C18 The purified compound was analyzed on an Agilent 1290 HPLC / 6120 single quadrupole LC / MS system (Agilent Technologies, Inc., Santa Clara, CA) using a 30×3 mm column (Phenomenex, Torrance, CA) and eluted with a 10% to 100% linear gradient of 0.1% formic acid / acetonitrile / 0.1% formic acid / water.
[0887] NMR: 1 H NMR spectra were collected on a Bruker AVANCE III 300 spectrometer (300 MHz) (Bruker Corporation, Billerica, MA). Chemical shifts are reported in parts per million (ppm).
[0888] Example 1: Preparation of Camptothecin Analogs with a Methyl Group at the C10 Position
[0889] 1.1: (S)-11-(Chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 1.1)
[0890]
[0891] The title compound was prepared according to the procedure provided in Li et al., 2019, ACS Med. Chem. Lett., 10(10): 1386-1392.
[0892] 1.2: (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 1.2)
[0893]
[0894] The title compound was prepared according to the procedure provided in Li et al., 2019, ACS Med. Chem. Lett., 10(10): 1386-1392.
[0895] 1.3: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methyl-11-(morpholinomethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 100)
[0896]
[0897] The title compound was prepared starting from compound 1.1 (10 mg) and morpholine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 3.6 mg, 26% yield).
[0898] LC / MS: C 26 H 26 Calculated value for FN3O5 m / z = 479.2, found [M+H] + =480.4.
[0899] 1 H NMR (300MHz, CDCl3) δ8.20(d,J=8.0Hz,1H),7.82(d,J=10.4Hz,1H),7.67(s,1H),5.77(d,J=16.4Hz,1H),5.42(s,2H),5.33(d,J=1 6.4Hz, 1H), 4.26 (s, 2H), 3.81 (t, J = 4.7Hz, 4H), 2.82–2.76 (m, 4H), 2.57 (d, J = 1.7Hz, 3H), 1.99–1.82 (m, 2H), 1.06 (t, J = 7.4Hz, 3H).
[0900] 1.4: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methyl-11-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 102)
[0901]
[0902] The title compound was prepared starting from compound 1.1 (10 mg) and 1-(phenylsulfonyl)piperazine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 3.6 mg, 21% yield).
[0903] LC / MS: C 32 H 31 Calculated value for FN4O6 m / z = 618.2, found [M+H] + =619.4.
[0904] 1 H NMR (300MHz, CDCl3) δ8.07(d,J=7.9Hz,1H),7.88–7.44(m,7H),5.73(d,J=16.4Hz,1H),5.33(s,2H),5.33–5.26( m,1H),4.19(s,2H),3.12(s,4H),2.80(s,4H),2.54(s,3H),1.90(dt,J=11.6,7.0Hz,2H),1.04(t,J=7.3Hz,3H).
[0905] 1.5: (S)-11-((4-((4-aminophenyl)sulfonyl)piperazin-1-yl)methyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 104)
[0906]
[0907] The title compound was prepared starting from compound 1.1 (10 mg) and 4-(piperazin-1-ylsulfonyl)aniline according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 4.7 mg, 27% yield).
[0908] LC / MS: C 32 H 32 Calculated value for FN5O6 m / z = 633.2, found [M+H] + =634.4.
[0909] 1 H NMR (300MHz, MeOD) δ8.32(d,J=8.0Hz,1H),7.85(d,J=10.5Hz,1H),7.65(s,1H),7.46(d,J=8.7Hz,2H),6.74(d,J=8.7Hz,2H),5.61(d,J= 16.5Hz,1H),5.44(s,2H),5.41(d,J=16.5Hz,1H),4.51(s,2H),3.22–3.07(m,8H),2.58(s,3H),2.03–1.93(m,2H),1.02(t,J=7.3Hz,3H).
[0910] 1.6: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methyl-11-((4-methylpiperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 106)
[0911]
[0912] The title compound was prepared starting from compound 1.1 (10 mg) and N-methylpiperazine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 3.6 mg, 25% yield).
[0913] LC / MS: C 27 H 29 Calculated value of FN4O4 m / z = 492.2, found value [M+H] + =493.4.
[0914] 1.7: (S)-11-((4-(4-aminophenyl)piperazin-1-yl)methyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 108)
[0915]
[0916] The title compound was prepared starting from compound 1.1 (10 mg) and 4-(piperazin-1-yl)aniline according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 3.7 mg, 23% yield).
[0917] LC / MS: C 32 H 32 Calculated value for FN5O4 m / z = 569.2, found [M+H] + =570.4.
[0918] 1 H NMR (300MHz, MeOD) δ8.39(d,J=8.1Hz,1H),7.79(d,J=10.6Hz,1H),7.21(d,J=9.0Hz,2H),7.14(d,J=9.0Hz,2H),5.62(d,J=16.4Hz,1H),5.49(s, 2H),5.41(d,J=16.4Hz,1H),4.45(s,2H),3.44–3.38(m,4H),3.06–3.00 (m,4H),2.58(d,J=1.8Hz,3H),2.00–1.89(m,2H),1.03(t,J=7.3Hz,3H).
[0919] 1.8: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methyl-11-(piperidin-1-ylmethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 110)
[0920]
[0921] The title compound was prepared starting from compound 1.1 (10 mg) and piperidine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 1.5 mg, 11% yield).
[0922] LC / MS: C 27 H 28 Calculated value of FN3O4 m / z = 477.2, found value [M+H] + =478.2.
[0923] 1H NMR (300MHz, MeOD) δ8.34(d,J=7.6Hz,1H),7.94(d,J=10.3Hz,1H),7.70(s,1H),5.63(d,J=16.4Hz,1H),5.52(s,2H),5.44( d,J=16.5Hz,1H),4.99(s,2H),3.73–3.46(m,4H),2.64(s,3H),2.03–1.90(m,2H),1.90–1.84(m,6H),1.03(t,J=7.4Hz,3H).
[0924] 1.9: (S)-tert-Butyl 4-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)piperazine-1-carboxylate (Compound 111)
[0925]
[0926] The title compound was prepared starting from compound 1.1 (10 mg) and tert-butyl piperazine-1-carboxylate according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 6.6 mg, 40% yield).
[0927] LC / MS: C 31 H 35 Calculated value for FN4O6 m / z = 578.2, found [M+H] + =579.4.
[0928] 1.10: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methyl-11-(piperazin-1-ylmethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 112)
[0929]
[0930] The title compound was prepared according to General Procedure 6 starting from compound 111 (5.0 mg) to afford the title compound as an off-white solid (TFA salt, 4.4 mg).
[0931] LC / MS: C 26 H 27 Calculated value of FN4O4 m / z = 478.2, found value [M+H] + =479.2.
[0932] 1.11: (S)-4-Ethyl-8-fluoro-4-hydroxy-11-(((R)-2-(hydroxymethyl)morpholino)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 113)
[0933]
[0934] The title compound was prepared starting from compound 1.1 (10 mg) and (R)-morpholin-2-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 4.6 mg, 32% yield).
[0935] LC / MS: C 27 H 28 Calculated value for FN3O6 m / z = 509.2, found [M+H] + =510.4.
[0936] 1.12: (4S)-4-Ethyl-8-fluoro-4-hydroxy-11-((3-(hydroxymethyl)thiomorpholino)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 114)
[0937]
[0938] The title compound was prepared starting from compound 1.1 (10 mg) and thiomorpholin-3-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 1.5 mg, 12% yield).
[0939] LC / MS: calculated value m / z = 525.6 (C 27 H 28 FN3O5S), found [M+H] + =526.5.
[0940] 1H NMR(300MHz,10%D2O / CD3CN)8.36(d,J=8.1Hz,1H),7.83(d,J=10.7Hz,1H),7.50(s ,1H),5.57(d,J=16.4Hz,1H),5.52–5.29(m,3H),5.02(d,J=14.6Hz,1H),4.71–4.54 (m,1H),4.27(dd,J=12.4,5.0Hz,1H),3.98(dd,J=12.3,3.4Hz,1H),3.55(s,1H),3. 30-3.03(m,4H)2.97–2.72(m,3H),2.62(s,1H),2.55(s,3H),0.95(t,J=7.4Hz,3H).
[0941] 1.13: (4S)-4-Ethyl-8-fluoro-4-hydroxy-11-((4-(hydroxymethyl)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 115)
[0942]
[0943] The title compound was prepared starting from compound 1.1 (10 mg) and 2-oxa-5-azabicyclo[2.2.1]heptan-4-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 10% to 60% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (TFA salt, 3.5 mg, 29% yield).
[0944] LC / MS: C 28 H 28 Calculated value for FN3O6 m / z = 521.5, found [M+H] + =522.5.
[0945] 1H NMR(300MHz,10%D2O / CD3CN)δ8.36(d,J=7.9Hz,1H),7.86(dd,J=10.6,5.0Hz,1H),7. 50(d,J=1.8Hz,1H),5.63–5.49(m,2H),5.37(dd,J=17.8,14.1Hz,2H),5.05(s,2H),4 .63(d,J=2.5Hz,1H),4.55(d,J=10.7Hz,1H),4.33(s,2H),3.92(d,J=10.7Hz,1H),3. 36(s,2H),2.57(s,3H),2.41–2.13(m,2H),1.97-1.85(m,2H),0.95(t,J=7.4Hz,3H).
[0946] 1.14: (4S)-4-Ethyl-8-fluoro-4-hydroxy-11-((3-(hydroxymethyl)-1,1-dioxothiomorpholino)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 116)
[0947]
[0948] The compound 1.1 (10 mg) and 3-(hydroxymethyl)-1λ were prepared according to the general procedure 1. 6 The title compound was prepared starting with -thiomorpholine-1,1-dione. Purification was accomplished as described in General Procedure 9 using a gradient elution from 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 0.2 mg, 2% yield).
[0949] LC / MS: calculated value m / z = 557.6 (C 27 H 28 FN3O7S), found [M+H] + =558.4.
[0950] 1H NMR(300MHz,10% D2O / CD3CN)δ8.44(d,J=8.2Hz,1H),7.80(d,J=11.0Hz,1H),7.50(s,1H),5 .58(d,J=16.5Hz,1H),5.45–5.26(m,3H),4.60(d,J=14.9Hz,1H),4.33(d,J =14.7Hz,1H),3.88(d,J=4.8Hz,2H),3.41-2.85(m,4H),2.53(s,2H),2.19( p,J=2.5Hz,2H),1.74(p,J=2.5Hz,2H),1.27(s,2H),0.95(t,J=7.4Hz,3H).
[0951] 1.15: (4S)-4-Ethyl-8-fluoro-4-hydroxy-11-((6-hydroxy-3-azabicyclo[3.1.1]hept-3-yl)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 117)
[0952]
[0953] The title compound was prepared starting from compound 1.1 (10 mg) and 3-azabicyclo[3.1.1]heptan-6-ol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 1.3 mg, 11% yield).
[0954] LC / MS: C 28 H 28 Calculated value for FN3O5 m / z = 505.5, found [M+H] + =506.6.
[0955] 1 H NMR(300MHz,10% D2O / CD3CN) δ8.25(d,J=7.9Hz,1H),7.87(d,J=10.6Hz,1H),7.50(s,1H),5.65–5.27(m,4H),4.98(s,2H ),4.24(s,1H),3.83–3.57(m,4H),2.54(s,5H),2.01-1.86(m,2H),1.70(s,2H),0.95(t,J=7.3Hz,3H).
[0956] 1.16: (S)-4-Ethyl-8-fluoro-11-((3-fluoro-3-(hydroxymethyl)azetidin-1-yl)methyl)-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 118)
[0957]
[0958] The title compound was prepared starting from compound 1.1 (10 mg) and 3-fluoroazetidin-3-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 1.4 mg, 12% yield).
[0959] LC / MS: calculated value m / z = 497.5 (C 26 H 25 F2N3O5), found [M+H] + =498.4.
[0960] 1 H NMR(300MHz,10% D2O / CD3CN) δ8.24(d,J=7.9Hz,1H),7.85(d,J=10.7Hz,1H),7.50(s,1H),5.57(d,J=16.5Hz,1H),5.48–5.2 8(m,3H),4.98(s,2H),4.44–4.14(m,4H),3.78(d,J=14.9Hz,2H),2.01-1.86(m,2H),0.95(t,J=7.4Hz,3H).
[0961] 1.17: (S)-4-Ethyl-8-fluoro-4-hydroxy-11-((3-(hydroxymethyl)azetidin-1-yl)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 119)
[0962]
[0963] The title compound was prepared starting from compound 1.1 (10 mg) and azetidin-3-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 0.5 mg, 4.5% yield).
[0964] LC / MS: C 26 H 26 Calculated value for FN3O5 m / z = 479.5, found [M+H] + =480.4.
[0965] 1 H NMR(300MHz,10% D2O / CD3CN) δ8.23(d,J=7.8Hz,1H),7.90(d,J=10.6Hz,1H),7.53(s,1H),5.58(d,J=16.5Hz,1H),5.50–5.28(m,3H),5.01( s,2H),4.31–4.17(m,2H),4.15–4.00(m,2H),3.62(d,J=3.9Hz,2H),2.58(s,3H),2.01-1.86(m,2H),0.96(t,J=7.4Hz,3H).
[0966] 1.18: (4S)-11-((4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)methyl)-4-ethyl-8-fluoro-4-hydroxy-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 120)
[0967]
[0968] The title compound was prepared starting from compound 1.1 (10 mg) and 4,4-difluoropiperidin-3-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 4 mg, 32% yield).
[0969] LC / MS: calculated value m / z=543.5 (C 28 H 28 F3N3O5), found [M+H] + =544.4.
[0970] 1H NMR(300MHz,10% D2O / CD3CN) δ8.25(d,J=8.0Hz,1H),7.77(dd,J=10.7,1.4Hz,1H),7.47(s,1H),5.55(d,J=16.5Hz,1H),5.42–5.25(m,3H),4.66 (d,J=3.2Hz,2H),3.90–3.77(m,1H),3.71–3.45(m,4H),2.24(q,J=11.8,9.2Hz,2H),2.01-1.86(m,2H),0.94(t,J=7.4Hz,3H).
[0971] 1.19: (S)-4-Ethyl-8-fluoro-4-hydroxy-11-((1-(hydroxymethyl)-7-azabicyclo[2.2.1]hept-7-yl)methyl)-9-methyl-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 121)
[0972]
[0973] The title compound was prepared starting from compound 1.1 (10 mg) and 7-azabicyclo[2.2.1]hept-1-ylmethanol according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (TFA salt, 0.8 mg, 6.6% yield).
[0974] LC / MS: C 29 H 30 Calculated value for FN3O5 m / z = 519.6, found [M+H] + =520.4.
[0975] 1 H NMR(300MHz,10% D2O / CD3CN) δ8.22(s,1H),7.92(d,J=10.7Hz,1H),7.54(s,1H),5.59(dd,J=17.6,7.6Hz,2H),5.33(t,J=17.4Hz,2H),4.98–4.8 1(m,1H),4.67–4.44(m,2H),4.28–3.93(m,4H),2.73(s,2H),2.34–2.03(m,4H),1.91(d,J=14.0Hz,5H),0.96(t,J=7.4Hz,3H).
[0976] 1.20: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)methanesulfonamide (Compound 122)
[0977]
[0978] The title compound was prepared starting from compound 1.2 (10 mg) and methanesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 10% to 50% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (0.8 mg, 7% yield).
[0979] LC / MS: C 23 H 22 Calculated value for FN3O6S m / z = 487.1, found [M+H] + =488.2.
[0980] 1 H NMR (300MHz, MeOD) δ8.33(d,J=8.1Hz,1H),7.83(d,J=10.8Hz,1H),7.68(s,1H),5.62(d,J=16.3Hz,1H),5.52(s ,2H),5.42(d,J=16.4Hz,1H),4.87(s,2H),3.06(s,3H),2.59(s,3H),2.06-1.93(m,2H),1.03(t,J=7.4Hz,3H).
[0981] 1.21: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-1-(4-nitrophenyl)methanesulfonamide (Compound 124)
[0982]
[0983] The title compound was prepared starting from compound 1.2 (20 mg) and (4-nitrophenyl)methanesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (5.0 mg, 17% yield).
[0984] LC / MS: C 29 H25 Calculated value for FN4O8S m / z = 608.1, found [M+H] + =609.2.
[0985] 1 H NMR (300MHz, CDCl3) δ8.02–7.92(m,3H),7.74(d,J=10.5Hz,1H),7.65(s,1H),7.33(d,J=8.6Hz,2H),5.66(d,J=16.8Hz,1H),5.28( d,J=16.5Hz,1H),5.14(d,J=5.4Hz,2H),4.67(s,2H),4.28(d,J=6.3Hz,2H),3.39(s,3H),2.03–1.83(m,2H),1.04(t,J=7.4Hz,3H).
[0986] 1.22: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)benzenesulfonamide (Compound 125)
[0987]
[0988] The title compound was prepared starting from compound 1.2 (10 mg) and benzenesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 10% to 50% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (9.8 mg, 73% yield).
[0989] LC / MS: C 28 H 24 Calculated value for FN3O6S m / z = 549.6, found [M+H] + =550.6.
[0990] 1H NMR (300MHz, DMSO-d6) δ8.60(t,J=6.2Hz,1H),8.17(d,J=8.1Hz,1H),7.83(d,J =10.8Hz,1H),7.71(dd,J=7.1,1.7Hz,2H),7.66–7.48(m,2H),7.46(dd,J=8.3,6 .8Hz,2H),7.40–7.27(m,2H),7.18(s,1H),7.01(s,1H),5.45(s,2H),5.33(s,2H ), 4.63 (d, J = 6.2Hz, 2H), 2.48 (s, 3H), 1.98–1.76 (m, 2H), 0.89 (t, J = 7.3Hz, 3H).
[0991] 1.23: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-4-nitrobenzenesulfonamide (Compound 1.23)
[0992]
[0993] The title compound was prepared starting from compound 1.2 (75 mg) and 4-nitrobenzenesulfonyl chloride according to General Procedure 3. Purification of the title compound was accomplished as described in General Procedure 9 using a 12 g C18 column and eluting with a gradient of 5% to 75% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (37.8 mg, 47% yield).
[0994] LC / MS: C 28 H 23 Calculated value for FN4O8S m / z = 594.6, found [M+H] + =595.2.
[0995] 1.24: (S)-4-Amino-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)benzenesulfonamide (Compound 127)
[0996]
[0997] To a solution of compound 1.23 (37.8 mg, 0.064 mmol) in methanol (6.4 mL) was added platinum 1% vanadium 2% on carbon (75 mg). The flask was purged with H2 and then stirred at room temperature under an H2 atmosphere for 45 minutes. The mixture was filtered through a pad of celite, washed with DMF, and the filtrate was evaporated to give the title compound (30 mg, 84% yield) as a light yellow solid.
[0998] LC / MS: C 28 H 24 Calculated value for FN4O6S m / z = 564.6, found [M+H] + =565.2.
[0999] 1 H NMR (300MHz, DMSO-d6) δ8.13(d,J=8.2Hz,1H),8.02(t,J=6.2Hz,1H),7.88(d,J=10.8Hz,1H),7.48–7.35(m,2H),7.31(d,J =8.4Hz,1H),6.63–6.45(m,2H),5.45(s,2H),5.36(s,2H),4.50(d,J=6.3Hz,2H),1.98–1.75(m,2H),0.89(t,J=7.3Hz,3H).
[1000] 1.25: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyethane-1-sulfonamide (Compound 129)
[1001]
[1002] The title compound was prepared starting from compound 1.2 (20 mg) and 2-hydroxyethanesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 25% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (1.3 mg, 13% yield).
[1003] LC / MS: C 24 H 24 Calculated value for FN3O7S m / z = 517.1, found [M+H] + =518.2.
[1004] 1H NMR (300MHz, DMSO-d6) δ8.30(d,J=8.4Hz,1H),7.91(d,J=10.9Hz,1H),7.84(t,J=6.3Hz,1H),7.33(s,1H),5.50-5.33(m,4H),5 .07(t,J=5.4Hz,1H),4.78(d,J=6.0Hz,2H),4.07(s,3H),3.80(dt,J=6.3Hz,J=5.8Hz,2H),1.86(m,2H),0.87(d,J=7.3Hz,3H).
[1005] 1.26: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)methanesulfonamide (Compound 131)
[1006]
[1007] To a solution (1mL) of chlorosulfonyl isocyanate (3uL) in dichloromethane, tert-butyl alcohol (3uL) is added. The solution is stirred for 1 hour, then compound 1.2 (13mg) dissolved in dichloromethane (1mL) is added, followed by triethylamine (13uL). The reactant is stirred for 1 hour and then concentrated to dryness. The preparative HPLC purification of intermediate Boc compound is completed as described in general procedure 9, wherein 10% to 50% CHCN / HO+0.1%TFA gradient elution is used. Trifluoroacetic acid (200uL) is added to the purified solid in dichloromethane (1mL). The reactant is stirred for 16 hours, then concentrated to dryness, to obtain the title compound (7.5mg, 48% yield) as a pale solid.
[1008] LC / MS: C 22 H 21 Calculated value for FN4O6S m / z = 488.1, found [M+H] + =489.0.
[1009] 1 H NMR(300MHz,MeOD)δ8.25(d,J=8.1Hz,1H),7.73(d,J=10.7Hz,1H),7.62(s,1H),5.59(d,J=16.4Hz,1H),5.45 (s,2H),5.39(d,J=16.4Hz,1H),4.81(s,2H),2.55(d,J=1.7Hz,3H),2.07–1.89(m,2H),1.03(t,J=7.4Hz,3H).
[1010] 1.27: (S)-4-Nitrophenyl((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 1.27)
[1011]
[1012] The title PNP-carbamate intermediate compound was prepared starting from compound 1.2 (24 mg) according to the first step of General Procedure 4. Purification was achieved using a 12 g C18 column as described in General Procedure 9, eluting with a gradient of 10% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (14 mg, 53% yield).
[1013] LC / MS: C 29 H 23 Calculated value for FN4O8S m / z = 574.2, found [M+H] + =575.2
[1014] 1.28: (S)-1-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-methylurea (Compound 132)
[1015]
[1016] The title compound was prepared starting from compound 1.2 (25 mg) and aqueous methylamine (500 uL, 40 wt% in water) as the primary amine according to General Procedure 4. In this case, the crude intermediate PNP-carbamate was used. Preparative HPLC purification was accomplished as described in General Procedure 9 using a 10% to 50% CH3CN / H2O + 0.1% TFA gradient to afford the title compound (8.9 mg, 31% yield) as an off-white solid.
[1017] LC / MS: C 24 H 23 Calculated value of FN4O5 m / z = 466.2, found value [M+H] + =467.2.
[1018] 1H NMR (300MHz, MeOD) δ8.26(d,J=8.2Hz,1H),7.79(d,J=10.7Hz,1H),7.66(s,1H),5.61(d,J=16.3Hz,1H),5.48(s ,2H),5.41(d,J=16.4Hz,1H),4.97(s,2H),2.73(s,3H),2.57(s,3H),2.08–1.93(m,2H),1.03(t,J=7.4Hz,3H).
[1019] 1.29: (S)-1-(4-aminobenzyl)-3-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)urea (Compound 134)
[1020]
[1021] The title compound was prepared using compound 1.27 (4 mg) as the PNP-carbamate and 4-(aminomethyl)aniline as the primary amine according to the second step of General Procedure 4. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 12% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (0.6 mg, 20% yield).
[1022] LC / MS: C 30 H 28 Calculated value for FN5O5 m / z = 557.2, found [M+H] + =558.4.
[1023] 1 H NMR (300MHz, MeOD) δ8.25(d,J=8.1Hz,1H),7.80(d,J=10.8Hz,1H),7.67(s,1H),7.43(d,J=8.2Hz,2H),7.24(d,J=8.3Hz,2H),5.63(d,J=16 .4Hz,1H),5.48(s,2H),5.43(d,J=16.4Hz,1H),5.01(s,2H),4.37(s,2H),2.56(d,J=1.7Hz,3H),2.05–1.94(m,2H),1.03(t,J=7.3Hz,3H).
[1024] 1.30: (S)-1-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-(2-hydroxyethyl)urea (Compound 136)
[1025]
[1026] The title compound was prepared using compound 1.27 (4 mg) as the PNP-carbamate and hydroxyethylamine as the primary amine according to the second step of General Procedure 4. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (2.4 mg, 66% yield).
[1027] LC / MS: C 25 H 25 Calculated value for FN4O6 m / z = 496.2, found [M+H] + =497.2.
[1028] 1 H NMR (300MHz, MeOD) δ8.08(d,J=8.0Hz,1H),7.74(d,J=10.5Hz,1H),7.68(s,1H),5.64(d,J=16.4Hz,1H),5.41(s,2H),5.31(d,J =16.4Hz,1H),4.96(s,2H),3.63(t,J=5.2Hz,2H),3.29(t,J=5.3Hz,2H),2.54(s,3H),1.98–1.87(m,2H),1.01(t,J=7.4Hz,3H).
[1029] 1.31: (S)-((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 138)
[1030]
[1031] The title compound was prepared starting from compound 1.2 (50 mg) and reacting methanol with the intermediate PNP-carbamate according to General Procedure 5. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (3.5 mg, 6% yield).
[1032] LC / MS: C 24 H 22 Calculated value of FN3O6 m / z = 467.2, found value [M+H] + =468.2.
[1033] 1 H NMR (300MHz, MeOD) δ8.17(d,J=8.2Hz,1H),7.77(d,J=10.5Hz,1H),7.69(s,1H),5.65(d,J=16.5Hz,1H),5.48(s,2H) ,5.33(d,J=16.4Hz,1H),4.86(d,J=5.6Hz,2H),3.65(s,3H),2.56(s,3H),2.02–1.89(m,2H),1.02(t,J=7.4Hz,3H).
[1034] 1.32: (S)-2-Hydroxyethyl ((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 139)
[1035]
[1036] The title compound was prepared starting from compound 1.2 (18 mg) and reacting 1,2-ethanediol with the intermediate PNP-carbamate according to General Procedure 5. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 10% to 60% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (4.2 mg, 19% yield).
[1037] LC / MS: C 25 H 24 Calculated value for FN3O7 m / z = 497.2, found [M+H] + =498.2.
[1038] 1H NMR (300MHz, DMSO) δ8.23(d,J=8.2Hz,1H),7.78(d,J=10.7Hz,1H),7.40(s,1H),5.47(d,J=16.5Hz,1H),5.42(s,2H),5.34(d, J=16.4Hz,1H),4.77(s,2H),3.99(t,J=4.9Hz,2H),3.64–3.38(m,2H),2.48(s,3H),2.02–1.67(m,2H),0.89(t,J=7.3Hz,3H).
[1039] Example 2: Preparation of Camptothecin Analogs with a Methoxy Group at the C10 Position
[1040] 2.1: 1-(2-amino-4-fluoro-5-methoxyphenyl)-2-chloroethane-1-one (Compound 2.1)
[1041]
[1042] A solution of 3-fluoro-4-methoxyaniline (10 g, 71 mmol) in DCM (100 mL) was cooled to 0 ° C. First, 1 M BCl was added to the solution in DCM (71 mL, 71 mmol), followed by 1 M chloro(diethyl)aluminum (71 mL, 71 mmol) and finally 2-chloroacetonitrile (6.4 g, 85 mmol). The solution was heated at reflux for 3 hours, cooled to room temperature and quenched by adding a 2 M HCl aqueous solution. The resulting heterogeneous mixture was heated at reflux for 1 hour, cooled to room temperature, and then adjusted to pH 12 with Na CO. The layers were separated and the aqueous layer was extracted with DCM (3 × 100 mL). The combined organic layers were dried over Na SO, concentrated, and rapidly purified using 0% to 20% EtOAc / hexane as described in General Procedure 9 to give the title compound (6 g, 28 mmol, 39% yield).
[1043] LC / MS: calculated for C9H9ClFNO2 m / z = 217.1, found [M+H] + =218.1.
[1044] 1 H NMR (400MHz, CDCl3) δ7.19(d,J=9.2Hz,1H),6.44(d,J=12.8Hz,1H),4.59(s,2H),3.86(s,3H)
[1045] 2.2: (S)-11-(Chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methoxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 2.2)
[1046]
[1047] Toluene-4-sulfonic acid (157 mg, 0.9 mmol) was added to a solution (200 mL) of compound 2.1 (1.65 g, 7.6 mmol) and (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (2 g, 7.6 mmol) in toluene. The solution was heated at 140 ° C for 3 hours and then cooled to room temperature. The product was collected as a yellow precipitate by filtration to obtain the title compound (1.27 g, 2.85 mmol, 37.5% yield).
[1048] LC / MS: C 22 H 18 Calculated value of ClFN2O5 m / z = 445.2, found [M+H] + =445.1.
[1049] 1 H NMR(400MHz, DMSO-d6)δ7.99(d,J=12.0Hz,1H)7.80(d,J=9.2Hz,1H)7.27(s,1H),6.50(s,1H) ,5.45(s,2H),5.41(s,2H),5.33(s,2H)4.08(s,3H),1.87-1.83(m,2H),0.87(t,J=7.2Hz,3H)
[1050] 2.3: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methoxy-11-(morpholinomethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 101)
[1051]
[1052] The title compound was prepared starting from compound 2.2 (10 mg) and morpholine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 41% to 60% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (5.6 mg, 20% yield).
[1053] LC / MS: C26 H 26 Calculated value for FN3O6 m / z = 495.2, found [M+H] + =496.4.
[1054] 1 H NMR(300MHz,MeOD)δ7.84–7.70(m,2H),7.59(s,1H),5.62(d,J=16.3Hz,1H),5.45–5.36(m,3H),4.29(s,2H),4 .12(s,3H),3.58–3.48(m,2H),3.28–3.09(m,2H),2.75–2.61(m,2H),2.05–1.91(m,2H),1.02(t,J=7.4Hz,3H).
[1055] 2.4: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methoxy-11-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 103)
[1056]
[1057] The title compound was prepared starting from compound 2.2 (10 mg) and 1-(phenylsulfonyl)piperazine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (2.5 mg, 14% yield).
[1058] LC / MS: C 32 H 31 Calculated value for FN4O7S m / z = 634.2, found [M+H] + =635.4.
[1059] 2.5: (S)-11-((4-((4-aminophenyl)sulfonyl)piperazin-1-yl)methyl)-4-ethyl-8-fluoro-4-hydroxy-9-methoxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 105)
[1060]
[1061] The title compound was prepared starting from compound 2.2 (10 mg) and 4-(piperazin-1-ylsulfonyl)aniline according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (4.0 mg, 23% yield).
[1062] LC / MS: C 32 H 32 Calculated value for FN5O7S m / z = 649.2, found [M+H] + =650.4.
[1063] 1 H NMR (300MHz, DMSO) δ8.08(s,2H),7.90–7.67(m,2H),7.35(s,1H),7.32–7.26(m,2H),6.67–6.57(m,2H),5.46(d,J=16.5 Hz,1H),5.33–5.22(m,3H),3.92(s,3H),3.02–2.72(m,4H),2.75–2.58(m,4H),1.97–1.70(m,2H),0.90(t,J=7.3Hz,3H).
[1064] 2.6: (S)-4-Ethyl-8-fluoro-4-hydroxy-9-methoxy-11-((4-methylpiperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 107)
[1065]
[1066] The title compound was prepared starting from compound 2.2 (10 mg) and N-methylpiperazine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (2.1 mg, 19% yield).
[1067] LC / MS: C 27 H 29 Calculated value for FN4O5 m / z = 508.2, found [M+H] + =509.4.
[1068] 2.7: (S)-11-((4-(4-aminophenyl)piperazin-1-yl)methyl)-4-ethyl-8-fluoro-4-hydroxy-9-methoxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 109)
[1069]
[1070] The title compound was prepared starting from compound 2.2 (10 mg) and 4-(piperazin-1-yl)aniline according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 20% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (3.2 mg, 20% yield).
[1071] LC / MS: C 32 H 32 Calculated value for FN5O5 m / z = 585.2, found [M+H] + =586.4.
[1072] 1 H NMR(300MHz,MeOD)δ7.83–7.74(m,2H),7.62(s,1H),7.06(d,J=8.9Hz,2H),6.98(d,J=8.9Hz,2H) ,5.65(d,J=16.4Hz,1H),5.36(s,2H),5.27(d,J=16.4Hz,1H),4.13(s,2H),4.06(s,3H),3.26(br s,4H),2.79(br s,4H),1.97–1.83(m,2H),1.00(t,J=7.4Hz,3H).
[1073] 2.8: (S)-11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-9-methoxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 2.8)
[1074]
[1075] To a solution of compound 2.2 (250 mg, 0.56 mmol) in ethanol (7 mL) was added hexamethylenetetramine (236 mg, 1.7 mmol) followed by iPr2NEt (100 uL, 0.56 mmol). The solution was heated to reflux for 5 hours, cooled to room temperature and quenched with a 12 M aqueous HCl solution (60 uL). The solution was concentrated to approximately 1 / 2 volume, and a 1 M aqueous HCl solution (1.5 mL) was added, stirred for 5 minutes, and then concentrated to give a brown residue. Purification was performed as described in General Procedure 9 using a 12 g C18 flash column with a 5% to 40% CH3CN / H2O+0.1% TFA gradient elution to give the title compound (179 mg, 75% yield) as a light yellow solid.
[1076] LC / MS: C 22 H 20 Calculated value of FN3O5 m / z = 425.4, found value [M+H] + =426.2
[1077] 2.9: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)methanesulfonamide (Compound 123)
[1078]
[1079] The title compound was prepared starting from compound 2.8 (10 mg) and methanesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 5% to 65% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (8.5 mg, 91% yield).
[1080] LC / MS: C 23 H 22 Calculated value for FN3O7S m / z = 503.1, found [M+H] + =504.2.
[1081] 1H NMR (300MHz, DMSO-d6) δ7.98(d,J=12.1Hz,1H),7.89(t,J=6.4Hz,1H),7.80(d,J=9.1Hz,1H),7.28(s,1H),5.42 (s,2H),5.39(s,2H),4.77(d,J=6.4Hz,2H),4.06(s,3H),3.06(s,3H),1.95-1.73(m,2H),0.88(d,J=7.3Hz,3H).
[1082] 2.10: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)benzenesulfonamide (Compound 126)
[1083]
[1084] The title compound was prepared starting from compound 2.8 (7.5 mg) and benzenesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 5% to 70% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (4.6 mg, 46% yield).
[1085] LC / MS: C 28 H 24 Calculated value for FN3O7S m / z = 565.6, found [M+H] + =566.2.
[1086] 1 H NMR (300MHz, DMSO-d6) δ8.59(t,J=6.3Hz,1H),7.94(d,J=12.2Hz,1H),7.82–7.68(m,2H),7.62–7.46(m,1H),7.51–7.40(m,1H),7.28( d,J=8.3Hz,1H),6.52(s,1H),5.44(s,1H),5.36(s,1H),4.64(d,J=6.3Hz,1H),4.09(s,2H),1.95–1.81(m,1H),0.89(t,J=7.3Hz,2H).
[1087] 2.11: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-4-nitrobenzenesulfonamide (Compound 2.11)
[1088]
[1089] The title compound was prepared from compound 2.8 (12 mg) and 4-nitrobenzenesulfonyl chloride according to General Procedure 3. Purification was accomplished using a 12 g C18 flash column and eluting with a gradient of 5% to 75% CH3CN / H2O + 0.1% TFA as described in General Procedure 9 to afford the title compound as a light yellow solid (9.7 mg, 71% yield).
[1090] LC / MS: C 28 H 23 Calculated value for FN4O9S m / z = 610.6, found [M+H] + =611.5.
[1091] 2.12: (S)-4-Amino-N-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)benzenesulfonamide (Compound 128)
[1092]
[1093] To a solution of compound 2.11 (9.7 mg, 0.016 mmol) in methanol (1.6 mL) was added platinum 1% vanadium 2% on carbon (15 mg). The flask was purged with H2 and then stirred at room temperature under an H2 atmosphere for 45 minutes. The mixture was filtered through a pad of celite, washed with DMF, and the filtrate was evaporated to give the title compound (1.5 mg, 16% yield) as a light yellow solid.
[1094] LC / MS: C 28 H 25 Calculated value for FN4O7S m / z = 580.6, found [M+H] + =581.4.
[1095] 1H NMR (300MHz, MeOD) δ7.77(d,J=11.0Hz,1H),7.58(s,1H),7.48(d,J=8.6Hz,1H),6.61(d,J=8.6Hz,1H),5.59(d,J=16.3Hz,1H),5.39(d ,J=16.4Hz,1H),5.30(s,1H),4.56(s,1H),4.10(d,J=3.7Hz,3H),2.04–1.91(m,2H),1.31(s,1H),1.02(t,J=7.3Hz,3H),0.90(s,1H).
[1096] 2.13: (S)-N-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizin[1,2-b]quinolin-11-yl)methyl)-2-hydroxyethane-1-sulfonamide (Compound 130)
[1097]
[1098] The title compound was prepared starting from compound 2.8 (8 mg) and 2-hydroxyethanesulfonyl chloride according to General Procedure 3. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 15% to 50% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (2.2 mg, 22% yield).
[1099] LC / MS: C 24 H 24 Calculated value for FN3O8S m / z = 533.1, found [M+H] + =534.2.
[1100] 1 H NMR(300MHz, DMSO-d6)δ7.99(d,J=12.2Hz,1H),7.89-7.79(m,2H),7.29(s,1H),5.43(s,2H),5.40(s,2H),4.76(d, J=6.4Hz,2H),4.06(s,3H),3.81(t,J=6.3Hz,2H),3.34(t,J=6.3Hz,2H),1.94-1.75(m,2H),0.87(d,J=7.4Hz,3H).
[1101] 2.14: (S)-4-Nitrophenyl ((4-ethyl-8-fluoro-4-hydroxy-9-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 2.14)
[1102]
[1103] The title PNP-carbamate intermediate compound was prepared according to the first step of General Procedure 4 starting from compound 2.8 (65 mg) using a 1:1 mixture of dimethylformamide and dichloromethane as solvent. Flash purification was accomplished as described in General Procedure 9 using a 12 g C12 column eluting with a 10% to 50% CH3CN / H2O+0.1% TFA gradient to afford the title compound as an off-white solid (61 mg, 86% yield). This intermediate was isolated and used to generate the following compounds.
[1104] LC / MS: C 29 H 23 Calculated value of FN4O9 m / z = 590.1, found value [M+H] + =591.2.
[1105] 2.15: (S)-1-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-methylenehydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-methylurea (Compound 133)
[1106]
[1107] The title compound was prepared using compound 2.14 (15 mg) as the PNP-carbamate and aqueous methylamine (500 uL, 40 wt% in water) as the primary amine according to the second step of General Procedure 4. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 47% to 60% CH3CN / H2O + 0.1% TFA gradient to afford the title compound (5.8 mg, 20% yield) as an off-white solid.
[1108] LC / MS: C 24 H 23 Calculated value for FN4O6 m / z = 482.2, found [M+H] + =483.2.
[1109] 1H NMR (300MHz, DMSO-d6) δ8.00–7.87(m,2H),7.31(s,1H),5.48–5.39(m,3H),4.81(s,3H),2.56(s,3H),1.93–1.81(m,2H),0.89(t,J=7.3Hz,3H).
[1110] 2.16: (S)-1-(4-Aminobenzyl)-3-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)urea (Compound 135)
[1111]
[1112] The title compound was prepared using compound 2.14 (15 mg) as the PNP-carbamate and 4-(aminomethyl)aniline as the primary amine according to the second step of General Procedure 4. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a 20% to 60% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (TFA salt, 2.1 mg, 12% yield).
[1113] LC / MS: C 30 H 28 Calculated value for FN5O6 m / z = 573.2, found [M+H] + =574.2.
[1114] 1 H NMR (300MHz, MeOD) δ7.79(d,J=11.9Hz,1H),7.74(d,J=9.0Hz,1H),7.59(s,1H),7.43(d,J=8.2Hz,2H),7.25(d,J=8.2Hz,2H) ,5.61(d,J=16.3Hz,1H),5.52–5.35(m,3H),4.98(s,2H),4.39(s,2H),4.01(s,3H),2.03–1.93(m,2H),1.03(t,J=7.4Hz,3H).
[1115] 2.17: (S)-1-((4-ethyl-8-fluoro-4-hydroxy-9-methoxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-(2-hydroxyethyl)urea (Compound 137)
[1116]
[1117] The title compound was prepared using compound 2.14 (15 mg) as the PNP-carbamate and hydroxyethylamine as the primary amine according to the second step of General Procedure 4. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 12% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as an off-white solid (1.5 mg, 20% yield).
[1118] LC / MS: C 25 H 25 Calculated value of FN4O7 m / z = 512.2, found value [M+H] + =513.2.
[1119] 1 H NMR (300MHz, MeOD) δ7.93(d,J=12.1Hz,1H),7.88(d,J=9.2Hz,1H),7.56(s,1H),5.62(d,J=16.2Hz,1H),5.52(s,2H),5.45(d,J =16.3Hz,1H),4.98(s,2H),4.17(s,3H),3.59(t,J=5.6Hz,2H),3.28(t,J=5.6Hz,2H),2.10–1.91(m,2H),1.05(t,J=7.3Hz,3H).
[1120] Example 3: Preparation of Camptothecin Analogs Having an Amino Group at the C10 Position
[1121] 3.1: 5-Bromo-4-fluoro-2-nitrobenzaldehyde (Compound 3.1)
[1122]
[1123] To a stirred solution of HNO (121.2 mL, 67% purity, 2.0 eq) in HSO (500 mL) at 0°C was added 3-bromo-4-fluorobenzaldehyde (180 g, 1.0 eq). After the addition was complete, the ice bath was removed and the reaction was stirred at 25°C for 5 hours. The mixture was poured into ice (5 L), filtered, and then dried under vacuum. The title compound (219 g) was obtained as a yellow solid.
[1124] 1 H NMR (400MHz, CDCl3) δ10.39 (s, 1H), 8.23 (d, J = 6.8 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H).
[1125] 3.2: (2-Fluoro-5-formyl-4-nitrophenyl)carbamic acid tert-butyric acid (Compound 3.2)
[1126]
[1127] A mixture of compound 3.1 (219g, 1.0 equivalent), tert-butyl carbamate (124g, 1.2 equivalent), CsCO(575g, 2.0 equivalent), Pd(dba)(40g, 0.05 equivalent) and XPhos (84g, 0.2 equivalent) in toluene (2000mL) is degassed and purged with N for three cycles. The mixture is then stirred at 90°C and under N atmosphere for 15 hours. The reaction mixture is diluted with HO (800mL) and extracted with EtOAc (300mL×2). The combined organic layer is washed with brine (200mL×2), then dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue is purified by column chromatography (SiO, petroleum ether: ethyl acetate=100: 1 to 20: 1) to obtain the title compound (140g, 56% yield) as a yellow solid.
[1128] 1 H NMR (400MHz, DMSO-d6) δ10.24(s,1H),9.94(s,1H),8.42(d,J=7.6Hz,1H),8.16(d,J=10.8Hz,1H),1.50(s,9H)
[1129] 3.3: tert-Butyl (4-amino-2-fluoro-5-formylphenyl)carbamate (Compound 3.3)
[1130]
[1131] To a solution of compound 3.2 (100 g, 1.0 equivalent) in H2O (300 mL) and EtOH (1200 mL) was added NH4Cl (30.5 g, 1.62 equivalents). Iron (78.6 g, 4.0 equivalents) was added in batches at 80 ° C. The mixture was stirred at 80 ° C for 6 hours. The mixture was filtered, water was added to the filtrate, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under vacuum. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 1: 0 to 0: 1) and TLC (petroleum ether) to give the title compound (19.0 g, 21% yield) as a yellow solid.
[1132] LC / MS: C 12 H 15 Calculated value for FN2O3 m / z = 254.1, found [M+H] + =255.0.
[1133] 1 H NMR (400MHz, DMSO-d6) δ9.73 (s, 1H), 8.57 (s, 1H), 7.58 (d, J = 4.8 Hz, 1H), 7.21 (s, 2H), 6.53 (d, J = 12.8 Hz, 1H), 1.43 (s, 9H).
[1134] 3.4: (S)-tert-Butyl (4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)carbamate (Compound 3.4)
[1135]
[1136] A mixture of compound 3.3 (4.20 g, 1.2 eq), (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (3.5 g, 1 eq) and TsOH (monohydrate, 253 mg, 0.1 eq) in toluene (350 mL) was stirred at 110 ° C for 2 hours. The reaction solution was cooled to 25 ° C, filtered, and the solid was washed with methyl tert-butyl ether (30 mL) and then dried in vacuo. The title compound (4.5 g, 62% yield) was obtained as a yellow solid.
[1137] LC / MS: C 25 H 24 Calculated value for FN3O6 m / z = 481.2, found [M+H] + =482.1.
[1138] 1 H NMR (400MHz, DMSO-d6) δ9.49(s,1H),8.65(s,1H),8.43(d,J=8.4Hz,1H),7.95(d,J=12.0Hz,1H),7.30 (s,1H),6.51(s,1H),5.42(s,2H),5.25(s,2H),1.80-1.92(m,2H),1.52(s,9H),0.88(t,J=7.2Hz,3H)
[1139] 3.5: (S)-tert-Butyl (4-ethyl-8-fluoro-4-hydroxy-11-(hydroxymethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)carbamate (Compound 3.5)
[1140]
[1141] To the mixture of compound 3.4 (4.00g) in MeOH (360mL), FeSO4 (heptahydrate, 1.2g), H2SO4 (280mL) in H2O (4mL) solution was added. The reaction mixture was heated at 65°C, while H2O2 (24mL, 30% purity) was added dropwise over 30 minutes, then stirred for 0.5 hours. The reaction solution was cooled to 25°C, then filtered to obtain the title compound (1.53g, 33.2% yield) as a yellow solid. H2O (400mL) was added to the filtrate, then quenched with saturated Na2S2O3 aqueous solution. With saturated Na2CO3 aqueous solution, the pH was adjusted to 7 to 8, then the solution was concentrated and filtered. The solid was ground with MeOH (30mL) at 55°C for 1 hour, then filtered to obtain the title compound (1.09g, 26% yield) as a second batch of brown solids.
[1142] LC / MS: C 26 H 26 Calculated value of FN3O7 m / z = 511.2, found value [M+H] + =512.2.
[1143] 1 H NMR(300MHz,d6-DMSO)δ9.47(s,1H),8.47(d,J=7.6Hz,1H),7.94(d,J=12.0Hz,1H),7.29(d,J=1.6Hz,1H),6.49(s,1H),5 .86-5.76(m,1H),5.42(s,2H),5.38(s,2H),5.16(d,J=4.4Hz,2H),1.90-1.83(m,2H),1.52(s,9H),0.88(t,J=6.4Hz,3H).
[1144] 3.6: (S)-tert-Butyl (4-ethyl-8-fluoro-11-formyl-4-hydroxy-3,14-dioxo-3,4,12,14-methanehydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)carbamate (Compound 3.6)
[1145]
[1146] In a 50mL round-bottom flask containing compound 3.5 (150mg, 0.293mmol), DCM (2.9mL) was added, followed by Dess-Martin periodinane (0.56g, 1.32mmol) and water (15.8μL, 0.88mmol). The solution was stirred at room temperature for 18 hours, then diluted with DCM and washed with saturated NaHCO3 aqueous solution and brine. The layers were separated and the combined organic layer was evaporated onto celite. Rapid purification was completed as described in General Procedure 9 using a 10g silica gel column eluted with 0% to 10% DCM / MeOH to give the title product (42.5mg, 28%) as an orange powder.
[1147] LC / MS: C 26 H 24 Calculated value for FN3O7 m / z = 509.2, found [M+H] + =510.4.
[1148] 1 H NMR (300 MHz, acetone-d6) δ 11.10 (s, 1H), 9.68 (d, J = 8.6 Hz, 1H), 8.81 (s, 1H), 8.04 (d, J = 11.9 Hz, 1H), 7.63 (s, 1H), 5.73 (s, 2H), 5.69 (d, J = 16.2 Hz, 1H), 5.42 (d, J = 16.2 Hz, 1H), 2.02-1.95 (m, 2H), 8.47 (d, J=7.6Hz,1H),7.94(d,J=12.0Hz,1H),7.29(d,J=1.6Hz,1H),6.49(s,1H),5.86-5.76(m,1H),5.42 (s,2H),5.38(s,2H),5.16(d,J=4.4Hz,2H),1.90-1.83(m,2H),1.52(s,9H),0.88(t,J=6.4Hz,3H).
[1149] 3.7: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 140)
[1150]
[1151] The title compound was prepared according to General Procedure 6 starting from compound 3.4 (40 mg) to afford the title compound as a red solid (TFA salt, 36 mg, 87% yield).
[1152] LC / MS: C 20 H16 Calculated value of FN3O4 m / z = 381.1, found value [M+H] + =382.2.
[1153] 1 H NMR (300MHz, DMSO) δ8.28(s,1H),7.72(d,J=12.5Hz,1H),7.21(d,J=7.3Hz,1H),5.43(d,J= 16.2Hz, 1H), 5.34 (d, J = 16.2Hz, 1H), 5.17 (s, 2H), 1.92–1.74 (m, 2H), 0.88 (t, J = 7.3Hz, 3H).
[1154] 3.8: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-(hydroxymethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 141)
[1155]
[1156] The title compound was prepared according to General Procedure 6 starting from compound 3.5 (5 mg) to afford the title compound as a red solid (TFA salt, 4.1 mg, 78% yield).
[1157] LC / MS: C 21 H 18 Calculated value for FN3O5 m / z = 411.2, found [M+H] + =412.2.
[1158] 1 H NMR(300MHz,MeOD)δ7.71(d,J=12.2Hz,1H),7.60(s,1H),7.29(d,J=9.5Hz,1H),5.61(d,J=16.3Hz ,1H),5.47(s,2H),5.40(d,J=16.3Hz,1H),5.25(s,2H),2.03–1.94(m,2H),1.03(t,J=7.4Hz,3H).
[1159] 3.9: (S)-tert-Butyl (11-(chloromethyl)-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-methyl-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)carbamate (Compound 3.9)
[1160]
[1161] To a stirred solution of compound 3.5 (100 mg) in dichloromethane (5 mL) was added a solution of thionyl chloride (14 uL) in dichloromethane (0.1 mL). After 1 hour, a solution of thionyl chloride (14 uL) in dichloromethane (0.1 mL) was added. After another hour, the reaction was diluted with dichloromethane (10 mL) and toluene (1 mL) and then concentrated in vacuo to give the title compound as a red solid, which was used in subsequent reactions without further purification.
[1162] LC / MS: C 26 H 25 Calculated value of ClFN3O6 m / z = 529.1, found value [M+H] + =530.2.
[1163] 3.10: (S)-(11-(Aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl)aminomethyl tert-butyl ester (Compound 3.10)
[1164]
[1165] To a solution of compound 3.9 (100 mg) in ethanol (500 uL) was added hexamethylenetetramine (79 mg) followed by DIPEA (99 uL). The solution was heated at 60°C for 16 hours and then concentrated to dryness in vacuo. Rapid purification was accomplished as described in General Procedure 9 using a 12 g C18 column eluted with a 10% to 50% CH3CN / H2O + 0.1% TFA gradient to afford the title compound as an off-white solid (TFA salt, 29 mg, 24% yield).
[1166] LC / MS: C 26 H 27 Calculated value for FN4O6 m / z = 510.2, found [M+H] + =511.4.
[1167] 1 H NMR(300MHz,MeOD)δ8.88(d,J=8.2Hz,1H),7.96(d,J=11.9Hz,1H),7.62(s,1H),5.60(d,J=16.4Hz,1H), 5.48(s,2H),5.41(d,J=16.4Hz,1H),4.80(s,2H),2.07–1.89(m,2H),1.64(s,9H),1.02(t,J=7.3Hz,3H).
[1168] 3.11: (S)-9-Amino-11-(aminomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 145)
[1169]
[1170] The title compound was prepared according to General Procedure 6 starting from compound 3.10 (2.1 mg) to afford the title compound as a red solid (TFA salt, 1.8 mg, 100% yield).
[1171] LC / MS: C 21 H 19 Calculated value of FN4O4 m / z = 410.1, found value [M+H] + =411.2.
[1172] 1 H NMR(300MHz,MeOD)δ7.82(d,J=12.1Hz,1H),7.60(s,1H),7.37(d,J=9.1Hz,1H),5.61(d,J=16.3Hz ,1H),5.42(s,2H),5.41(d,J=16.3Hz,1H),4.69(s,2H),2.08–1.94(m,2H),1.03(t,J=7.4Hz,3H).
[1173] Example 3.12: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-(morpholinomethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 3.12)
[1174]
[1175] The title compound was prepared starting from compound 3.9 (150 mg) and morpholine according to General Procedure 1. Preparative HPLC purification was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA to afford the title compound as a red solid (TFA salt, 103 mg, 52% yield).
[1176] LC / MS: C 30 H 33 Calculated value for FN4O7 m / z = 580.2, found [M+H] + =581.4.
[1177] 1 H NMR (300MHz, MeOD) δ9.06(d,J=8.3Hz,1H),7.93(d,J=12.0Hz,1H),7.66(s,1H),5.63(d,J=16.3Hz,1H),5.51(s,2H),5. 43(d,J=16.4Hz,1H),4.92(s,2H),3.84(s,4H),3.10(s,4H),1.99(d,J=5.5Hz,2H),1.63(s,9H),1.03(t,J=7.4Hz,3H).
[1178] 3.13: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-(morpholinomethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 142)
[1179]
[1180] The title compound was prepared according to General Procedure 6 starting from compound 3.12 (45 mg) to afford the title compound as a red solid (TFA salt, 37 mg, 99% yield).
[1181] LC / MS: C 25 H 25 Calculated value of FN4O5 m / z = 480.2, found value [M+H] + =481.4.
[1182] 1 H NMR(300MHz,MeOD)δ7.73(d,J=12.0Hz,1H),7.54(s,1H),7.48(d,J=9.2Hz,1H),5.60(d,J=16.3Hz,1H),5.4 7–5.34(m,3H),4.65(s,2H),3.91–3.85(m,4H),3.30–3.24(m,4H),2.08–1.91(m,2H),1.02(t,J=7.3Hz,3H).
[1183] 3.14: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-(piperidin-1-ylmethyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 148)
[1184]
[1185] To a 5mL flask containing compound 3.6 (37mg, 0.067mmol), dichloromethane (1.45mL) was added, followed by acetic acid (18.69μL, 0.327mmol), piperidines (21.52μL, 0.218mmol) and sodium triacetoxyborohydride (23.0mg, 0.109mmol). The solution was then stirred at room temperature for 2 hours, quenched by adding water+0.1% TFA and DMF (1:1, 1.0mL), and partially evaporated. Purification was completed as described in general procedure 9 using 12g C18 flash columns and eluted with 5% to 40% CH3CN / H2O+0.1% TFA gradient to obtain the Boc-protected intermediate as a yellow powder. The intermediate was then deprotected according to general procedure 6 to obtain the title compound (TFA salt, 32.5mg, 98% yield) as a yellow solid.
[1186] LC / MS: C 26 H 27 Calculated value of FN4O4 m / z = 478.2, found value [M+H] + =479.4.
[1187] 1 H NMR(300MHz,MeOD)δ7.78(d,J=12.1Hz,1H),7.56(s,1H),7.41(d,J=9.1Hz,1H),5.60(d,J=16.4Hz,1H),5.4 7–5.35(m,3H),4.86(s,2H),3.80–3.68(m,2H),3.28–3.19(m,2H),2.02–1.68(m,8H),1.01(t,J=7.4Hz,3H).
[1188] 3.15: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-((4-methylpiperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 149)
[1189]
[1190] To a 2mL vial containing compound 3.6 (15mg, 0.029mmol), dichloromethane (0.59mL), acetic acid (7.58μL, 0.132mmol) and N-methylpiperazine (4.90μL, 0.044mmol) were added. The solution was stirred at room temperature for 4 hours, then sodium triacetoxyborohydride (7.8mg, 0.037mmol) was added and stirred for another 45 minutes. Excess hydride was then quenched by adding a 0.1% TFA aqueous solution (0.5mL). Purification was completed as described in general procedure 9 using 12g C18 flash columns and eluted with 5% to 40% CH3CN / H2O+0.1% TFA gradient to obtain the intermediate protected by Boc, which was a yellow powder. The intermediate was deprotected according to general procedure 6 to obtain the title product (TFA salt, 1.5mg, 7.1% yield) as a yellow solid.
[1191] LC / MS: C 26 H 28 Calculated value for FN5O4 m / z = 493.2, found [M+H] + =494.4.
[1192] 1 H NMR(300MHz,MeOD)δ7.68(d,J=12.2Hz,1H),7.56(s,1H),7.53(d,J=9.5Hz,1H),5.60(d,J=16.3Hz,1H),5.45-5.30(m,3H),4 .15(s,2H),3.55–3.44(m,2H),3.18–3.07(m,2H),2.93(s,3H),2.70–2.51(m,2H),2.03–1.89(m,2H),1.02(t,J=7.4Hz,3H).
[1193] 3.16: (S)-9-Amino-4-ethyl-8-fluoro-4-hydroxy-11-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 153)
[1194]
[1195] The Boc-protected precursor of the title compound was prepared starting from compound 3.9 (10 mg) and 1-(phenylsulfonyl)piperazine according to General Procedure 1. Preparative HPLC was performed as described in General Procedure 9, eluting with a gradient of 35% to 44% CH3CN / H2O + 0.1% TFA to afford the Boc-protected intermediate as a yellow powder. This intermediate was then deprotected according to General Procedure 6 to afford the title compound (TFA salt, 2.4 mg, 17% yield over 2 steps).
[1196] LC / MS: C 31 H 30 Calculated value for FN5O6S m / z = 619.2, found [M+H] + =520.4.
[1197] 1 H NMR (300MHz, MeOD) δ7.81-7.60(m,7H),7.34(s,1H),5.51(d,J=16.4Hz,1H),5.35(d,J=16.4Hz,1H),5. 22(s,2H),4.10(s,2H),3.15-3.02(m,4H),2.79-2.71(m,4H),2.00-1.93(m,2H),1.00(t,J=7.4Hz,3H).
[1198] 3.17: (S)-N-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)acetamide (Compound 147)
[1199]
[1200] The title compound was prepared starting from compound 3.10 (8 mg) and acetic acid according to General Procedure 2, followed by General Procedure 6. Preparative HPLC purification of the intermediate Boc-protected compound was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA. The title compound was obtained as a red solid (4.0 mg, 56% yield).
[1201] LC / MS: C 23 H 21 Calculated value of FN4O5 m / z = 452.2, found value [M+H] + =453.2.
[1202] 1H NMR(300MHz,MeOD)δ7.69(d,J=12.1Hz,1H),7.56(s,1H),7.38(d,J=9.3Hz,1H),5.59(d,J=16.3 Hz,1H),5.44–5.33(m,3H),4.85(s,3H),2.03(s,3H),2.00–1.84(m,2H),1.03(t,J=7.4Hz,3H).
[1203] 3.18: (S)-N-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)methanesulfonamide (Compound 146)
[1204]
[1205] The title compound was prepared starting from compound 3.10 (8 mg) and methanesulfonyl chloride according to General Procedure 3, followed by General Procedure 6. Preparative HPLC purification of the intermediate Boc-protected compound was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA. The title compound was obtained as a red solid (4.4 mg, 57% yield).
[1206] LC / MS: C 22 H 21 Calculated value for FN4O6S m / z = 488.1, found [M+H] + =489.2.
[1207] 1 H NMR(300MHz,MeOD)δ7.74(d,J=12.2Hz,1H),7.60(s,1H),7.49(d,J=9.3Hz,1H),5.61(d,J=16.2Hz,1H), 5.45(s,2H),5.40(d,J=16.2Hz,1H),4.78(s,2H),3.05(s,3H),2.08–1.94(m,2H),1.03(t,J=7.4Hz,3H).
[1208] 3.19: (S)-N-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-2-hydroxyethane-1-sulfonamide (Compound 150)
[1209]
[1210] The title compound was prepared starting from compound 3.10 (6 mg) and 2-hydroxyethanesulfonyl chloride according to General Procedure 3, followed by General Procedure 6. Preparative HPLC purification of the intermediate Boc-protected compound was accomplished as described in General Procedure 9, eluting with a gradient of 10% to 60% CH3CN / H2O + 0.1% TFA. The title compound was obtained as a red solid (1 mg, 16% yield).
[1211] LC / MS: C 23 H 23 Calculated value for FN4O7S m / z = 518.5, found [M+H] + =519.5.
[1212] 1 H NMR(300MHz,10% D2O / CD3CN) δ7.77–7.61(m,1H),7.48–7.30(m,2H),5.53(d,J=16.3Hz,1H),5.31(d,J=15.4Hz,3H),4.69(s,2 H), 3.97 (dd, J = 6.6, 4.9Hz, 2H), 3.39 (t, J = 5.8Hz, 2H), 2.93 (s, 1H), 1.99-1.83 (m, 2H), 0.94 (t, J = 7.3Hz, 3H).
[1213] 3.20: (S)-4-Nitrophenyl ((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 3.20)
[1214]
[1215] To a solution of compound 3.10 (10 mg, 0.02 mmol) in DMF (400 uL, 0.05 M) was added 4-nitrophenyl carbonate (12 mg, 0.04 mmol) and diisopropylethylamine (6.8 uL, 0.04 mmol). The solution was stirred at room temperature for about 30 minutes and then used directly in the subsequent reaction.
[1216] 3.21: (S)-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)carbamate (Compound 143)
[1217]
[1218] The title compound was prepared by adding MeOH (100 uL) to a 200 uL solution of compound 3.20. The solution was stirred at room temperature for 30 minutes. Preparative HPLC purification of the intermediate Boc-protected compound was performed as described in General Procedure 9 using a 10% to 60% CH 3 CN / H 2 O + 0.1% TFA gradient elution. The title compound was obtained as a red solid (2.1 mg, 47% yield) according to General Procedure 6.
[1219] LC / MS: C 23 H 21 Calculated value for FN4O6 m / z = 468.4, found [M+H] + =468.3.
[1220] 1 H NMR(300MHz,10% D2O / CD3CN) δ7.72(d,J=12.2Hz,1H),7.41(d,J=18.1Hz,1H),6.96(s,1H),5.52(d,J=3.6Hz,1H),5.39–5.2 3(m,3H),4.82(s,1H),4.73(s,1H),3.63(d,J=1.2Hz,3H),1.56(s,3H),1.27(s,2H),0.94(t,J=7.4Hz,3H).
[1221] 3.22: (S)-1-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-methylurea (Compound 144)
[1222]
[1223] The title compound was prepared by adding methylamine hydrochloride (10 mg) to a 200 μl solution of compound 3.20, followed by iPr NEt (5 μL). The solution was stirred at room temperature for 30 minutes. Preparative HPLC purification of the intermediate Boc-protected compound was performed as described in General Procedure 9, using a 10% to 60% CH 3 CN / H 2 O + 0.1% TFA gradient elution. The title compound was obtained as a red solid (2.9 mg, 64.5% yield) according to General Procedure 6.
[1224] LC / MS: C 23 H 21 Calculated value for FN5O5 m / z = 467.5, found [M+H]+ =468.5.
[1225] 1 H NMR(300MHz,10% D2O / CD3CN) δ8.13(d,J=9.2Hz,1H),7.92(s,1H),7.73(d,J=12.3Hz,1H),7.52–7.35(m,2H),6.94(d,J=9.2Hz,2H),5.55(d,J =16.5Hz,2H),5.44–5.27(m,4H),4.85(s,2H),4.78(s,1H),1.56(d,J=2.5Hz,3H),1.27(s,2H),0.93(q,J=11.7,9.5Hz,3H).
[1226] 3.23: (S)-1-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-(2-hydroxyethyl)urea (Compound 151)
[1227]
[1228] The title compound was prepared by adding ethanolamine (100 μL) to a 200 μL solution of compound 3.20. The solution was stirred at room temperature for 30 minutes. Preparative HPLC purification of the intermediate Boc-protected compound was performed as described in General Procedure 9 using a 10% to 60% CH 3 CN / H 2 O + 0.1% TFA gradient elution. The title compound was obtained as a red solid (0.5 mg, 8.5% yield) according to General Procedure 6.
[1229] LC / MS: C 24 H 24 Calculated value for FN5O6 m / z = 497.5, found [M+H] + =498.5.
[1230] 1 H NMR(300MHz,10% D2O / CD3CN) δ7.77–7.61(m,1H),7.48–7.30(m,2H),5.53(d,J=16.3Hz,1H),5.31(d,J=15.4Hz,1H),5.19(s,2H),4.6 9(s,2H),3.97(dd,J=6.6,4.9Hz,2H),3.39(t,J=5.8Hz,2H),2.93(s,1H),2.01-1.83(m,2H),0.94(t,J=7.3Hz,3H).
[1231] 3.24: (S)-9-Amino-11-(azidomethyl)-4-ethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 152)
[1232]
[1233] To a stirred solution of compound 3.5 (100 mg) in 2 mL of dichloromethane, thionyl chloride (35 mL, 2.5 equivalents) was added. The solution was stirred at room temperature for 20 minutes, and then thionyl chloride (35 mL, 2.5 equivalents) was added. After 20 minutes, toluene (1 mL) was added and the reaction mixture was concentrated in vacuo. The crude solid was suspended in DMSO (1 mL) and sodium azide (19 mg, 1.5 equivalents) was added. The solution was stirred at room temperature for 16 hours. Purification was completed as described in general procedure 9, with 5% to 50% CH3CN / H2O+0.1% TFA gradient elution to give the title compound (20 mg, 23% yield) as a pale solid.
[1234] LC / MS: C 21 H 17 Calculated value of FN6O4 m / z = 436.1, found value [M+H] + =437.2.
[1235] 1 H NMR(300MHz,MeOD)δ7.75(d,J=12.2Hz,1H),7.60(s,1H),7.38(d,J=9.3Hz,1H),5.61(d, J=16.3Hz,1H),5.46–5.35(m,3H),5.07(s,2H),2.03–1.97(m,2H),1.03(t,J=7.3Hz,3H).
[1236] 3.25: (S)-N-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)acetamide (Compound 164)
[1237]
[1238] The title compound was prepared starting from compound 145 (10 mg) and glycolic acid according to General Procedure 2. Preparative HPLC purification was performed as described in General Procedure 9, eluting with a gradient of 10% to 45% CH 3 CN / H 2 O + 0.1% TFA. The title compound was obtained as a yellow solid (6.9 mg, 60% yield).
[1239] LC / MS: C 23 H 21 Calculated value of FN4O6 m / z = 468.1, found value [M+H] + =469.2.
[1240] 1 H NMR (300MHz, MeOD)7.70(d,J=12.2Hz,1H),7.60(s,1H),7.42(d,J=9.4Hz,1H),5.62(d,J=16.3Hz,1H),5.43( s,2H),5.36(d,J=16.2Hz,1H),4.95(d,J=5.9Hz,2H),4.08(s,2H),2.04–1.90(m,1H),1.03(t,J=7.4Hz,3H).
[1241] 3.26: (S)-1-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)-3-methylthiourea (Compound 161)
[1242]
[1243] To a solution of compound 145 (9 mg, 1.0 equivalents) in DMF (1 mL) was added thiocarbonyldiimidazole (6 mg, 1.5 equivalents) followed by DIPEA (8 μL, 2.0 equivalents). The resulting solution was stirred at 25 ° C for 2 hours after which it was observed that the isothiocyanate intermediate was completely converted. Methylammonium chloride (3 mg, 2.0 equivalents) was then added and the reaction mixture was heated at 60 ° C for 30 minutes. Preparation HPLC purification was completed as described in general procedure 9 using a 10% to 45% CH CN / H O+0.1% TFA gradient elution. The title compound (2.3 mg, 22% yield) was obtained as a yellow solid.
[1244] LC / MS: C 23 H 22 Calculated value for FN5O4S m / z = 483.1, found [M+H] + =484.2.
[1245] 1 H NMR(300MHz,MeOD)δ7.70(d,J=12.0Hz,1H),7.60(s,1H),7.38(d,J=9.3Hz,1H),5.62(d,J=16.2Hz,1H), 5.36(s,2H),5.31(d,J=16.2Hz,1H),5.30(s,2H),3.04(s,3H),1.99–1.90(m,2H),1.02(t,J=7.4Hz,3H).
[1246] 3.27: (S)-(2-Hydroxyethyl)-((9-amino-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-11-yl)methyl)thiocarbamate (Compound 160)
[1247]
[1248] The title compound was prepared starting from compound 145 (10 mg) and 2-mercaptoethanol according to General Procedure 5. Preparative HPLC purification was performed as described in General Procedure 9, eluting with a gradient of 10% to 45% CH3CN / H2O + 0.1% TFA. The title compound was obtained as a yellow solid (4.2 mg, 43% yield).
[1249] LC / MS: C 24 H 23 Calculated value for FN4O6S m / z = 514.1, found [M+H] + =515.2.
[1250] 1 H NMR (300MHz, MeOD) δ7.71(d,J=12.1Hz,1H),7.60(s,1H),7.36(d,J=9.4Hz,1H),5.62(d,J=16.3Hz,1H),5.42(s,2H),5.35(d, J=16.2Hz,1H),4.88(d,J=4.6Hz,2H),3.68(t,J=6.4Hz,2H),3.03(t,J=6.5Hz,2H),2.04–1.92(m,2H),1.03(t,J=7.4Hz,3H).
[1251] 3.28: (S)-9-Amino-4,11-diethyl-8-fluoro-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (Compound 154)
[1252]
[1253] To a 5mL flask containing compound 140 (50mg) was added water (0.72mL), FeSO4 (heptahydrate, 11.0mg) and propionaldehyde (74μL). The resulting suspension was cooled to -15°C using an ice-salt bath, and sulfuric acid (0.40mL) was then added dropwise. Hydrogen peroxide (95μL) was then added dropwise. The mixture was stirred at -15°C for 10 minutes, then warmed to room temperature and stirred for 2 hours. The reaction mixture was diluted with water (30mL) and the resulting suspension was extracted with DCM (3×30mL). The organic phase was then evaporated to dryness. Preparative HPLC purification was completed as described in general procedure 9, with 25% to 70% CH3CN / H2O+0.1%TFA gradient elution to give the title compound (2.4mg, 4.4% yield) as a dark orange solid.
[1254] LC / MS: C 22 H 20 Calculated value of FN3O4 m / z = 410.1, found value [M+H] + =410.2.
[1255] 1 H NMR (300MHz, MeOD) δ7.63(d,J=12.3Hz,1H),7.55(s,1H),7.36(d,J=9.4Hz,1H),5.57(d,J=16.4Hz,1H),5.37(d,J =16.4Hz,1H),5.21(s,2H),3.13(q,J=7.7Hz,2H),2.02–1.90(m,2H),1.38(t,J=7.7Hz,3H),1.01(t,J=7.3Hz,3H).
[1256] 3.29: (S)-tert-Butyl (11-((Carbamoyloxy)methyl)-4-ethyl-8-fluoro-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-...
Claims
1. An antibody-drug conjugate having formula (X): T-[L-(D) m ] n (X) in: m is between 1 and 4; n is between 1 and 10; T is an anti-FRα antibody construct comprising an antigen binding domain that specifically binds to an epitope within human folate receptor α (hFRα) comprising amino acid residues E120, D121, R123, T124, S125, and Y126 of SEQ ID NO: 15; L is a connector, and D is a compound of formula I: in: R 1 is selected from: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3, -OCF3 and -NH2, and R 2 Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3, And among them: When R 1 When it is -NH2, then R is R 3 or R 4 , and when R 1 If it is not -NH2, then R is R 4 ; R 3 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -CO2R 8 , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl; R 4 Selected from: R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -aryl and -(C1-C6 alkyl)-aryl; R 6 and R 7 Each is independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ; R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; Each R 10 Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -NR 14 R 14’ , -aryl, -heteroaryl and -(C1-C6alkyl)-aryl; R 10’ Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 11 Selected from: -H and -C1-C6 alkyl; R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and R 13 Selected from: -H and -C1-C6 alkyl; R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 18 and R 19 Together with the N atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ; R 24 , R 25 and R 26 Each is -C1-C6 alkyl; X a and X b are each independently selected from: NH, O and S, and X c Selected from: O, S and S(O)2, Provided that the compound is not (S)-9-amino-11-butyl-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione.
2. The antibody-drug construct of claim 1, wherein the antigen binding domain comprises a heavy chain CDR amino acid sequence (HCDR1, HCDR2 and HCDR3) and a light chain CDR amino acid sequence (LCDR1, LCDR2 and LCDR3), wherein the heavy chain CDR amino acid sequence comprises the sequence shown in SEQ ID NOs: 3, 4 and 5, and the light chain CDR amino acid sequence comprises the sequence shown in SEQ ID NOs: 6, 7 and 8.
3. The antibody-drug conjugate of claim 1, wherein the antigen binding domain comprises a CDR sequence of a VH domain having a sequence as shown in any one of SEQ ID NO: 19, 50, 54, 57, 61, 76, 79, 82, 85, 88, 91, 99, 106, 113, 116, 133 or 136.
4. The antibody-drug conjugate according to claim 1 or 3, wherein the antigen binding domain comprises a CDR sequence of a VL domain having a sequence as shown in any one of SEQ ID NO: 39, 64, 119, 124 or 130.
5. The antibody-drug conjugate of claim 1, wherein the antigen binding domain comprises: (i) a HCDR1 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 20, 23, 26, 28, 31, 92, 93, 94, 95 or 96; a HCDR2 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 21, 24, 27, 29, 32, 51, 58, 100, 101, 102, 103, 109, 137, 138 or 139; and a HCDR3 amino acid sequence selected from the group consisting of the amino acid sequences shown in any one of SEQ ID NOs: 22, 25, 30, 107, 108 or 110, and (ii) a LCDR1 amino acid sequence selected from the group consisting of an amino acid sequence as shown in any one of SEQ ID NOs: 40, 43, 45, 65, 125, 126 or 127; a LCDR2 amino acid sequence selected from the group consisting of an amino acid sequence as shown in any one of SEQ ID NOs: 41, 44 or 46; and a LCDR3 amino acid sequence selected from the group consisting of an amino acid sequence as shown in any one of SEQ ID NOs: 42, 47, 120 or 121.
6. The antibody-drug conjugate according to any one of claims 1 to 5, wherein D is a compound of formula (IV): in: R 1a Selected from: -H, -CH3, -CHF2, -CF3, -F, -Br, -Cl, -OH, -OCH3, -OCF3 and -NH2; R 2a Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3; X is -O-, -S- or -NH-, and R 4a Selected from: wherein * is the point of attachment to X, and wherein p is 1, 2, 3 or 4; or X is O, and R 4a -X- is selected from: R 5a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 8a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; Each R 9a R is independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; or 9a does not exist, and X b =X; Each R 10a are independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and Each R 10a’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; Each R 10b Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 11a Not present or -C1-C6 alkyl; R 12a Selected from: -C1-C6 alkyl, -CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16a and R 13a Selected from: -H and -C1-C6 alkyl; R 14a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 14a’ Selected from: H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 16a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 21 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5a ; R 22 and R 23 Each is independently selected from: -H, -halogen, -C1-C6 alkyl and -C3-C8 cycloalkyl; R 24 , R 25 and R 26 Each is -C1-C6 alkyl; X a and X b Each independently selected from: NH, O and S; X c is selected from: O, S and S(O)2, and Indicates the connection point with the linker L.
7. The antibody-drug conjugate according to claim 6, wherein R 1a Selected from: -CH3, -CF3, -OCH3, -OCF3 and -NH2.
8. The antibody-drug conjugate according to claim 6, wherein R 1a Selected from: -CH3, -OCH3 and NH2.
9. The antibody-drug conjugate according to any one of claims 6 to 8, wherein R 2a Selected from: -H, -F, -Br and -Cl.
10. The antibody-drug conjugate according to any one of claims 6 to 9, wherein X is -O-, -S- or -NH-, and R 4a Selected from:
11. The antibody-drug conjugate according to any one of claims 1 to 5, wherein D is a compound of formula (V): in: R 2a Selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3; R 20a Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, R 5 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 6 and R 7 Each is independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5 , -C3-C8 heterocycloalkyl and -C(O)R 17 ; R 8 Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; Each R 9 Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; Each R 10a are independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and -NR 14 R 14’ ; Each R 10a’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 11 Selected from: -H and -C1-C6 alkyl; R 12 Selected from: -H, -C1-C6 alkyl, -CO2R 8 , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16 and R 13 Selected from: -H and -C1-C6 alkyl; R 14 and R 14’ Each is independently selected from: -H, C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 16 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 17 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 18 and R 19 Together with the N atom to which they are bound, they form a 4-, 5-, 6- or 7-membered ring having 0 to 3 substituents selected from the group consisting of halogen, -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5 ; R 24 , R 25 and R 26 Each is -C1-C6 alkyl; X a and X b Each independently selected from: NH, O and S; X c is selected from: O, S and S(O)2, and Indicates the connection point with the linker L.
12. The antibody-drug conjugate according to claim 11, wherein R 2a For F.
13. The antibody-drug conjugate according to claim 11 or 12, wherein R 20a Selected from: -H, -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5 , -(C1-C6 alkyl)-aryl, 14. The antibody-drug conjugate according to any one of claims 1 to 5, wherein D is a compound of formula (VI): in: R 2a Selected from: -H, -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3; X is -O-, -S- or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a 、-CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, wherein * is the point of attachment to X, and wherein p is 1, 2, 3 or 4; or X is O, and R 25 -X- is selected from: R 5a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 6a Selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 7a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -(C1-C6 alkyl)-OR 5a , -C3-C8 heterocycloalkyl and -C(O)R 17a ; R 8a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; Each R 9a R is independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; or 9a does not exist, and X b =X; Each R 10a are independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl and Each R 10a’ Independently selected from: -H, -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; Each R 10b Independently selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 11a Not present or -C1-C6 alkyl; R 12a Selected from: -C1-C6 alkyl, -CO2R 8a , -aryl, -heteroaryl, -(C1-C6 alkyl)-aryl, -S(O)2R 16a and R 13a Selected from: -H and -C1-C6 alkyl; R 14a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 14a’ Selected from: H, -C1-C6 alkyl, -C3-C8 cycloalkyl and -C3-C8 heterocycloalkyl; R 16a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 17a Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl, -C3-C8 heterocycloalkyl, -(C1-C6 alkyl)-C3-C8 heterocycloalkyl, -aryl, -heteroaryl and -(C1-C6 alkyl)-aryl; R 21 Selected from: -C1-C6 alkyl, -C3-C8 cycloalkyl and -(C1-C6 alkyl)-OR 5a ; R 22 and R 23 Each is independently selected from: -H, -halogen, -C1-C6 alkyl and -C3-C8 cycloalkyl; R 24 , R 25 and R 26 Each is -C1-C6 alkyl; X a and X b Each independently selected from: NH, O and S; X c is selected from: O, S and S(O)2, and Indicates the connection point with the linker L.
15. The antibody-drug conjugate according to claim 14, wherein R 2a Selected from: -CH3, -CF3, -F, -Br, -Cl, -OH, -OCH3 and -OCF3.
16. The antibody-drug conjugate of claim 14, wherein R 2a For F.
17. The antibody-drug conjugate according to any one of claims 14 to 16, wherein X is -O-, -S- or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a , –(C1-C6 alkyl)-aryl, or X is O, and R 25 -X- is selected from:
18. The antibody-drug conjugate of any one of claims 14 to 16, wherein X is -O-, -S- or -NH-, and R 25 Selected from: -C1-C6 alkyl, -(C1-C6 alkyl)-OR 5a , -(C1-C6 alkyl)-aryl, 19. The antibody-drug conjugate of any one of claims 1 to 18, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl, sulfonamido, alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.
20. The antibody-drug conjugate of any one of claims 1 to 18, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is optionally substituted with one or more substituents selected from the group consisting of halogen, acyl, acyloxy, alkoxy, carboxyl, hydroxy, amino, amido, nitro, cyano, azido, alkylthio, thio, sulfonyl and sulfonamido.
21. The antibody-drug conjugate according to any one of claims 1 to 5, wherein D has the structure of any one of the compounds shown in Table 6 or Table 7.
22. The antibody-drug conjugate of any one of claims 1 to 5, wherein D is Compound 139 or Compound 141.
23. The antibody-drug conjugate of any one of claims 1 to 22, wherein L is a cleavable linker.
24. The antibody-drug conjugate of claim 23, wherein L is a protease cleavable linker.
25. The antibody-drug conjugate of claim 23 or 24, wherein L comprises a dipeptide, a tripeptide or a tetrapeptide.
26. The antibody-drug conjugate according to any one of claims 23 to 25, wherein L has: (a) Formula (XI) in: Z is a functional group capable of reacting with a target group on the anti-FRα antibody construct T; Str is the extension segment; AA1 and AA2 are each independently an amino acid, wherein AA1-[AA2] r Formation of protease cleavage sites; X is a self-decomposing group; q is 0 or 1; r is 1, 2, or 3; s is 0, 1, or 2; # is the connection point with the anti-FRα antibody construct T, and % is the point of connection with the camptothecin analog D, or (b) Formula (XII) in: Z is a functional group capable of reacting with a target group on the anti-FRα antibody construct T; Str is the extension segment; AA1 and AA2 are each independently an amino acid, wherein AA1-[AA2] r Formation of protease cleavage sites; Y is -NH-CH2- or -NH-CH2-C(O)-; q is 0 or 1; r is 1, 2, or 3; v is 0 or 1; # is the connection point with the anti-FRα antibody construct T, and % is the point of attachment to the camptothecin analog D.
27. The antibody-drug conjugate according to any one of claims 1 to 5, wherein L-(D) in formula (X) has the structure of any one of the drug-linkers (DL) shown in Tables 8-10.
28. The antibody-drug conjugate according to any one of claims 1 to 5, wherein L-(D) in formula (X) has the structure of any one of the drug-linkers (DL) shown in Table 8 or Table 9.
29. The antibody-drug conjugate according to any one of claims 1 to 5, wherein L-(D) in formula (X) is: MT-GGFG-AM-Compound 139 MC-GGFG-AM-Compound 139 MT-GGFG-AM-Compound 141 MC-GGFG-AM-Compound 141 MT-GGFG-Compound 141 or MC-GGFG-Compound 141 30. The antibody-drug conjugate according to any one of claims 1 to 29, wherein m is between 1 and 2.
31. The antibody-drug conjugate of any one of claims 1 to 29, wherein m is 1.
32. The antibody-drug conjugate of any one of claims 1 to 31, wherein n is between 2 and 8.
33. The antibody-drug conjugate of any one of claims 1 to 31, wherein n is between 4 and 8.
34. The antibody-drug conjugate of any one of claims 1 to 33, wherein the anti-FRα antibody construct further comprises a scaffold, and wherein the antigen binding domain is operably linked to the scaffold.
35. The antibody-drug conjugate of claim 34, wherein the scaffold comprises an IgG Fc region.
36. An antibody-drug conjugate having a structure selected from the group consisting of: in: T is an anti-FRα antibody construct comprising two antigen binding domains operably linked to an IgG Fc region, each of the antigen binding domains comprising: (a) the VL amino acid sequence as shown in SEQ ID NO:39 and the VH amino acid sequence as shown in SEQ ID NO:19; or (b) the VL amino acid sequence as shown in SEQ ID NO: 124 and the VH amino acid sequence as shown in SEQ ID NO: 91; or (c) the VL amino acid sequence as shown in SEQ ID NO: 64 and (i) the VH amino acid sequence as shown in SEQ ID NO: 50, or (ii) the VH amino acid sequence as shown in SEQ ID NO: 54, or (iii) the VH amino acid sequence as shown in SEQ ID NO: 57, or (iv) the VH amino acid sequence as shown in SEQ ID NO: 61, or (v) the VH amino acid sequence as shown in SEQ ID NO: 76, or (vi) the VH amino acid sequence as shown in SEQ ID NO: 79, or (vii) the VH amino acid sequence as shown in SEQ ID NO: 82, or (viii) the VH amino acid sequence as shown in SEQ ID NO: 85, or (ix) the VH amino acid sequence as shown in SEQ ID NO: 88, or (x) the VH amino acid sequence as shown in SEQ ID NO: 106; or (d) the VL amino acid sequence as shown in SEQ ID NO: 130 and (i) the VH amino acid sequence as shown in SEQ ID NO: 99, or (ii) the VH amino acid sequence as shown in SEQ ID NO: 106, or (iii) the VH amino acid sequence as shown in SEQ ID NO: 113, or (iv) the VH amino acid sequence as shown in SEQ ID NO: 116, or (v) the VH amino acid sequence as shown in SEQ ID NO: 133, or (vi) the VH amino acid sequence as shown in SEQ ID NO: 136; or (e) the VL amino acid sequence as shown in SEQ ID NO: 119 and (i) the VH amino acid sequence as shown in SEQ ID NO: 106, or (ii) the VH amino acid sequence as shown in SEQ ID NO: 116, And wherein n is between 4 and 8.
37. A pharmaceutical composition comprising the antibody-drug conjugate according to any one of claims 1 to 36 and a pharmaceutically acceptable carrier or diluent.
38. A method of inhibiting cancer cell proliferation, comprising contacting the cell with an effective amount of the antibody-drug conjugate according to any one of claims 1 to 36.
39. A method of killing cancer cells, comprising contacting the cells with an effective amount of an antibody-drug conjugate according to any one of claims 1 to 36.
40. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of the antibody-drug conjugate of any one of claims 1 to 36.
41. The method of claim 40, wherein the cancer is breast cancer, ovarian cancer, colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, or endometrial cancer.
42. The antibody-drug conjugate of any one of claims 1 to 36 for use in therapy.
43. The antibody-drug conjugate according to any one of claims 1 to 36 for use in the treatment of cancer.
44. The antibody-drug conjugate for use according to claim 43, wherein the cancer is breast cancer, ovarian cancer, colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer or endometrial cancer.
45. Use of an antibody-drug conjugate according to any one of claims 1 to 36 in the manufacture of a medicament for treating cancer.
46. Use according to claim 45, wherein the cancer is breast cancer, ovarian cancer, colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer or endometrial cancer.
